The Regulation of Glycoprotein130 Dependent Inflammatory Cytokines one Basal and Mechanical Stimuli Induced Protein Synthesis in Myotubes and Skeletal Muscles by Gao, Song




The Regulation of Glycoprotein130 Dependent
Inflammatory Cytokines one Basal and Mechanical
Stimuli Induced Protein Synthesis in Myotubes and
Skeletal Muscles
Song Gao
University of South Carolina
Follow this and additional works at: https://scholarcommons.sc.edu/etd
Part of the Exercise Science Commons
This Open Access Dissertation is brought to you by Scholar Commons. It has been accepted for inclusion in Theses and Dissertations by an authorized
administrator of Scholar Commons. For more information, please contact dillarda@mailbox.sc.edu.
Recommended Citation
Gao, S.(2017). The Regulation of Glycoprotein130 Dependent Inflammatory Cytokines one Basal and Mechanical Stimuli Induced Protein
Synthesis in Myotubes and Skeletal Muscles. (Doctoral dissertation). Retrieved from https://scholarcommons.sc.edu/etd/4295
 
 
THE REGULATION OF GLYCOPROTEIN130 DEPENDENT INFLAMMATORY 
CYTOKINES ONE BASAL AND MECHANICAL STIMULI INDUCED PROTEIN 






Bachelor of Science 
Nanjing University, 2006 
 
Master of Science 
Nanjing University, 2009 
__________________________________________ 
Submitted in Partial Fulfillment of the Requirements 
For the Degree of Doctor of Philosophy in 
Exercise Science 
Norman J. Arnold School of Public Health 
University of South Carolina 
2017 
Accepted by: 
James A. Carson, Major Professor 
Larry J. Durstine, Committee Member 
Ho-Jin Koh, Committee Member 
Wayne E. Carver, Committee Membe 
Norma Frizzell, Committee Member 
















































I need to first thank my parents Xiang Gao and Meifang Geng for their care, education and 
inspiration.  I would like to thank Dr. James Carson whose patience and guidance have 
helped me achieve more than I could have imagined in scienctific research. I would like to 
thank my dissertation committee members Dr. Larry Durstine, Dr. Ho-Jin Koh, Dr. Wayne 
Carver and Dr. Norma Frizzell, who have given their patience and expertise to better my 
work. I thank them for their contribution and their good-natured support. I would like to 
thank the members both past and present of the IMB lab who have assisted me throughout 
my time: James White, Shu Sato, Kandy Velazquez, Melissa Puppa, Aditi Narsale, Justin 
Hardee, Kimbell Hetzler, Dennis Fix, Brandon Vanderveen, Brittany Counts and any not 
specifically mentioned here.  
 
All research of this dissertation was primarily supported by NIH Grant R01 CA121249-01 





Maintaining skeletal muscle mass has a well-documented role in health and quality of life. 
Two members of IL-6 family of cytokines, IL-6 and LIF, and have a paradoxical role in 
skeletal muscle mass regulation: short term elevation of IL-6 and LIF plays a key role in 
mechanical stimuli induced muscle growth and muscle hypertrophy, while the long term 
elevated IL-6 and LIF regulate muscle wasting during cancer cachexia by disrupting 
muscle protein turnover regulation. The regulation of muscle protein synthesis is an 
important determinant of mechanical stimuli induced muscle hypertrophy and muscle 
wasting during cancer cachexia. IL-6 family of cytokines can induce intracellular signaling 
pathways involved in muscle mass regulation, including STAT3, ERK1/2, PI3K/Akt and 
AMPK via their functional receptor complex containing gp130. However, it is still 
unknown whether physiologically and pathologically elevated IL-6 or LIF can regulate 
basal mechanical stimuli induced muscle protein synthesis. The overall purpose of this 
dissertation was to determine if physiological short term or pathological long term exposure 
of IL-6 and LIF would regulate basal protein synthesis or protein synthesis induction by 
mechanical stimuli in cultured myotubes and skeletal muscles. Specific aim 1 investigated 
if physiological short term exposure of IL-6 or LIF would activate myotube protein 
synthesis by activating gp130-Akt-mTOR signaling cascade. Short term IL-6 and LIF 
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exposure increased myotube protein synthesis, which was associated with the induction of 
gp130-Akt signaling pathway. Either gp130 siRNA knock-down or Akt signaling inhibition 
blocked IL-6/LIF induction of myotube protein synthesis, Interestingly, mTORC1 or 
STAT3 signaling inhibition did not completed blocked IL-6/LIF induction of myotube 
protein synthesis. Specific aim 2 investigated if pathological long term IL-6 or LIF 
exposure would suppress myotube protein synthesis by activating AMPK signaling. We 
reported long term exposure of IL-6 and LIF suppressed myotube mTORC1 signaling and 
protein synthesis, which was rescued by the pharmaceutical inhibition of AMPK signaling 
during IL-6/LIF exposure. However, long term AMPK signaling resulted suppression of 
basal myotube protein synthesis. Specific aim 3 investigated if short term or long term IL-
6/LIF exposure would regulate stretch induction of protein synthesis in myotubes and 
eccentric contraction induction of protein synthesis in skeletal muscles, respectively. We 
reported that both short term and long term IL-6/LIF disrupted stretch induction of myotube 
protein synthesis in vitro, but in vivo IL-6 overexpression had no effect on muscle protein 
synthesis induction by eccentric contractions. Taken together, our results demonstrate that 
short term IL-6 or LIF exposure can stimulate protein synthesis in myotubes by activating 
gp130-Akt signaling, but is not dependent on mTOR signaling. Long term pathological 
exposure of IL-6 or LIF suppressed myotube protein synthesis though the activation of 
AMPK signaling. However, the IL-6/LIF regulation of mechanical stimulus induction of 
protein synthesis is dependent on different mechanical stimuli models. These findings 
vi 
 
provide new insight of the IL-6/LIF role in skeletal muscle mass regulation under 
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Skeletal muscle provides a fundamental basis for human function, including 
locomotion, respiration and homeostasis of metabolism. Maintaining skeletal muscle mass 
is critical for physical activity level, quality of life and decreased mortality. The skeletal 
muscle mass is sensitive to multiple systematic changes related to nutritional status, 
physical activity level, inflammatory cytokines and muscle wasting diseases. The 
regulation of skeletal muscle mass involves the balance between protein synthesis and 
degradation, which is termed protein turnover (1). However, significant gaps remain in our 
understanding of skeletal muscle protein turnover regulation by hypertrophic or atrophic 
stimuli in health and disease. 
 
The Interleukin-6 (IL-6) family of cytokines regulate many physiological and 
pathological processes including immune system regulation, inflammation, wound healing 
and cell survival (2). Skeletal muscle serves as both a biological target and source of the 
IL-6 family of cytokines. IL-6 family of cytokines induce intracellular signaling pathways 
via their trans-membrane receptor complex containing glycoprotein 130 (gp130). gp130 is 
signal-transducing receptor that forms part of the receptor complex for IL-6 family of 
cytokines (3). Formation of functional ligand-receptor complex results in gp130 activation 
of multiple downstream signaling pathways, including STAT3, ERK1/2 and PI3K-Akt (4). 
Two members of IL-6 family of cytokines, IL-6 and Leukemia Inhibitory Factor (LIF), 
have recognized roles in skeletal muscle mass regulation (5). Repeated contractions or 
overload IL-6 and LIF can induce a short the plasma elevation and muscle expression of 
IL-6 and LIF (6), which is thought to initiate important autocrine and paracrine signaling 
that contributes to metabolic adaptations and muscle hypertrophy through, at least in part, 
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the activation of satellite cell proliferation and fusion to myofibers (7, 8). However, long-
lasting elevated systemic levels of IL-6 family of cytokines is associated with the 
pathological inflammatory conditions in some types of cancer and other chronic disease 
states. Long term elevation of IL-6 has been demonstrated as a key mediator of different 
muscle wasting diseases such as rheumatoid arthritis, chronic kidney disease and cancer 
cachexia (9-11). Currently, there is no clear understanding of this complex dichotomy 
involving the effects LIF and IL-6 on muscle mass regulation. 
 
The muscle protein synthesis regulation is a key determinant of muscle mass (12).  
The integration of muscle protein synthesis through mTORC1 is an acknowledged control 
point of skeletal muscle mass (12). Activation of mTOR signaling plays a central role in 
muscle hypertrophic response to multiple hypertrophic stimulus, including growth factors, 
hormones, nutrition and mechanical stimuli (16), while the muscle mTOR signaling and 
protein synthesis suppression is associated with muscle wasting (17-19). Once activated, 
mTOR can induce muscle protein synthesis through the phosphorylation of the p70S6K 
and 4E-BP1 (13). Multiple upstream signaling pathways, including PI3K-Akt, ERK1/2 and 
AMPK, regulate mTORC1 by phosphorylating different sites of tuberous sclerosis 1/2 
(TSC1/2). TSC2 phosphorylation by PI3K-Akt or ERK1/2 can relieve TSC1/2 suppression 
on Ras homolog enriched in brain (Rheb), allowing Rheb to stimulate mTOR signaling 
(14-16), while AMPK suppress mTOR signaling by phosphorylation of TSC2 and 
subsequent enhancement of the inhibition of TSC1/2 on mTOR (17).  
Although short term physiological and long term pathological elevation of IL-6 
and LIF is involved in both muscle hypertrophy and atrophy respectively, the 
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potential gp130 signaling regulation of muscle protein synthesis in physiological or 
pathological conditions still needs to be determined. gp130 induction can activate 
PI3K/Akt and ERK1/2 signaling, two upstream stimulator of mTOR, through JAK and Ras 
dependent mechanisms, respectively (3). Short term IL-6 or LIF exposure induces gp130 
activation of Akt-mTOR signaling in cardiomyocytes, which is a key mechanism of IL-6 
and LIF induced cardiac hypertrophy (18, 25). However, the specific interaction between 
these cytokines and the PI3K/Akt-mTORC1 or gp130-ERK1/2-mTORC1 signaling axis 
within skeletal muscle fibers needs further investigation. Unlike the potential anabolic 
effects of short term IL-6/gp130 signaling action, pathological long term activation of IL-
6-gp130 dependent signaling is associated with suppression of muscle protein synthesis 
(18, 19). Chronic in vivo systemic IL-6 overexpression or in vitro IL-6 administration can 
decrease mTOR and p70S6K phosphorylation in skeletal muscles or cultured myotubes 
(20). The induction of AMPK signaling is a potential mediator of IL-6 suppression of 
muscle mTOR signaling (20), but the mechanisms of IL-6 induction of muscle AMPK 
signaling is not well understood. 
 
Mechanical stimuli such as loading, stretch or muscle contractions can induce skeletal 
muscle hypertrophy by stimulating muscle protein synthesis (21, 22), that is important for 
the maintenance of mass and function (23). The induction of mTOR signaling through 
TSC2 dependent mechanisms plays a key role (24), but the biochemical events connecting 
the mechanical stimuli and mTOR activation still need to be determined. Physiological 
elevation of IL-6 family of cytokines during exercise or overload have a documented role 
in muscle metabolic adaptations and muscle hypertrophy (4-6). Pathological induction of 
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muscle inflammatory or stress signaling pathways has the potential to inhibit muscle 
anabolic signaling induced by mechanical stimuli. Muscle contraction-induced mTOR 
signaling is attenuated in severely cachectic ApcMin/+ mice, which is associated with 
muscle STAT3 and NF-κB signaling activation (25). AMPK activation is also sufficient to 
prevent mTOR induction by electrically-stimulated muscle contractions (26). However, the 
role of physiological or pathological IL-6/gp130 signaling in mechanical stimuli induced 
muscle protein synthesis have not been investigated. 
 
The overall goal of this dissertation is to examine gp130 regulation of anabolic 
signaling in skeletal muscle during physiological and pathological conditions. 
Specifically, we will investigate the role of gp130 signaling in basal muscle protein 
synthesis regulation during either physiological short term or pathological long term 
exposure to inflammatory cytokines. Additionally, we will investigate if physiological or 
pathological gp130 signaling regulates the induction of protein synthesis by mechanical 
stimuli. We hypothesize that physiological, short term inflammatory cytokine exposure will 
induce basal muscle protein synthesis through gp130 activation of Akt-mTOR signaling, 
while pathological, long term cytokine exposure will suppress basal muscle protein 
synthesis through gp130 activation of AMPK signaling. Furthermore, physiological or 
pathological cytokine exposure will either amplify or suppress mechanical regulation of 
muscle protein synthesis, respectively. 
 
In this study, we propose to address the following specific aims. 
Aim. 1: Determine if physiological, short term exposure of inflammatory 
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cytokines IL-6 or LIF can stimulate muscle protein synthesis through gp130 
regulation of Akt-mTOR signaling.  
Aim. 2: Determine if pathological, long term IL-6 and LIF exposure can suppress 
muscle protein synthesis through AMPK signaling.  
Aim 3: Determine if physiological or pathological administration of IL-6 or LIF 
cytokines can regulate the induction of protein synthesis by mechanical stimuli.  
 


















Figure 1.1 Working Model: IL-6 and LIF are able to activate or 
suppress skeletal muscle mTOR signaling and protein synthesis, 
which is determined by the duration of cytokine exposure. Short term 
IL-6 or LIF can induce mTOR signaling and subsequent protein 
synthesis through gp130-PI3K/Akt signaling axis under physiological 
conditions, while pathological long term IL-6 or LIF exposure can 
suppress muscle mTOR signaling and protein synthesis, which is 
dependent on gp130 and AMPK signaling. Furthermore, short term or 
long term IL-6/LIF exposure can potentiate or suppress muscle protein 










Skeletal muscle composes ~50% of total body mass, and is fundamental for basic 
functions of human bodies. Maintaining skeletal muscle mass and function is critical for 
disease prevention, mobility and quality of life, and whole-body metabolism. Increasing 
skeletal muscle mass is desired by many types of athletes to enhance athletic performance, 
increase body size, and improve aesthetic appearance. More importantly, reduction in 
skeletal muscle mass occurs in aging people and patients of many chronic diseases. 
Maintenance of skeletal muscle mass contributes significantly to disease prevention and is 
associated with improved quality of life. Skeletal muscle mass and muscle fiber size are 
sensitive to various physiological and pathological conditions. An increase in muscle mass 
and fiber size, or muscle growth or hypertrophy, occurs during development and in 
response to mechanical overload or anabolic hormonal stimulation. While a decrease in 
muscle mass and fiber size, or muscle atrophy, results from aging, starvation, cancer, 
diabetes, bed rest, loss of neural input or catabolic hormonal stimulation. As skeletal muscle 
consists of the largest pool of proteins in the whole organism, the regulation of muscle mass 
and fiber size is largely determined by protein turnover, which is the balance between 
protein synthesis and degradation within the muscle fibers. An increase in skeletal muscle 
mass can occur when protein synthesis exceeds protein degradation.  Hyper-activation of 
protein degradation pathways, on the other hand, causes muscle atrophy involves the 
shrinkage of myofibers due to a net loss of proteins, organelles and cytoplasm, which 
occurs in many pathological conditions. In addition to protein turnover regulation, skeletal 
muscle mass may also be affected by cell or nuclear turnover, i.e. addition of new 
myonuclei, due to fusion of satellite cells, or loss of myonuclei, due to nuclear apoptosis. 
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Increases in the number of individual myofibers within a muscle, termed hyperplasia, is 
another potential mechanism contributing to muscle growth. 
 
Mechanical stimuli is a potent stimulator of skeletal muscle mass. Increase in 
mechanical loading results in muscle hypertrophy and a decrease in mechanical loading 
results in muscle atrophy (27). It has also been demonstrated that mechanical stimuli 
induced changes in muscle mass are highly associated with changes in the rate of protein 
synthesis. Muscle hypertrophy induced by increased mechanical is accompanied by an 
increase in the rate of protein synthesis, while muscle atrophy induced by a decrease in 
mechanical stimuli is accompanied by a decrease in the rate of protein synthesis (28-30). 
Thus, muscle protein synthesis regulation appears to play a fundamental role in the 
mechanical regulation of muscle mass. However, the molecular mechanisms through which 
mechanical stimuli regulate changes in the rate of protein synthesis, and ultimately muscle 
mass, have only been vaguely defined. 
 
Cachexia, derived from the Greek word ‘kachexia’ (kakos = bad; hexis = state), is a 
typical muscle wasting disease. It is defined as a malnourished, wasting state observed 
during the later stages of many chronic diseases including cancer, AIDS, COPD (31). The 
typical symptoms of cachexia includes an ongoing loss of skeletal muscle mass, a loss of 
fat mass, leading to progressive functional impairment (32). Cachexia is prevalent in many 
cancer types, with the highest rates found for cancers of the lung and upper gastrointestinal 
tract, where over half of all patients are affected at diagnosis (32, 33). Cachexia is 
responsible for the death of about 20% of cancer patients, which is 2 million worldwide 
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every year (34). Loss of skeletal muscle mass, or skeletal muscle atrophy, is common 
symptom in all cachexia patients (32). Functional consequences of muscle mass loss in 
cachexia include exercise intolerance, reduced muscle function, reduced exercise capacity, 
and physical inactivity, all of which impact adversely on a patient's quality of life, level of 
independence and survival (35). However, no therapeutic interventions are established to 
successfully treat muscle wasting in cachexia. Mechanical stimuli have been demonstrated 
to stimulate muscle mass increase. Therefore, it represents a promising intervention that 
has the potential to attenuate or even reverse the process of muscle wasting. As such, a 
better understanding of the mechanisms contributing to muscle mass regulation by 
mechanical stimuli and cachexia is critical for clinical applications of mechanical stimuli 
on muscle mass preservation of cachexia patients. 
 
gp130 is a ubiquitously expressed transmembrane receptor protein, which mediate 
signaling transduction of IL-6 family of cytokines. Interestingly, the gp130 ligands and 
downstream signaling pathways are involved in both muscle hypertrophy response by 
mechanical stimuli and atrophic response in cachexia. IL-6 cytokine family has pleiotropic 
functions in different tissues and organs, including skeletal muscles. Circulation level and 
IL-6 cytokine family are tightly associated with both muscle hypertrophy and atrophy. 
Several members of IL-6 cytokine family, including IL-6 and LIF, are produced by the 
working skeletal muscle by mechanical stimuli and act on to myofibers or other kinds of 
muscle cells, eg. satellite cells and myoblasts, through autocrine/paracrine manner (7, 8). 
IL-6 signaling is associated with stimulation of hypertrophic muscle growth and 
myogenesis through regulation of the proliferation, differentiation and fusion of muscle 
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stem cells (36, 37). Paradoxically, deleterious actions for IL-6 family of cytokines have 
also been proposed, such as promotion of atrophy and muscle wasting in cachexia (9).  
Elevation of IL-6 and its downstream signaling STAT3, are directly associated with muscle 
mass loss in both cachexia patients and animal models (38, 39). However, there is no clear 
explanation of the apparently paradoxical role of gp130 ligands and gp130 dependent 
signaling pathways in muscle mass regulation. 
 
Changes in muscle protein synthesis play a fundamental role in the regulation of 
muscle mass by mechanical stimuli and cachexia. gp130 cytokines and gp130 downstream 
pathways have a documented role in muscle hypertrophy induced by mechanical stimuli 
and muscle atrophy in cachexia, but its role in mechanical stimuli and cachexia regulation 
in muscle protein synthesis still need to be determined. This review will focus on 4 major 
topics: 1) Muscle protein synthesis regulation, 2) Mechanical stimuli induction of muscle 
protein synthesis and hypertrophy, 3) Muscle protein synthesis regulation in cachexia, 4) 
Role of gp130 dependent signaling in muscle mass regulation. 
 
2.2 Muscle protein synthesis regulation 
Regulation of Protein Translation  
The efficiency of translation process in ribosomes is the key determinant of protein 
synthesis. mRNA translation process occurs through a series of molecular events that can 
be functionally divided into three phases: initiation, elongation, and termination (40). The 
majority of mechanisms known to regulate mRNA translation and protein synthesis involve 
the initiation phase, with many fewer occurring at elongation or termination (40). Therefore, 





The first steps in translation initiation is the formation of a ternary complex consisting 
of eukaryotic initiation factor eIF-2, GTP, and initiator methionyl-tRNA (Met- tRNAi) (40). 
The ternary complex then associates with other initiation factors to form a multifactor 
complex that subsequently binds to the 40S ribosomal subunit to form the 43S preinitiation 
complex. The next step is the binding of mRNA to the 43S preinitiation complex. eIF4E 
binds to the m7GTP cap structure at the 5’-end of the mRNA, and the eIF4E•mRNA 
complex then interacts with eIF4G in association with eIF4A to form the eIF4F•mRNA 
complex. eIF4B modulates the assembly of eIF4A into the eIF4F complex (41). eIF4B also 
enhances the RNA helicase activity of eIF4A (42). As part of the eIF4F complex, eIF4G 
subsequently interacts with eIF3 that is associated with the 43S pre-initiation complex to 
form the 48S preinitiation complex. The 48S pre-initiation complex then scans along the 
5’-untranslated region (5’-UTR) of the mRNA, and stops at the AUG start codon. The GTP 
bound to eIF2 is then hydrolyzed and the eIF2•GDP complex along with most of the other 
initiation factors are released from the 40S ribosomal subunit. The 60S ribosomal subunit 
then joins, and the resulting 80S initiation complex is competent to proceed with peptide 
chain elongation. The GDP bound to eIF2 must then be exchanged for GTP to permit 
formation of the ternary complex and efficient recycling of eIF2, because the affinity of 
Met-tRNAi for the eIF2•GDP complex is significantly lower compared to its affinity for 





Regulatory Points of Protein Translation: There are three well-characterized 
mechanisms for regulating translation initiation, which involve phosphorylation of eIF4B 
protein complex (eIF2α and eIF2Bε subunits), release of 4E-BP1 from eIF4E and release 
of programmed cell death 4 (PDCD4) from eIF4A, which modulate cap-dependent mRNA 
translation. eIF2α phosphorylation on S51 indirectly inhibits translation initiation. The 
phosphorylated eIF2α competitively binds to eIF2B and inhibit its GEF activity, which 
results in accumulation of the eIF2•GDP complex that has limited affinity for Met-tRNAi, 
and subsequent decrease in the amount of the active Met-tRNAi•eIF2•GTP complex 
available to participate in assembly of the 43S pre-initiation complex (43). eIF2B GEF 
activity is suppressed in response to phosphorylation of the catalytic eIF2Bε subunit. 
Amino acid deprivation results in phosphorylation of eIF2Bε on S525 and repression of 
eIF2B GEF activity (44). Phosphorylation of eIF2Bε on S540 by glycogen synthase kinase 
3 (GSK-3) also leads to inhibition of eIF2B GEF activity (45). 
 
Assemble of eIF4A, eIF4E, and eIF4G into the active eIF4F complex is the key process 
of cap-dependent protein translation. The binding of eIF4E to eIF4G is predominantly 
regulated by a family of eIF4E binding proteins (4E-BP) that bind to the same domain on 
eIF4E as does eIF4G. Thus, the binding of 4E-BP to eIF4E prevents its association with 
eIF4G, and therefore attenuates cap-dependent binding of mRNA to the 43S preinitiation 
complex. The association of 4E-BPs with eIF4E is controlled by phosphorylation: 
hyperphosphorylated forms of the 4EBP1 at T37/46 and S65 sites do not bind to eIF4E, 
while none-phosphorylated or hypophosphorylated forms of 4EBP1 have high affinity to 
eIF4E. Therefore, 4E-BP1 phosphorylation leads to the dissociation of 4E-BP1 from eIF4E, 
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which allows eIF4G to bind to eIF4E and promotes an increase in cap-dependent 
translation (46). Similar to the function of 4E-BP1 to inhibit assembly of the eIF4E•eIF4G 
complex, PDCD4 interacts with eIF4A and prevents its association with eIF4G (47). 
Phosphorylation of PDCD4 permits eIF4E•eIF4G complex. Finally, eIF4B 
phosphorylation leads to the assembly of eIF4A into the eIF4F complex. The 
phosphorylation of 4EBP1, PDCD4 and eIF4B are tightly regulated by mTOR-p70S6K 
signaling pathway, which will be discussed later. 
 
mTOR signaling pathway 
mTOR: In 1965 it was discovered that a microorganism (Streptomyces hygroscopicus) 
in the soil of Rapa Nui (Easter Island) produced a compound that possessed antibiotic 
properties. This compound was subsequently given the name rapamycin (48). Subsequent 
research showed rapamycin was able to inhibit the growth of a variety of eukaryotic 
organisms (49). It was later determined that the growth regulatory effects of rapamycin 
were a result of its ability to inhibit signaling by two closely related serine / threonine 
kinases in yeast, which were designated the target of rapamycin (mTOR) (50). In vivo, 
rapamycin forms a complex with the immunophilin FKBP12, and this complex has been 
shown to bind to mTOR in a region termed the FRB domain. To date, numerous studies 
have shown that mTOR plays a critical role in regulating protein synthesis and cell 
growth/hypertrophy in skeletal muscle (14, 51-54). mTOR is a serine/threonine kinase of 
the phosphatidylinositol kinase-related kinase family. mTOR signaling pathway has a wide 
range of functions including regulation of protein synthesis, cell proliferation, apoptosis, 




It has been well established that mTOR is the central component of a signaling network 
that controls cellular growth and a large number of studies focus on understanding how 
mTOR signaling is regulated. In mammalian cells, mTOR protein functions in two distinct 
multi-protein complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), 
only mTORC1 is inhibited by the FKBP12-rapamycin complex (13). mTORC1 is a protein 
complex comprised of mTOR, regulatory associated protein of mTOR (Raptor), and G 
protein β-subunit-like (Gβl/also known as mLST8). The primary role of mTORC1 is 
regulating protein synthesis, this protein complex also mediates autophagy, lysosome 
biogenesis, and lipid biosynthesis, thereby broadly integrating and regulating cellular 
energy metabolism (13). The mTORC2 complex is comprised of mTOR, rapamycin-
insensitive companion of mTOR (Rictor), stress-activated-protein-kinase-interacting 
protein 1 (SIN1), and Gβl. The role of mTOR complex 2 (mTORC2) is less well understood 
but includes effects on cytoskeletal organization as well as growth, differentiation, and 
survival (13).  Because of the major role of mTORC1 in mTOR regulation of muscle 
protein synthesis, we will focus on mTORC1 effectors and regulation in this review. 
 
mTOR downstream effectors: mTORC1 activation leads to increased protein synthesis 
increase through different mechanisms, which include both protein translation efficiency 
and capacity increase. Two of the most studied mTORC1 targets are the eukaryotic 
initiation factor 4E binding protein (4E-BP1) and the ribosomal S6 kinase (p70S6K1), 
which play an important role in protein translation initiation and elongation (14). Protein 
translation initiation factor, eIF4E, which binds to the 7-methyl-guanosine ‘cap’ (on the 5’-
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end of all cellular mRNAs), is inhibited from binding to eIF4G by 4E-BP1, thus 
suppressing cap-dependent translation initiation. 4E-BP1 phosphorylation by mTORC1 
results in the dissociation of 4E-BP1 from eIF4E, which allows eIF4G to bind to eIF4E and 
promotes an increase in cap-dependent translation (46). The phosphorylation of p70S6K 
on Thr 389 by mTORC1 allows p70S6K phosphorylates several downstream targets 
involved in protein translation initiation, including two proteins that modulate cap-
dependent mRNA translation, eIF4B and PDCD4, which are key modulators of cap-
dependent mRNA translation.  Another downstream phosphorylation target of p70S6K is 
S6 ribosomal protein (S6RP) phosphorylation. S6 phosphorylation selectively increases the 
translation of mRNA transcripts containing a tract of pyrimidine (TOP) motif. These TOP-
containing mRNAs often code for ribosomal proteins and other translational regulators, 
therefore S6RP phosphorylation by p70S6K leads to the increased translational capacity 
(55). p70S6K also increases eEF2 activity through the phosphorylation and inhibition of 
eEF2K, a upstream suppressor of eEF2 (55).  
 
Upstream regulator of mTOR 
TSC1/TSC2: Signaling through mTOR is modulated through changes in activation of 
multiple upstream pathways, many of which converge on the tuberous sclerosis complex 
(TSC) proteins TSC1 and TSC2 (56, 57). Together, TSC1 and TSC2 function to promote 
GTP hydrolysis by the small GTPase referred to as Ras homolog enriched in brain (Rheb). 
When it is associated with GTP, but not GDP, Rheb can activate mTORC1. By stimulating 
the GTPase activity of Rheb, the TSC complex converts Rheb from a GTP-bound to a 
GDP-bound form, thereby inhibiting mTORC1 activity (57). The GTPase-activating 
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function of the TSC complex is repressed through phosphorylation of TSC2 by Akt and 
ERK, and activated through phosphorylation by AMPK (57).  
 
IGF-1/PI3K/Akt: The most well-defined pathway regulating mTORC1 activity in 
skeletal muscle is the IGF-1/insulin pathway (54). Binding of the growth factor IGF-1 
induces a conformational change in the IGF-1 receptor tyrosine kinase, resulting in its 
trans-phosphorylation and the subsequent phosphorylation of insulin receptor substrate 1 
(IRS-1). In turn, this results in the activation of PI3K. Activation of PI3K results in the 
production of phosphatidylinositol-3,4,5-trisphosphate, which provides a membrane-
binding site for the serine/threonine kinase Akt. After translocating to cell membrane, Akt 
is phosphorylated on threonine 308 site and subsequently activated. Activated Akt then 
stimulates mTOR signaling through regulation of the TSC1/2 complex. Akt directly 
phosphorylates TSC2 on multiple residues, including Ser939 and Thr1462 (15).  This 
phosphorylation of TSC2 by Akt/PKB inhibits its GAP activity, allowing Rheb to 
accumulate in its active GTP-bound form and stimulate mTOR signaling (15). This leads 
to the well-established growth factor associated signaling cascade through PI3K-Akt/PKB-
TSC1/2-Rheb-mTOR seen in muscle as well as other cell types. 
 
Amino Acids: In addition to growth factors, mTOR can also be regulated by amino 
acids availability (58-61). Among the amino acids, changes in leucine levels alone are 
sufficient to regulate the phosphorylation state and activity of the mTOR pathway (60). 
Several studies have shown that ingestion of essential amino acids (specifically leucine) 
leads to increased protein synthesis in skeletal muscle primarily through activation of 
18 
 
mTOR signaling (62-64). However, precise mechanisms of amino acids regulation on 
mTOR signaling remains poorly understood. It has been demonstrated that hVps34, a class 
III PI3K, is implicated in the amino acid-induced activation of mTOR signaling (65), which 
is independent of Akt/PKB-TSC-Rheb pathway (66, 67), but more work is still required to 
determine the detailed mechanisms. 
 
Mechanical Stimulation: One of the important variables contributing to the 
hypertrophy and growth response in skeletal muscle is the application of mechanical 
stimuli, from resistance exercise, high-force contraction or overload. Induction of mTOR 
signaling was critical for mechanical overload-induced skeletal muscle hypertrophy (14). 
Many studies have further confirmed the association between mechanical loading and 
activation of mTOR signaling in mammalian muscle. While the effect of resistance 
exercise/contraction on muscle mass has long been recognized, the mechanisms underlying 
the link between mechanical stimuli and muscle protein synthesis increase is not fully 
understood. The potential biochemical events that link the mechanical loading of a 
muscle/muscle fiber to mTOR signaling will be discussed in section 3. 
 
Energy Status and AMPK: AMPK is an intracellular sensor of energy stress that 
negatively regulates muscle protein synthesis in response to energy deficiency or catabolic 
cytokines in cachexia. AMPK is a protein complex contains three subunits: α, β and γ. The 
phosphorylation of AMPKα subunit at T172 increases activity of AMPK protein complex. 
Decreased intracellular ATP/ADP ratio and AMP build up, which is a marker of energy 
deficiency, results in a conformational change of AMPK γ subunit, which allows the 
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phosphorylation of AMPKα subunit at Thr172 by AMPK upstream activator, LKB1. 
Phosphorylation of AMPKα results in the activation of AMPK complex activity. AMPK is 
also pathologically activated in muscle catabolic diseases, including cachexia (18, 19).  
Activated AMPK phosphorylates TSC2 on Thr1227 and Ser1345 residues (56). 
Phosphorylation of TSC2 on Ser1387 by AMPK also results in further phosphorylation of 
TSC2 by GSK-3 on multiple residues (56). TSC2 phsophorylation by AMPK and GSK-3 
enhances its inhibitory function on mTOR activity (56). AMPK can also directly 
phosphorylate the Raptor protein on two serine residues (Ser722/Ser792), which is required 
to inhibit mTOR activity through cellular energy stress-induced AMPK activation (17). 
Consistent with these observations, many in vivo and in vitro experiments demonstrated 
that AMPK activation results in decreased protein synthesis and a repression of mTOR-
mediated signaling in skeletal muscle (68-70). 
 
REDD1/2: REgulated in Development and DNA damage responses 1 (REDD1) and 
REDD2 were firstly identified as negative regulators of the Drosophila TOR pathway (71). 
REDD1 is ubiquitously expressed in all cell types while expression of REDD2 is 
significantly enriched in human and mouse skeletal muscle. REDD1 and REDD2 can 
inhibit mTOR kinase activity downstream of Akt/PKB but upstream of TSC2 (72-75). The 
upregulation of REDD1/2 is a potential mediator of mTOR signaling and protein synthesis 
inhibition in many muscle catabolic conditions, including hindlimb unloading (76), 
dexamethasone administration and alcohol intoxication (75, 77), while the rapid 
degradation of REDD1 in muscle was associated with enhanced mTOR signaling (78). 
These observations suggest REDD1 and REDD2 are stress responsive negative regulators 
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of mTOR signaling and implicate skeletal muscle size regulation. 
 
2.3 Mechanical stimuli induction of muscle hypertrophy 
Mechanical stimuli can initiate muscle hypertrophy through a multifaceted series of 
events contributing to mechanical stimuli induced muscle hypertrophy. Induction of protein 
translation and synthesis drives protein accretion, while satellite cells activation and 
incorporation of satellite cells facilitates the addition of newly formed myofibrils to the 
contractile machinery. The molecular mechanisms converting the mechanical stimulus into 
intracellular biochemical responses are known as mechanotransduction. Work by Bodine 
et al. firstly established that mechanical overload-induced signaling through mTOR was 
necessary for skeletal muscle hypertrophy (79). Since then, many studies have confirmed 
the association between mechanical loading and activation of mTOR signaling and 
subsequent protein synthesis induction in mammalian muscle, although the 
mechanotransduction signaling pathways inducing muscle mTOR still remain poorly 
understood. In this section, we will 1) describe the research models of mechanical stimuli 
induced muscle hypertrophy; 2) summarize our current knowledge of the potential 
mechanisms involved in the mechanical activation of mTOR signaling and protein 
synthesis; 3) review other mechanisms contributing muscle hypertrophy by mechanical 
stimuli.  
 
Research models of muscle mass regulation by mechanical stimuli 
In vitro model for stretch-induced hypertrophy of skeletal muscle cells was firstly 
established in 1979 (80), Their models included both static stretch and stretch oscillations 
on embryonic chicken skeletal myotubes, and resulted in several biomechanical changes 
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related to muscle hypertrophy, including amino acid accumulation, increased protein 
synthesis, total protein level and myosin heavy chain level. Since then, a large variety of 
muscle cell stretch models have been developed, which differs in direction (radial stretch 
or one-axial stretch), type (cyclic stretch or chronic constant stretch), frequency and 
duration. Many of them have been demonstrated to induce anabolic signaling pathways, 
protein accumulation or hypertrophy in cultured muscle cells (81, 82). However, a widely 
accepted in vitro stretch model has not been fully established. It is difficult to compare 
results from different research because the variability in stretch parameters. In fact, the 
effect of cyclic stretch on protein synthesis in cultured myotubes can be influenced by 
stretch type, duration and frequency (83). It was also reported cyclic stretch may also have 
the potential to decrease myotube protein synthesis, despite the activation of anabolic 
signaling in L6 cells (84). Recently, another in vitro mechanical stimuli system is developed, 
in which mouse C2C12 myotubes underwent electric pulse stimulation to induce 
spontaneous contractions, and mimic the electric stimulation induced muscle concentric 
contraction (85). But its effect on myotube hypertrophic response, including protein 
synthesis induction, still needs to be determined. 
 
To complement the in vivo studies, several labs have employed both in vivo animal 
models and ex vivo tissue models to evaluate the contribution of mechanical stimuli on 
protein synthesis. Carson et al. applied passive stretch on anterior latissimus dorsi muscle 
of quail by attaching weigh onto their upper hindlimbs, which has been demonstrated to 
induce satellite cell activation, myofiber growth, myosin expression and muscle 
hypertrophy in 30 days (86-88). Because of their clear genetic background and feasibility 
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to conduct genetic manipulations, mouse and rat are more widely used in mechanistic 
investigations of mechanical signaling pathways. A widely-used model of mechanical 
stimuli induced muscle hypertrophy in adult mice or rats is compensatory hypertrophy 
induced by ablation of synergist muscles: for example, hypertrophy of the plantaris or 
soleus muscle after removal of the gastrocnemius, or hypertrophy of the extensor digitorum 
longus after removal of the tibialis anterior muscle. This model of acute functional overload 
causes induction of muscle protein synthesis, immediate satellite cell proliferation and 
fusion to myofibers (16, 89). A similarly dramatic increase in mechanical load may be 
induced in human skeletal muscle by high-intensity eccentric contractions, which also 
cause activation of muscle protein synthesis, proliferation of satellite cells and, when 
repeated, are known to induce muscle hypertrophy (90). Muscle concentric contraction 
induced by low frequency electrical stimulation also demonstrated its ability to induce 
mTOR signaling in mouse muscle (25). More recently, Hornberger et al. (52) used an ex 
vivo system to test the contribution of mechanical strain oscillations on the regulation of 
protein synthesis in mammalian muscle. Mouse extensor digitorum longus (EDL) muscles 
were incubated in an organ bath and passively stretched 15% of resting length for up to 90 
min. The results of these experiments found that passive stretch was sufficient to induce 
increases in protein synthesis. 
 
Mechanical Stimuli induction of Muscle mTOR signaling and Protein Synthesis 
Due to the importance of protein synthesis exceeding breakdown over an extended 
period of time, the degree of muscle hypertrophic response by mechanical stimuli is 
strongly associated with the phosphorylation of p70S6K, a major controller of protein 
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translation machinery (90). Until now, mTOR (or more specificly, mTORC1) is the only 
molecular pathway that has repeatedly been identified to be necessary for growth of 
skeletal muscle induced by various mechanically stimuli. However, the molecular events 
connecting mechanical stimuli to mTOR activation is poorly understood. Numerous 
investigations have been aimed at defining how mechanical stimuli activate mTOR 
signaling. 
 
PI3K/Akt signaling: The most widely discussed model is that mechanical stimuli 
activate mTOR through a mechanism involving the IGF-1 and the PI3K-Akt-mTOR 
signaling axis. Resistant exercise can induce muscle expression of growth factors which 
can stimulate PI3K/Akt signaling, including insulin, IGF, MGF (91, 92). It has been 
demonstrated that mTOR is liable of being activated by Akt dependent mechanisms in 
synergist ablation induced hypertrophic muscles (79). Many studies carried out in humans 
and animals also observed Akt activation under acute contractile stimuli (93-96). However, 
exercise can also induce muscle mTOR/p70S6K signaling in the absence of Akt activation 
(97-100). It is possible that different contraction patterns are capable of activating Akt in a 
distinct manner, although the mechanisms are still not fully understood. Intermittent stretch 
induced signaling through mTOR/p70S6K was not disrupted in the presence of PI3K 
inhibitor wortmannin (101) or in muscles from Akt1-/- mice (52), suggesting the presence 
of alternative pathways to activate mTOR signaling in response to acute contraction. It has 
been demonstrated that at least acute activation of muscle mTOR signaling can be mediated 
through Akt independent mechanisms (16). In conclusion, Akt contributes to acute 
activation of mTOR/p70S6K by certain types of mechanical stimuli, and growth factors 
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leading to PI3K/Akt/mTOR activation seem to be part of a late component of protein 
synthesis activation in chronic muscle hypertrophy induced by exercise training. 
 
Amino Acids: Amino acids have been implicated in the regulation of mTORC1 
signaling through PI3K/PKB independent mechanisms. Mechanical stimuli have been 
shown to induce an increase in amino acid uptake and hVps34 signaling activation (102, 
103), which suggest amino acids may contribute to PI3K/PKB-independent mTOR 
activation mechanism in response to mechanical stimuli. However, it has also been reported 
that eccentric contractions induced mTOR activation precedes the increase in intracellular 
amino acids (103). Ex vivo stretch of isolated muscle can also activate mTOR the absence 
of exogenous amino acids (101). Thus, although amino acids signaling can contribute to 
mechnical activation of mTOR, mechanical stimuli appear to activate mTOR signaling via 
a mechanism that is distinct from amino acids. 
 
ERK1/2: Extracellular signal-Regulated Kinases 1/2 (ERK1/2), act in a signaling 
cascade that regulates various cellular processes such as proliferation, differentiation, and 
cell cycle progression in response to a variety of extracellular signals, including mechanical 
stimuli. Exercise caused a rapid and sustained activation of the MEK1/2-ERK1/2-p90RSK 
pathway in skeletal muscles, resulting in increased phosphorylation of downstream targets 
including eIF4E and the RPS6 (104). Another study showed MEK/ERK-dependent 
pathway was activated at the early stage of overload (105). ERK1/2 can contribute to 
induction of muscle mTOR signaling and protein synthesis through the phosphorylation of 
TSC2 at S464 and subsequent suppression of GTPase activity of TSC1/2 complex, which 
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is independent of Akt (105). However, ERK1/2 inhibitor did not influence the stretch 
induction of p70S6K phosphorylation in cultured myotubes (83), which suggest ERK1/2 
signaling activation is not the only mechanism mediating mTOR induction in some 
mechanical stimuli models. At least, activation of ERK1/2 is contributes to acute induction 
of muscle mTOR signaling by mechanical stimuli. 
 
Phosphatidic acid: Phosphatidic acid (PA) is a well-known lipid based second 
messenger which plays a role in several signaling systems, whose activation influences 
mitogenesis, secretory processes and cytoskeleton reorganization. PA activation depends 
on phospholipase D (PLD) enzyme activity, which hydrolyses phosphatidilcholine in PA 
and choline (106). Once synthesized, PA binds to the FRB domain of mTOR protein, which 
results in increased mTOR kinase activity and p70S6K phosphorylation (107). PA also 
competes with the FKBP12-rapamycin complex for binding to the FRB domain (107, 108). 
Hornberger et al. reported ex vivo stretch of mouse muscles induced PA accumulation and 
p70S6K phosphorylation, while treating muscles with a PLD inhibitor neutralized the 
stretching effects over p70S6K in a dose dependent manner (101). Incubating C2C12 
myoblasts with exogenous PA is sufficient to induce a rapid induction of mTOR signaling 
(101). These results clearly demonstrate that mechanical stimulation acutely activates 
mTOR pathway through increments in intracellular concentration of PA. Although PA 
increment also activates PI3K in cultured fibroblast cells (109), mechanical stimulation of 
mTOR does not seem to be dependent on PI3K-Akt signaling activation (52, 101). 
However, the precise mechanism underlying muscle contraction induced PA increments is 




Other Signaling pathways contributing mechanical stimuli induced muscle hypertrophy 
Satellite cell activation and Myogenesis: Skeletal muscle satellite cells are quiescent 
cells located adjacent to muscle fibers and beneath the fiber basal lamina, which can be 
induced to divide during conditions of muscle damage or increased activation. Subsequent 
fusion with an existing myofiber results in the addition of a myonucleus to the fiber 
syncytium. The proposed role of the satellite cells in muscle hypertrophy revolves around 
the concept of a myonuclear domain—a theoretical volume of cytoplasm associated with a 
single myonucleus—and each myofiber being composed of many myonuclear domains 
(110). Cytokines, such as IL-4 (111) and IL-6 (36) have been implicated in satellite cell 
proliferation. However, the role of satellite cells in hypertrophy of adult skeletal muscle is 
still under debate (112). For example, in satellite cell depletion experimental models, 
overload induced skeletal muscle fiber hypertrophy is observed without obligatory satellite 
cell incorporation, whereas regeneration from acute muscle injury is impaired, suggesting 
that the role of satellite cells is markedly different between the two muscle growth 
paradigms (113). However, synegist ablation induced functional overload produces supra-
physiological gains in muscle size in a short time frame, and may not adequately represent 
human adaptation (114). 
 
SRF signaling pathway: Serum response factor (SRF) is a transcriptional factors 
belonging to MADS superfamily. SRF binds to the serum response element (SRE) in the 
promoter region of target genes and regulates the expression of genes participating in cell 
cycle regulation, apoptosis, cell growth, and cell differentiation (115). SRF was found to 
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be required for muscle hypertrophy induced by synergist elimination. In this model, the 
effect of SRF activation by overload leads to myofiber release of IL-4 and IL-6, which act 
in a paracrine manner to induce satellite cell proliferation and fusion, respectively (8). 
Another study reported that SRF is able to activate the Akt pathway via a muscle-enriched 
microRNA, miR-486, which targets the phosphatase and tensin homolog PTEN, a negative 
regulator of PI3K–Akt signaling (116). However, the Akt phosphorylation is unchanged in 
both control and SRF deficient muscles at during the synergist ablation induced 
hypertrophic process, and future research is required to determine the role of SRF-miR-
486-PTEN-PI3K–Akt signaling axis in mechanical stimuli induced muscle hypertrophy. 
Finally, SRF is known to control the transcription of several cytoskeletal and sarcomeric 
protein genes, including α-actin, by binding to CArG box regulatory elements (117). It has 
been demonstrated that both in vivo and in vitro stretch can induce SRF protein and 
transcriptional activity, which is associated with increased α-actin transcription and muscle 
hypertrophy. 
 
2.4 Muscle Wasting in Cachexia 
Muscle atrophy in cachexia is caused by the protein turnover balance shift to the 
catabolic side, which involves increase in muscle protein breakdown and decrease in 
muscle protein synthesis. Increased protein breakdown, in particular breakdown of the 
myofibrillar proteins actin and myosin, is the most important mechanism of muscle wasting 
(118). It has been demonstrated that the ubiquitin-proteasome signaling (UPS) pathway 
plays an important role in the development of muscle wasting in cancer cachexia (119), 
and protein synthesis suppression is another important contributor (120, 121).  In this 
28 
 
section, we will go over the current research models of cachexia, major signaling pathways 
involved in muscle wasting in cachexia. Because protein synthesis is the major outcome of 
our proposed study, this section will focus of mechanisms involved in the impairment of 
muscle protein synthesis associated with cachexia. 
 
Research models of cachexia  
Because of the difficulty to recruit patients and technical limitations to control 
experiment conditions and variables in human, most mechanistic investigations of cachexia 
are conducted in cell culture models and animal models. A highly simplified cachexia 
model is cell culture, where C2C12 myotubes (from mouse), L3 myotubes (from rat) or 
primary cultured myotubes are exposed to conditioned media of cancer cells or specific 
molecules which have the potential to mediate muscle wasting in cachexia. The cell culture 
model allows investigator easily manipulating signaling pathways, and is a strong tool to 
investigate mechanisms driving muscle protein turnover disruption in cachexia. It is also 
useful to rapidly screen compounds for their anti-cachectic activity, prior to their use in 
vivo. In terms of multicellular organisms, murine models (rats and mice) are widely used 
to reproduce clinical features of cachexia patients. Injection of cancer cell lines in 
syngeneic animals have been used to set up in vivo experimental cachexia models, 
including C-26, Walker 256, MAC16, AH-130, LLC and B16 melanoma (122). The feature 
of each of these tumor cell lines that induce cachexia is the release of humoral mediators 
either from the cancer cells or by the host, therefore mimicking the etiology of cachexia in 
humans. Injecting cancer cells derived from patients that exhibited cancer cachexia into 
immune-deficient mice is also a cachexia animal model, although these experiments are 
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not very common (123). Among these cell lines, C-26 and LLC cells are most widely used. 
C-26 tumor was originally chemically induced in BALB/c mice (124). LLC cells were 
isolated from a spontaneous tumor in a C57BL/6 mouse (by Margaret Lewis at the Wistar 
Institute in 1951). Both C-26 and LLC models are easy to manage and cancer cells can be 
maintained and expanded either in vitro with standard adherent cell culture conditions or 
in vivo by means of mouse-to-mouse transplantation. Subcutaneously injection of C26 into 
Balb/C mice or IP-injection of LLC in C57BL/6 mice can induce several typical symptoms 
of cachexia within one month, including loss of body weight (~15%), muscle mass, grip 
strength and elevation of serum inflammatory cytokines (124). Moreover, the LLC model 
is often used to model cachexia in transgenic or knockout mice since the most frequent 
background used for producing transgenic animals is the C57BL/6 strain, which is 
syngeneic to LLC cells. 
 
The major limitations of tumor cell injection models are their 'acute' cachexia 
progression, which is not the natural history of the tumor and prevent us to investigate the 
early alterations that drive the onset of cachexia. Using the genetic engineered mouse 
models, which is characterized by the spontaneous tumor growth can, partially at least, 
circumvent these drawbacks. The best characterized genetic engineered model of cachexia 
is the ApcMin/+ mouse, which was introduced by the Carson's laboratory (18, 125). The 
acronym specifies that these mice bear a heterozygous mutation in the APC gene, which is 
sufficient to determine the appearance of intestinal polyps as soon as 4 weeks after birth. 
Cachexia has an average onset 10 weeks, which makes this model suitable for intervention 
studies. At least 18 papers support the use of the model (125). Similar to C-26 model, 
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cachexia progression in ApcMin/+ mouse is highly associated with IL-6, which is a 
promising therapeutic target of cachexia (125).  
 
Important mediators of cachexia induced muscle wasting.  
Disruption of muscle protein turnover caused by hyperactivation of proteolysis and 
suppression of protein synthesis plays a key role in muscle wasting during cachexia. The 
role of protein degradation during cancer cachexia has been well established. The major 
proteolytic pathway responsible for skeletal muscle protein degradation is ubiquitin-
proteasome pathway (UPS) (126). Several inflammatory signaling pathways appear to be 
a potent mediator of cachexia-induced muscle proteolysis. Here, we will briefly review the 
mechanisms of UPS mediated proteolysis and important signaling pathways mediating 
UPS activation in cachexia. The mechanism of cachexia suppression of muscle protein 
synthesis will be detailed reviewed in next section. 
 
Induction of ubiquitin-proteasome system: In the ubiquitin-proteasome system, 
proteins are targeted for degradation by the 26S proteasome through covalent attachment 
of a chain of ubiquitin molecules. Ubiquitinated proteins are then recognized and degraded 
by the large proteolytic 26S proteasome though a highly complicated process (127). 
Different classes of enzymes, named E1, E2 and E3, are involved in protein ubiquitination. 
The ubiquitin ligase enzyme, or E3, binds the protein substrate and catalyzes the movement 
of the ubiquitin from the E2 enzyme to the substrate, which is the rate-limiting step of the 
ubiquitination process. Once the protein is ubiquitinated, it is docked to the proteasome for 
degradation. Different E2-E3 pairs function in the degradation of different proteins, and 
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the specificity of the E3s for specific groups of proteins provides exquisite selectivity to 
this degradation process. Different E2 and E3 proteins are involved in the precise regulation 
of different cellular processes. 
 
In muscles, there are two specific E3 ubiquitin ligases, atrogin-1 (also known as 
MAFbx or FBXO32) and muscle RING finger-1 (MuRF1, also known as E3 ubiquitin-
protein ligase TRIM63), which are considered the main markers of muscle atrophy because 
they are strongly upregulated in different types of muscular atrophy (127-129). MuRF1 and 
Atrogin-1 mediate ubiquitination and degradation of their specific proteins. MuRF1 is 
localized to the sarcomere, and induces muscle atrophy by directly attacking the thick 
filament of the sarcomere and causing the proteolysis of myosin proteins including 
ubiquitinate myosin heavy chain (MyHC), myosin light chain and myosin binding protein 
C. Large myofibrillar protein titin is also a potential substrate for MuRF. Identified 
substrates of atrogin-1 include MyoD (130, 131) and calcineurin (132). Atrogin-1 also 
mediates the ubiquitin degradation of eIF3-f, a protein initiation factor, which suggests that 
Atrogin-1 can result in muscle atrophy through the downregulation of protein synthesis 
(133, 134). Expression of Atrogin-1 and MuRF1 requires the FOXO family of transcription 
factors, which locates in nucleus when they are not phosphorylated (135, 136). Activation 
of Akt can in turn inhibit the transcriptional upregulation of Atrogin-1 and MuRF1 through 
phosphorylating FOXOs, and making them translocate to cytoplasm and induce expression 
of their target genes (137). 
 
TNF-α/ NF-κB and TNF-α/ p38 MAPK Signaling pathways: IL-1 and TNF-α levels 
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are elevated in the circulations of patients with cancer cachexia, contributing to negative 
nitrogen balance (138). TNF-α can induce muscle expression of genes involved in the UPS 
proteolysis pathway, and was believed to have a crucial role in the weight loss observed in 
tumour-bearing mice (139, 140). TNF-α and IL-1 are involved in two established pathways, 
the NF-κB pathway and the p38 MAPK pathway, both of which have a documented role in 
cachexia induced muscle wasting. Another TNF-α family cytokine TWEAK, induces 
MuRF1 upregulation via NF-κB, resulting in MyHC loss (141). Many studies demonstrated 
NF-κB signaling is necessary and sufficient to induce proteolysis and muscle atrophy in 
cachexia. Muscle specific activation of NF-κB signaling by the over-expression of either 
constitutively active IKKβ or a dominant inhibitory form of IκBα can directly induce 
expression of MURF1. Overexpression of IκBα could block loss of myosin in TNF-α 
treated C2C12 myotube (142). In vivo inhibition of classical NF-κB  signaling also 
significantly decreased tumor-induced muscle loss, at least in part, by inhibiting the 
upregulation of MuRF1 (143, 144). Another TNF-α downstream pathway, p38 MAPK, can 
also upregulate atrogin-1 expression in skeletal muscle via p38 MAPK-mediated C/EBPβ 
phosphorylation (145, 146).  In addition to proteolysis, NF-κB signaling also mediates 
cachexia factors induced Pax7 dysregulation, which contributes to an impaired 
regenerative capacity of myogenic cells in cachexia (147). 
 
IL-6/STAT3: Circulation level of IL-6 is upregulated in cachexia, and IL-6 levels 
correlate with weight and muscle loss in certain human cancers (38, 148-150). IL-6 for 
inducing muscle mass loss has been confirmed by many studies. The overexpression of IL-
6 in transgenic mice induced skeletal muscle atrophy (151). Administration of IL-6 to 
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C2C12 myotubes increases atrogin-1 protein expression (20). Moreover, cachexia can be 
ameliorated in mice treated with IL-6-targeted antibodies (39). IL-6 induces intracelluar 
STAT3 signaling through binding to the receptor complex consisting IL-6r and gp130. IL-
6 is also associated with AMPK and NF-κB activation indirectly.  It has been 
demonstrated IL-6-gp130-STAT3 signaling axis plays is a central regulator of in muscle 
wasting in several cachexia animal models, which will be reviewed in detail in section 2. 
 
Myostatin: Myostatin is a member of the transforming growth factor-β (TGF-β) 
superfamily that acts as a negative regulator of muscle growth (152-154). Once bounding 
to its type I [Activin Receptor II A or B (ActRIIA or B)] and type II [Activin-Like Kinase-
4 or 5 (ALK-4 or 5)] receptors, myostatin activates intracellular signaling via the 
phosphorylation and activation of the transcription factors Smad 2 and 3, which translocate 
to the nucleus and activate target genes (155). Myostatin is involved in skeletal muscle 
wasting in different catabolic conditions, including cancer (156). Inactivation of myostatin 
and other TGF-β family proteins by treatment with a soluble form of ACTRIIB (sACTRIIB) 
ablates the muscle wasting and other symptoms of cancer cachexia in LLC tumor bearing 
mice (157, 158). It has been demonstrated myotatin is a strong catabolic regulator of muscle 
protein turnover. Myostatin induces muscle wasting by activating the ubiquitin proteolytic 
system through an NF-κB-independent, FoxO1-dependent mechanism (159). Myostatin 
also negatively regulates Akt signaling, an upstream stimulator of muscle protein synthesis 
(160). 
 
Suppression of Muscle Protein Synthesis in cachexia 
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Rates of muscle protein synthesis are significantly reduced in patients with cancer 
cachexia (161) and muscle of cachectic patients is resistant anabolic stimulation (162). The 
suppression of muscle protein synthesis contributes to muscle wasting in cachexia (118), 
but the understanding of muscle protein synthesis suppression in cachexia falls behind our 
understanding of protein degradation. Due to the difficult nature of studying muscle protein 
synthesis regulation in cachexia patients, most of our mechanistic understanding have been 
delineated using mouse models. The ApcMin/+ mouse, which is characterized by slow 
progression of cachexia, shows significantly decreased rates of myofibrillar protein 
synthesis (18). The dysregulation of protein synthesis in early stage of cachexia is 
associated with suppression mTOR signaling as assessed by decreased phosphorylation of 
both 4E-BP1 and p70S6K1. However, no change in phosphorylation of Akt, mTOR, or 
AMPK is observed, suggesting that mTORC1 signaling might be regulated by another 
upstream regulator(s) (18). A further decline in the rate of myofibrillar protein synthesis, 
beyond that seen in early cachexia, occurs in advanced cachexia, suggesting mechanisms 
which regulate protein synthesis at more advanced stages may occur through mechanisms 
distinct from those in early cachexia. Interestingly, AMPK phosphorylation and AMPK 
activity increase significantly during late stages of cachexia (18). Moreover, late stage of 
cachexia manifests repressed phosphorylation of mTOR and phosphorylation of mTOR 
substrates, p70S6K and 4EBP1, show further declines compared to early cachexia, despite 
the paradoxically increased phosphorylation of the upstream mTORC1 regulator, Akt (18). 
In LLC tumor bearing mice, another sever cachexia model, muscle mTOR signaling, 
including phosphorylation of p70S6K, S6RP, 4EBP1, and protein synthesis were also 
suppressed, which is accompanied with increased AMPK phosphorylation (19). LLC 
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released factors also induce myotube protein synthesis suppression and AMPK activation, 
although Akt phosphorylation is increased (19). The apparent disconnect that occurs 
between Akt and mTOR signaling during advanced cachexia may be related to activation 
of AMPK because AMPK activation in muscle overcomes insulin-induced activation of 
mTOR with no effect on insulin-induced phosphorylation of Akt (163). The cachexia-
associated activation of AMPK could be caused by mitochondrial dysfunction. Muscle 
mitochondrial size is significantly reduced in Apcmin/+ mice which is prior to the onset of 
cachexia (164). The protein level of mitofusin 1 and 2 which promote mitochondrial fusion 
and maintain metabolic function (165, 166) are also decreased during early stage of 
cachexia (18, 164). The protein expression of Fis1, which promotes fragmenting of 
mitochondria (167), is increased during late stage of cachexia, which coincides with AMPK 
activation (164). These results suggest that mitochondrial dysfunction may results in 
energy deficiency and further AMPK signaling activation during later stages of cachexia 
leading to further reductions in mTOR signaling and the rates of protein synthesis. 
 
Down-regulation of insulin/IGF-1 signaling is another potential mechanism 
underlying the muscle protein synthesis suppression in cachexia. IGF-1 mRNA expression 
is significantly reduced upon the initiation of cachexia (18). IGF-1 administration can 
attenuate loss of body weight in rats inoculated with AH-130 cancer cells (168). However, 
serum IGF-1 does not change in cachexia patients (169). A possible explanation for this 
dichotomy may be that the cachexia-induced decrease in muscle IGF-1 mRNA expression 
in animal models results in reduced intramuscular concentrations of the hormone, leading 
to repressed autocrine/paracrine function, while circulating IGF-1 is not affected. It is also 
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possible that wasting muscles in cachexia have disrupted Akt-mTORC1 signaling axis and 
reduced sensitivity to insulin/IGF-1. There is evidence of skeletal muscle insulin resistance 
in human cancer patients (170) and increased plasma insulin concentrations in cachexia 
patients (169). Furthermore, plasma insulin levels as well as the phosphorylation of Akt are 
significantly cachectic mice despite reduced protein synthesis (18, 171). As mentioned 
above, this dissociation may be a consequence of chronic AMPK signaling activation. 
 
Muscle anabolic Resistance in cachexia 
In additional to suppression of basal protein synthesis in muscle, cachexia can also 
prevent muscle protein synthesis induction by anabolic stimuli, which is known as anabolic 
resistance (162). Some evidence suggests that the muscle anabolic resistance in cachexia 
is associated with induction of inflammatory signaling pathways and muscle proteolysis. 
For example, TNF-α can inactivate PI3K/Akt signaling pathway (172) and attenuates 
insulin-stimulated protein synthesis (173). TNF-α leads to serine phosphorylation of IRS-
1, inhibiting its recruitment to the insulin/IGF-1 receptor. TNF-α can also impinge on the 
insulin/IGF-1 signaling via direct interaction between the IKK complexes and IRS-1. TNF-
α induced activation of JNK may also play a role, because TNF-α does not downregulation 
of the IGF-1-dependent signaling in the presence of a JNK inhibitor (174). TNF-α 
downstream NF-κB signaling activation is associated with anabolic resistance to amino 
acids and resistance exercise in muscle wasting conditions, such as sarcopenia or sepsis 
(175). Muscle contraction-induced mTOR signaling is attenuated in severely cachectic 
ApcMin/+ mice (25). Interestingly, administration of PDTC, a NF-κB and STAT3 inhibitor, 
to these cachectic mice can rescue contraction-induced mTOR activation (25). These 
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results suggest cachexia induced inflammatory environment can interact with and impinge 
anabolic signaling pathways leading to protein synthesis in skeletal muscle. 
 
Activation of UPS dependent proteolysis in wasting muscles induced cachexia also 
has strong potential to block protein synthesis induction by anabolic stimuli. Many 
signaling molecules contributing to muscle protein synthesis induction by anabolic stimuli 
can be targeted by E3 ubiquitin ligase. For example, Atrogin-1, whose expression is 
strongly induced by cachexia, can mediate the ubiquitinization of protein translation factor 
eIF3f (134), which block the stimulation of protein synthesis by mTOR/p70S6K signaling 
pathway (176, 177). Other E3 ligases include Fbx-containing protein Fbxo40 and cullin-
RING E3 ubiquitin ligase 7 (CRL7), can ubiquitinize and degrade IRS1, preventing 
signaling transduction from IGF-1 to Akt (178, 179). The UPS-dependent IRS1 
degradation is a negative feedback mechanism preventing hyperactivation of Akt signaling 
under physiological condition, but its role in cachexia induced muscle anabolic resistance 
still needs to be determined. 
 
2.5 Role of gp130 signaling in muscle mass regulation 
gp130 signaling is involved in both muscle hypertrophy and atrophy. gp130 cytokines, 
IL-6 and LIF, are known as ‘myokines’, which means they are produced and released from 
skeletal muscles during exercise and are involved muscle adaptation to exercise in 
autocrine/paracrine manner. Both IL-6 and LIF have demonstrated their role in overload 
induced muscle hypertrophy. Further research showed that IL-6 and LIF can stimulate 
satellite cell proliferation which contribute to muscle hypertrophy. However, chronic 
elevation of gp130 cytokines and/or activation of gp130 downstream signaling pathways 
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in skeletal muscles, are key mediators of muscle wasting in cancer cachexia. In this section, 
we will review (1) major gp130 ligands and gp130 downstream signaling pathways, (2) 
role of gp130 cytokines and downstream signaling pathways in muscle hypertrophy and 
myogenesis and (3) role of gp130 cytokines and downstream signaling pathways in muscle 
wasting. 
 
gp130 ligands and downstream pathways. 
Glycoprotein 130 kDa (gp130) is a ubiquitously expressed trans-membrane protein. It 
serves as the signal transduction unit of a family of cytokines: the IL-6 family. The 
members of this family are IL-6, IL-11, IL-27, IL-30, IL-31, oncostatin M (OSM), 
leukemia inhibitory factor (LIF), cardiotrophin-1 (CT-1), cardiotrophin-like cytokine (CLC) 
and ciliary neurotrophic factor (CNTF) (2). These cytokines utilize type I cytokine 
receptors which consist of a ligand binding α-receptor subunit and a signal transducing β-
receptor subunit containing a cytoplasmic signaling domain. Each gp130 cytokine is 
characterized by a certain profile of receptor recruitment but all cases involve at least one 
molecule of gp130. IL-6, IL-11 and CNTF first bind specifically to their respective α-
receptor subunits. Once bound to the α-receptor, the complex then binds to two β-receptors 
to form a dimer. The remaining gp130 cytokines do not bind to an α-receptor, but bind to 
their respective β-receptor directly and signal via heterodimers of either gp130 and the 
LIFR (LIF, CNTF, CT-1 and CLC) or gp130 and the OSMR (OSM). Regardless of different 
binding pattern, this ligand-receptor protein complex then activates constitutively bound 
Janus family kinases, JAK1, JAK2 or Tyk2, which then phosphorylates tyrosine residues 
in the distal cytoplasmic domains of gp130. Phosphorylated gp130 can act as a docking 
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site for SH2 domains of Signal Transducer and Activator of Transcription (STAT) family 
of transcription factors (STAT1, 3 and 5). Subsequent phosphorylation of STATs by gp130 
then induces STAT dimerization and translocation to the nucleus where they induce gene 
transcription. Thus, JAK/STAT activation is a classical hallmark of gp130 dependent 
cytokine signaling. Dimerization of gp130 cytokine receptors also leads to the induction of 
the MAPK cascade, including ERK1/2, JNK1/2 and p38 MAPK. gp130 activation of 
MAPKs is primary mediated through the recruitment of the protein tyrosine phosphatase 
SHP2 to the gp130 phosphorylation site. Phosphorylation of Tyr759 on gp130 results in 
the recruitment of SHP-2 (Src homology domain-containing protein tyrosine phosphatase-
2), allowing its phosphorylation by JAK. Phosphorylated SHP-2 then interacts with Grb2 
(growth-factor receptor bound protein 2), which leads to the activation of the Ras-Raf- 
ERK1/2 cascade (2). gp130 cytokines can also activate the stress-activated members of the 
MAPK family: p38 and JNK (180, 181), but the signal transduction pathways resulting in 
their activation remain poorly understood. 
 
gp130 cytokines can also lead to the activation signaling cascades involving PI3K. 
This enzyme modifies certain phosphatidylinositides, so that the serine/threonine Akt is 
recruited to the plasma membrane, where it becomes activated through phosphorylation by 
PDK1 (phosphoinositide-dependent kinase-1).  can induce the activation of mTOR 
signaling IL-6-induced activation of the PI3K/Akt pathway is involved in protection 
against apoptosis, as well as in enhanced proliferation in multiple myeloma cells (182-184), 
cardiac myocytes (185, 186) and basal carcinoma cells (187). The molecular mechanism 
linking gp130 engagement to the activation of the PI3K/Akt pathway is not well understood. 
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Some evidence exist suggesting that IRS-1 and its adaptor protein Gab1 are involved in 
gp130 activation of PI3K (188, 189). Notably, PI3K activation upon gp130 cytokines is 
observed in a cell-type specific manner. For example, no significant Akt activation could 
be observed in IL-6 treated HepG2 hepatoma cells (190). Whether gp130 cytokines can 
induce PI3K/Akt signaling activation in skeletal muscle cells has not been examined. 
 
Activation of gp130/STAT3 signaling is transient in most biological systems because 
of the efficient inhibition mechanisms for STAT inactivation. This inhibition mechanisms 
of gp130/STAT signaling pathway can inhibit the constant activation of 
JAK1/STAT1/STAT3 pathway. Three families of regulators of JAK/STAT signaling are 
known: the SOCS family of proteins, the protein inhibitor of activated STAT (PIAS) family 
of proteins and the SH2-containing phosphatase family of proteins (191). These proteins 
target to distinct members of the gp130/STAT signaling pathway: SOCS1 and SOCS3 
target JAK1 and gp130, respectively, near the plasma membrane to prevent cytoplasmic 
STATs from being activated, whereas PIAS1 principally targets activated STAT proteins in 
the cell nucleus and prevents it from binding to DNA (191). SOCS proteins transcription 
is induced by IL-6 and LIF and since they inhibit tyrosine phosphorylation of gp130, 
STAT1 and STAT3. SOCS proteins contain a SH2 domain and was shown to directly 
interact with the kinase domain of JAK2, resulting in a reduced tyrosine kinase activity of 
JAK2. Thus SOCS is a JAK inhibitor that is induced by the STAT3 activation and 
eventually leads to feedback regulation of gp130/STAT3 
 
Role of gp130 signaling in muscle hypertrophy 
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IL-6 and LIF are induced in overloaded muscles during the process of hypertrophy in 
rodents (7). LIF and IL-6 expression is also significantly induced by resistance exercise in 
human muscle and in electrically stimulated cultured human myotubes (192). Both LIF and 
IL-6 knockout mice were shown to have an impaired hypertrophic response to overloading, 
which confirms the role of these cytokines in muscle hypertrophy (7, 8). Overload induced 
protein synthesis induction was not attenuated by IL-6 knock-out mice. It was believed that 
impaired hypertrophic muscle growth is ascribed to blunted accretion of myonuclei, which 
is caused by the defective proliferation and migration capacities of satellite cells in the 
absence of IL-6 (8). Indeed, IL-6 can activate murine satellite cell proliferation via 
regulation of cyclin D1 and c-myc (193). Similarly, exogenous LIF can induce human 
myoblast proliferation via induction of the cell proliferation associated factors c-Myc and 
JunB (192). The overload induced myofiber hypertrophy also requires IL-4, which 
promotes myoblast fusion without affecting their proliferative capacity. Similar to IL-6, IL-
4 is expressed in skeletal muscles in response to overload and exercise (8, 194). The 
expression of both cytokines has been shown to depend on the transcription factor serum 
response factor (8). Thus, serum response factor can be used by the myofibers to translate 
mechanical cues into paracrine growth-promoting signals that impact positively on satellite 
cell proliferation and fusion. Collectively, these results demonstrate that gp130 family of 
cytokines contribute to myogenesis in vitro and muscle regeneration and growth in vivo, 
acting at distinct stages of these processes in a timely and regulated fashion, through 
distinct signaling pathways and effectors. 
 
Consistent with the functions of IL-6 and LIF in myogenesis, the gp130 downstream 
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JAK/STAT signaling pathway is also associated with muscle growth and hypertrophy 
through the promotion of myoblast proliferation. Proliferating satellite cells in regenerating 
muscle showed activated STAT3 (195). STAT3 signaling directly associates with MyoD 
expression and overexpression of d.n.STAT3 in C2C12 myoblast can inhibit its myogenic 
activities (196).  JAK1, STAT1 and STAT3 signaling pathways are activated in early stage 
of muscle regeneration which is characterized by rapid proliferation of satellite cells (197). 
Consistent with this, the JAK1/STAT1/STAT3 pathway was shown to be necessary for 
myoblast proliferation in vitro, based on its capacity to regulate the expression of cell cycle 
associated genes. STAT1/STAT3 complex is also necessary for LIF stimulation of myoblast 
proliferation (197), which is consistent with the delayed muscle regeneration of LIF knock-
out mice, which can be rescued by delivery of exogenous LIF (7). However, activation of 
the JAK1/STAT1/STAT3 pathway can also prevent premature differentiation of myoblasts 
by blocking the expression of genes critical for myoblast differentiation and fusion, such 
as MyoD, MEF2 and myogenin, while knockdown of JAK1 or STAT1 reduces myoblast 
proliferation and leads to premature differentiation (197). These results suggest that the 
JAK1/STAT1/STAT3 pathway serves as a differentiation checkpoint, ensuring that 
differentiation commences only when a sufficient number of myoblast cell progeny have 
been generated during the proliferative phase. SOCS dependent negative feedback is 
important to inhibit JAK1/STAT signaling, which allows the cessation of myoblast 
proliferation and commencement of differentiation. Kinase activity of JAK1 is reduced 
upon differentiation, which is associated with increased expression of SOCS1 and SOCS2 
(195). In conclusion, LIF and IL-6 induction of JAK1/STAT1/STAT3 pathway plays dual 
role in proliferating myoblasts, that is, promote their proliferation and also inhibit their 
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precocious differentiation.  
 
In addition to JAK/STAT3 signaling pathway, several intracellular signaling pathways 
downstream gp130 are known to regulate myogenesis. The p38 MAPK, PI3K/AKT, 
calcium/calmodulin activated protein kinase, and calcineurin positively regulate myogenic 
differentiation (198), while ERK1/2 pathway activates myoblast proliferation and inhibits 
differentiation at the early stage of differentiation, but promotes myocyte fusion at the late 
stages of differentiation (199, 200). Similarly, NF-ĸB also promotes myoblast proliferation, 
while also favoring differentiation at later stages by acting as a downstream mediator of 
p38 MAPK signaling (201). 
 
Role of gp130 cytokines in muscle atrophy 
Since early 1990’s, it has been recognized that elevated circulating IL-6, as well as 
complex underlying cytokine network, could participate in cachexia development (118). 
IL-6/gp130 signaling has been demonstrated to play a key role in several cancer cachexia 
animal models. Inhibiting IL-6 signaling by neutralizing antibodies showed a protective 
effect on body weight loss in C26 tumor bearing mice (39). The IL-6 dependent muscle 
mass loss has also been demonstrated in ApcMin/+ and C26 tumor-implanted mice (125, 
202, 203). Recently, LIF has also been demonstrated to play a key role in C26 induced 
muscle wasting (204). However, whether IL-6/gp130 signaling is sufficient and/or has a 
direct role in the induction of muscle atrophy remains controversial. Further research is 
still required to determine the mechanisms underlying IL-6 /gp130 signaling in cachexia 




Whether IL-6 induces muscle protein degradation is still under debate. In fact, different 
in vivo and in vitro studies got controversial results. Several early studies showed protein 
degradation rate in isolated rat muscles exposed to recombinant IL-6 (205), or after 
injection of IL-6 into wild type mice (206, 207), was unaltered. Similarly, exogenous IL-6 
administration showed no effect on the proteolytic rate of rat and murine myotubes (208). 
These results are also supported by the fact that infusion of a single dose of IL-6 to rats did 
not induce ubiquitin gene upregulation in muscle (209). In contrast to these negative results, 
increased muscle proteolysis was observed after high doses or long-term administration of 
IL-6 in rats or mice (210). IL-6 transgenic mice showed elevated circulating levels IL-6 
and displayed severe muscle atrophy by the age of 10 weeks, together with the activation 
of the proteolysis in muscles (211). The inhibition of IL-6 signaling by sustained 
administration of mouse IL-6R antibody completely reversed the muscle wasting in IL-6 
overexpressing mice (212) and C26 tumor bearing wild type mice (151). These results 
demonstrate that IL-6 at least has a permissive role in the development of skeletal muscle 
proteolysis and muscle wasting when other cachectic factors are also present. Some 
evidence suggest IL-6 may synergize with other cytokines to induce muscular atrophy in 
some disease states. For example, activation of the rennin-angiotensin system can cause 
severe muscle wasting, which is commonly found in congestive heart failure or chronic 
kidney disease (213). 
 
Consistent with IL-6 and LIF role, the role of STAT3 signaling in cachexia induced 
muscle wasting has been well established. Increased muscle STAT3 phosphorylation has 
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been observed in several cachexia models. Overexpression of constitutively active STAT3 
in normal mouse muscle by plasmid transfection induced a significant reduction of 
myofiber cross sectional area (202, 214). Transfection of dominant negative STAT3 
mutants, or STAT3 short hairpin, prevented the atrophy induced by injection of Chinese 
hamster ovary cells overexpressing IL-6 in athymic nude mice and in the C26 
adenocarcinoma mouse model (202). A recent study further demonstrates STAT3 signaling 
activation contributes to muscle wasting in C26 and LLC cachexia model by inhibiting 
muscle protein synthesis, as well as stimulating caspase-3, myostatin, and the ubiquitin-
proteasome system (215). The disruption of SOCS3 dependent negative feedback loop may 
contribute to constant muscle STAT3 signaling activation in cachexia. Indeed, augmented 
SOCS3 mRNA expression was reported in cachexia induced wasting muscle undergoing 
an exacerbated proteolysis. Interestingly, the SOCS3 protein level was unchanged or even 
reduced in this model, despite SOCS3 mRNA upregulation. This discrepancy can be 
interpreted as a JAK/STAT-driven increase in proteolytic degradation of SOCS3 protein 
(202). Taken together, these results strongly suggest STAT3 activation is the major 
mediator of IL-6 dependent muscle wasting in cachexia. 
 
The role of STAT3 activation in cachexia induced muscle protein synthesis suppression 
still needs to be examined. Some evidence support IL-6 may indirectly suppress muscle 
protein synthesis though its interference with the growth hormone/IGF-1 axis. Suppressed 
serum IGF-1 and muscle IGF-1/Akt signaling was observed in ApcMin/+ mice, an IL-6 
dependent cachexia model (18). Short term IL-6 administration to wild type mice and 
humans reduced circulating IGF-1 levels. Transgenic mouse models overexpressing IL-6 
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showed reduced growth, which is accompanied with high serum IL-6 level, low serum IGF-
1 levels and enhanced muscle SOCS3 mRNA expression (216). Neutralization of IL-6 
activities in IL-6 transgenic mice rescued the circulating IGF1 levels and fully restored 
growth, reinforcing the casual relationship between high IL-6 and low IGF1 levels in 
plasma (216). Some existing evidence also suggests that AMPK signaling activation is 
involved in IL-6 suppression of muscle protein synthesis. Late stage of cachectic ApcMin/+ 
showed increased muscle AMPK phosphorylation (18). Systemic IL-6 overexpression in 
ApcMin/+ mice produced a dose-dependent suppression of mTOR signaling which 
correspond to AMPK phosphorylation, and chronic IL-6 administration was enough to 
induce AMPK phosphorylation in cultured myotubes (20). IL-6 suppression of myotube 
mTOR activity was rescued by AMPK inhibition (20). However, induction of muscle and 
myotube AMPK phosphorylation by LLC, which is another gp130 dependent cachexia 
model, was not attenuated by IL-6 or gp130 signaling inhibition (19), which indicates IL-
6/gp130 signaling is not the only inducer of muscle AMPK signaling in cachexia. 
 
2.6 Conclusion 
Taken together, the current literature has many gaps in understanding the gp130 
signaling regulation of muscle protein synthesis during mechanical stimuli induction of 
hypertrophy and cachexia induced atrophy. gp130 cytokines IL-6 and LIF are necessary 
for overload induction of muscle hypertrophy. A wide body of literature shows 
gp130/STAT3 signaling in muscle hypertrophy has documented this role in satellite cell 
proliferation and myogenesis, suggesting that IL-6 and LIF may induce muscle 
hypertrophy through stimulating satellite cell proliferation during overload induced 
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hypertrophic process. But the role of satellite cell’s role in mechanical stimuli induction of 
muscle hypertrophy is questionable. Induction of mTOR signaling dependent protein 
synthesis plays a central role in mechanical stimuli induction of muscle hypertrophy, but 
the role gp130 signaling in muscle protein synthesis regulation by mechanical stimuli still 
needs to be determined. Cancer cachexia induced muscle gp130/STAT3 signaling 
activation is a key mediator of increased proteolysis and muscle mass loss. gp130 signaling 
dependent cachexia models showed muscle AMPK signaling activation, and cachexia 
activation of gp130 downstream signaling including STAT3 and NFκB can interact 
mechanical signaling in skeletal muscles, which is associated with muscle protein synthesis 
suppression and anabolic resistance in cachexia. But the potential interaction of gp130 with 
anabolic signaling induced by mechanical stimuli in cachexia has not been determined. 
Finally, the paradoxical role of gp130 signaling in muscle mass regulation has not been 
clearly explained. The current proposal aims to the gp130 signaling regulation muscle 
protein synthesis during mechanical stimuli induced hypertrophy and cachexia induced 
atrophy process, and if gp130 cytokine regulation can differentially regulate protein 
synthesis in cultured myotubes in a time and dose dependent manner through differentially 
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IL-6 and LIF are members of the IL-6 family of cytokines that have recognized 
paradoxical regulatory roles in skeletal muscle mass. Short term muscle production of IL-
6 and LIF are necessary for overload induced muscle hypertrophy, but the cellular 
mechanisms involved in this regulation have not been completely identified. mTOR 
signaling is a key controller of muscle protein synthesis, which is a driver of muscle mass 
regulation. IL-6 family of cytokines regulates upstream activators of mTORC1 including 
PI3K/Akt and ERK1/2, but the muscle mTOR signaling regulation of by the IL-6 family 
of cytokines remains poorly understood. Therefore, we investigated the short term effects 
of IL-6 and LIF induced cellular signaling on the regulation of C2C12 myotube mTORC1 
signaling and protein synthesis. C2C12 myotubes were subjected to short term IL-6 or LIF 
adminsitration. Signaling through the gp130 receptor and downstream effectors including 
PI3K/Akt, STAT3 and ERK1/2 were investigated by administration of specific siRNA or 
pharmaceutical inhibitors. Short term IL-6 or LIF administration increased myotube 
protein synthesis and activated STAT3 and Akt-mTOR signaling pathways. The induction 
of mTOR signaling and protein synthesis by IL-6 or LIF was attenuated by either gp130 
siRNA knock-down or Akt signaling inhibition. Inhibition of STAT3 and mTOR signaling 
did not block the IL-6/LIF induction of myotube protein synthesis. These results 
demonstrate that short term IL-6 and LIF exposure can induce protein synthesis in culture 
myotubes through the activation of gp130-Akt signaling pathway, and IL-6/LIF induced 
Akt signaling can activate protein synthesis via mTOR independent mechanisms. 
 




Skeletal muscle mass has a well-documented role in health and quality of life. To this 
end, our knowledge of processes governing skeletal muscle mass, which involves the 
balance between protein synthesis and degradation, have been rapidly expanding (1). 
However, significant gaps remain in our understanding of skeletal muscle regulation of 
protein turnover by systemic changes related to nutritional status, physical activity level, 
inflammation and underlying disease. The effectors of these systemic conditions targeting 
skeletal muscle protein turnover include mechanical stimuli, cytokines, growth factors, and 
hormones (1, 217). The Interleukin-6 (IL-6) family of cytokines regulate many 
physiological and pathological processes including immune system regulation, 
inflammation, wound healing, and cell survival (2). Skeletal muscle serves as both a 
biological target and source of the IL-6 family of cytokines. Two members of IL-6 family 
of cytokines, IL-6 and Leukemia Inhibitory Factor (LIF), have recognized roles in both 
skeletal muscle hypertrophy and atrophy (5, 218). Under physiological conditions, repeated 
contractions during exercise, overload or muscle injury can induce plasma elevation and 
muscle production of IL-6 and LIF (192, 219), which is thought to initiate important 
autocrine and paracrine signaling that contributes to muscle hypertrophy by stimulate 
myocyte proliferation and differentiation (7, 8, 192). Notably, the systematic IL-6 release 
in response to exercise is in a temporal manner, increasing rapidly and remaining elevated 
for a few hours (36, 220). Unlike the beneficial effects of short term actions of IL-6 and 
LIF under physiological conditions, long term, pathological elevation of circulating IL-6 
and LIF are tightly associated with muscle wasting (9, 118, 204, 221, 222). Currently, the 
duration of IL-6 family of cytokines exposure is the plausible explanation of their 
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differential effects on muscle mass regulation (5), but further research is still needed to 
understand this complex dichotomy.  
 
IL-6 and LIF can induce multiple intracellular signaling pathways via type I cytokine 
receptors. These receptors contain a ligand binding α-receptor subunit and two signal 
transducing β-receptor subunits, which contain a cytoplasmic signaling transducing 
domain (2, 223). Glycoprotein 130 (gp130), a transmembrane protein, functions as the β-
receptor subunits for the IL-6 and LIF. The ligand-receptor protein complex activates 
constitutively bound Janus family kinases 2 (JAK2), which phosphorylates tyrosine 
residues in the cytoplasmic domains of gp130 (2, 223). Phosphorylated gp130 can 
phosphorylate and activate STAT3, leading to STAT3 dimerization and nuclear 
translocation to induce target gene transcription. Notably, activated STAT3 signaling 
induces SOCS3 expression. SOCS3 can suppress gp130 dependent signaling through direct 
interaction with the kinase domain of JAK2 (2, 224), which forms a feedback inhibition 
mechanisms that prevents constant induction of gp130 dependent signaling pathways under 
physiological conditions (224). Phosphorylated gp130 also induces ERK1/2 signaling 
through the recruitment of protein tyrosine phosphatase SHP-2 (Src homology domain-
containing protein tyrosine phosphatase 2), allowing SHP2 phosphorylation by JAK2. 
Phosphorylated SHP2 then interacts with Grb2 (growth-factor receptor bound protein 2), 
leading to the activation of the Ras-Raf-ERK1/2 cascade (2). Finally, IL-6 family of 
cytokines can induce the phospho-inositide-3-kinase (PI3K)/Akt signaling axis (2), but the 
molecular events mediating this regulation are not well understood. PI3K-Akt and ERK1/2 
signaling induction by the IL-6 also demonstrates cell-type specific regulation. For 
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example, PI3K/Akt activation could be observed in IL-6 treated multiple myeloma cells 
(182-184), cardiac myocytes (185, 186) and basal carcinoma cells (187), but not HepG2 
hepatoma cells (190).  Despite a growing body of evidence for cytokine induced gp130 
signaling in cells, additional work is needed to better define the specific regulatory role of 
this signaling pathway in skeletal muscle fibers.  
 
The induction of protein synthesis has a well-documented role in skeletal muscle 
hypertrophy (1). The mammalian target of rapamycin (mTOR), which functions in the 
multi-protein complex, mTORC1, plays an essential role in the regulation of protein 
synthesis and skeletal muscle mass (14). Activated mTORC1 can induce muscle protein 
synthesis through the phosphorylation of the p70 ribosomal S6 kinase (p70S6K) and 
eukaryotic initiation factor 4E binding protein (4E-BP1), leading to increased ribosomal 
biogenesis and cap-dependent protein translation initiation (13). Many muscle 
hypertrophic factors, such as growth factors like insulin-like growth factor 1 (IGF-1) and 
mechanical stimuli, can stimulate muscle mTOR signaling and protein synthesis through 
signaling pathways which converge on the phosphorylation of mTORC1 suppressor, 
tuberous sclerosis 1/2 (TSC1/2). IGF-1 can activate PI3K-Akt signaling, which further 
relieves TSC1/2 suppression on Ras homolog enriched in brain (Rheb) by phosphorylation 
of TSC2, allowing Rheb to stimulate mTORC1 (14, 15). Induction of Extracellular signal-
Regulated Kinases 1/2 (ERK1/2) signaling by mechanical overload also phosphorylates 
and inhibits TSC2, which contributes to early activation of muscle mTORC1 (16). Muscle 
produced of IL-6 and LIF also plays a key role in muscle overload induced muscle 
hypertrophy. However, whether they can stimulate mTOR signaling and subsequent protein 
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synthesis still need to be investigated.  
 
gp130 signaling induction by IL-6 family of cytokines have the potential to induce 
upstream stimulators of mTOR, including Akt and ERK1/2 signaling pathways, leading to 
the increased protein synthesis. In cardiomyocytes, induction of gp130 by IL-6 or LIF leads 
to PI3K/Akt signaling activation and subsequent protein synthesis increase, which is a key 
mechanism of IL-6 and LIF induction of cardiac hypertrophy (186, 225). IL-6 induction of 
ERK1/2 signaling in cardiomyocytes has also been demonstrated to be necessary and 
sufficient for its cardioprotection effect (186). However, the specific interaction between 
gp130 and the PI3K/Akt-mTORC1 or ERK1/2-mTORC1 signaling axis within muscle 
cells requires further investigation. The purpose of this study is to investigate if short term 
administration of IL-6 family of cytokines, IL-6 or LIF will regulate myotube protein 
synthesis by activating gp130 dependent signaling pathways. We hypothesized that short 
term IL-6 or LIF will induce mTOR signaling and protein synthesis in cultured myotubes 
by activation the gp130-Akt-mTOR signaling axis. The role of gp130 and its potential 
downstream effectors, including PI3K-Akt-mTOR, STAT3, ERK1/2 signaling pathways 





C2C12 myoblasts (American Type Culture Collection, Manassas, VA) were cultured 
in DMEM supplemented with 10% FBS, 50 U/ml penicillin, and 50 μg/ml streptomycin. 
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To induce C2C12 myoblast differentiation, C2C12 myoblasts were incubated in DMEM 
supplemented with 2% horse serum, 50 U/ml penicillin, and 50 μg/ml streptomycin for 4 
days after they reached ∼95% confluence. 
 
Cytokine treatment 
Differentiated C2C12 myotubes were treated with different doses (5, 10, 20 or 
100ng/ml) of IL-6 (Sigma-Aldrich, St. Louis, MO) or LIF (Thermo Scientific, Waltham, 
MA) for different time periods (30min, 1h, 2h or 4h). To exclude the potential effects of 




Three days after the onset of differentiation, C2C12 myotubes were transfected with 
scramble siRNA (GE Dharmacon, Lafayette, CO, USA) or siRNA targeting to gp130, 
STAT3, SOCS3 or AMPK (Santa Cruz Biotech, Santa Cruz, CA, USA) using Dharmafect 
3 transfection reagent (GE Dharmacon) according to the manufacturer’s instructions. 
Briefly, siRNA and transfection reagent were separately diluted in serum-free and 
antibiotics-free DMEM and incubated at RT for 5min. The diluted transfection reagent was 
then added to the siRNA mixture and allowed to complex with siRNA for 20 min. siRNA-
transfection reagent complexes were then added to the antibiotics-free differentiation 
medium, and myotubes were incubated for 24 h in the medium containing the transfection 




Intracellular signaling inhibition 
To inhibit gp130 dependent STAT3, ERK1/2 and PI3K/Akt signaling pathways, and 
Akt downstream target mTOR signaling pathway, STAT3 specific inhibitor LLL12 (1μM, 
BioVision, Milpitas, CA, USA), ERK1/2 inhibitor PD98059 (20μM, Cell Signaling 
Technology, Danvers, MA, USA), PI3K inhibitor specific wortmannin (2μM, Cell 
Signaling Technology) or mTORC1 inhibitor rapamycin (20nM, Cell Signaling 
Technology), was added to cell culture medium 1h before the IL-6 or LIF administration. 




Western blot analysis was performed as previously described (226). Briefly, cells were 
washed by ice-cold PBS and then scraped into ice-cold RIPA buffer [50 mM Tris, 150 mM 
NaCl, 1% Triton X-100, 1 mM EDTA, 0.5% sodium deoxycholate, 0.1% SDS, 5 mM NaF, 
1 mM NaVO4, 1 mM β-glycerophosphate, and 1% protease inhibitor cocktail (Sigma-
Aldrich)]. Cell lysates were homogenized on ice and centrifuged at 4°C, and supernatants 
were collected. Protein concentrations were determined by the Bradford reagent (Bio-Rad) 
following the manufacturer’s instructions. Protein were fractionated in SDS-
polyacrylamide gels and transferred to polyvinylidene fluoride membranes. After the 
membranes were blocked, antibodies for phosphorylated/total ERK1/2, STAT3, NF-κB p65, 
Akt, p70S6K, 4EBP1, GAPDH (Cell Signaling Technology), gp130 (Santa Cruz 
Biotechnology), and puromycin (Millipore, Billerica, MA) were incubated at dilutions 
from 1:2,000 to 1:8,000 overnight at 4°C in 2% Tris-buffered saline-Tween 20 milk. Anti-
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rabbit or anti-mouse IgG-conjugated secondary antibodies (Cell Signaling Technology) 
were incubated with the membranes at 1:2,000 to 1:5,000 dilutions for 2 h in 2% Tris-
buffered saline-Tween 20 milk. Enhanced chemiluminescence (Advansta, Menlo Park, CA) 
developed by autoradiography was used to visualize the antibody-antigen interactions. 
Blots were analyzed by measuring the integrated optical density (IOD) of each band with 
ImageJ software (National Institutes of Health, Bethesda, MD). 
 
Protein synthesis measurement 
The myotube protein synthesis was determined by puromycin incorporation as 
previously described (227). In brief, puromycin (EMD Chemicals, San Diego, CA) was 
added into cell culture media (1 μM final concentration) 30 min before protein collection. 
The amount of puromycin incorporated into newly synthesized protein was determined by 
Western blots. The protein samples from myotubes without puromycin labelling were used 
as negative control. 
 
RNA isolation, cDNA synthesis, and real-time PCR 
RNA isolation was performed using Trizol Reagent (Thermo scientific) according to 
the manufacturer’s instructions. cDNA synthesis, and real-time PCR were performed as 
previously described, using reagents from Applied Biosystems (Foster City, CA, USA). 
Quantitative real-time PCR analysis was carried out in 20-ul reactions consisting of 2 × 
SYBR Green PCR buffer (AmpliTaq Gold DNA Polymerase, Buffer, dNTP mix, AmpErase 
UNG, MgCl2), 0.1ul of cDNA, RNase-free water, and 60 nM of each primer. The 
sequences of SOCS3 primers set are5’-TGCAGGAGAGCTGATTCTAC-3’ (forward) and 
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5’-TGACGCTCAACGTGAAGAAG (reverse). The sequence of GAPDH primers were 
published elsewhere (19). Data were analyzed by ABI software using the cycle threshold 
(CT), which is the cycle number at which the fluorescence emission is midway between 
detection and saturation of the reaction. The SOCS3 data of each sample was normalized 
by its GAPDH results.  
 
Statistical Analysis 
Student's t-test, one-way ANOVA, and two-way ANOVA (indicated in figure legends) 
were used to examine the effects of stretch and culture conditions. Post hoc analyses were 
performed with Student-Newman-Keuls method. For all comparisons, six replicates from 
two independent experiments were included. P values < 0.05 were considered significant. 
 
3.4 Results 
Regulation of myotubes protein synthesis and mTOR signaling by different doses of 
cytokines 
To determine the effect of short term administration of IL-6 family of cytokines, IL-6 
and LIF, on myotube protein synthesis and mTOR signaling, myotubes were treated with 
different doses (5ng/ml, 10ng/ml, 20ng/ml and 100ng/ml) of IL-6 or LIF for 2h. IL-6 
induced myotube protein synthesis in a dose dependent manner from 5ng/ml to 20ng/ml, 
and 100ng/ml IL-6 showed no further induction (Fig. 1A and B). All doses of LIF 
significantly increased myotube protein synthesis (Fig. 1A and B). Interestingly, 10ng/ml 
LIF demonstrated the maximal induction of protein synthesis (Fig. 1 A and B). Unlike the 
effects of IL-6 or LIF, TNF-α, which is not the member of IL-6 family of cytokines, did 
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not change myotube protein synthesis at low doses (5ng/ml and 10ng/ml), and decreased 
myotube protein synthesis at 20ng/ml. All doses of TNF-α increased phosphorylation of 
NF-κB, the direct downstream target of TNF-α (Fig. 1C), which demonstrated the action 
of TNF-α on myotubes. As mTORC1 signaling is the central regulator of protein synthesis, 
phosphorylation was also measured using two downstream targets of mTORC1, p70S6K 
and 4EBP1, in myotubes treated with different doses of IL-6 or LIF. Administration of low 
dosage of IL-6 (5ng/ml, 10ng/ml and 20ng/ml) and LIF (5ng/ml and 10ng/ml) significantly 
increased p70S6K phosphorylation (Fig. 1D), while high doses of IL-6 or LIF did not 
change (100ng/ml IL-6 and 20ng/ml LIF) or even decreased (100ng/ml LIF) p70S6K 
phosphorylation (Fig. 1D). However, either IL-6 or LIF administration did not change 
4EBP1 phosphorylation (Fig. 1D). These results demonstrate short term IL-6 related 
cytokines, IL-6 and LIF, are able to induce myotube protein synthesis and mTOR signaling 
in a dose sensitive manner. 
 
IL-6 family of cytokines can control the satellite cells expansion and myogenic 
differentiation process by regulating cyclin D1 expression (36, 228, 229). Interestingly, 
activation of mTOR signaling is also necessary for satellite cell proliferating and 
myogenssis (230). To exclude the possibility that IL-6 or LIF regulates mTOR signaling 
and protein synthesis only in the residual myoblasts in C2C12 myotube culture, we 
measured the expression of cyclin D1, a molecular marker of proliferating myoblasts, and 
myogenin, a molecular marker of differentiated myotubes. The cyclin D1 protein was 
expressed in proliferating C2C12 myoblasts, but not in 4 days differentiated myotubes (Fig. 
3.8A), and short term (2h) IL-6 or LIF administration did not induce cyclin D1 expression 
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in myotubes (Fig. 3.8A). Unlike cyclin D1, myogenin is only expressed in differentiated 
myotubes, but not myoblasts (Fig. 3.8B). To exclude the residual myoblasts in myotube 
culture, we differentiated myotubes for 8 days (Fig. 3.8C) or pretreated myotubes with 
50μM cell cycle inhibitor Ara-C for 24h (Fig. 3.8C). Short term (2h) administration of IL-
6 or LIF increased protein synthesis in both 8 days differentiated myotubes (Fig. 3.8C) and 
Ara-C pretreated myotubes (Fig. 3.8D). These results demonstrate that the protein synthesis 
regulation by IL-6 or LIF happens in differentiated myotubes. 
 
gp130 knock-down attenuated myotube protein synthesis induction by IL-6 or LIF 
The IL-6 family of cytokines regulate intracellular signal transducers through the 
interaction with their specific cytokine receptors and the gp130 transmembrane protein. To 
determine whether gp130 is necessary for myotube protein synthesis induction by IL-6 or 
LIF, we transfected myotubes with gp130 siRNA to inhibit gp130 dependent signaling 
pathways. gp130 siRNA transfections significantly decreased myotube gp130 protein 
expression, while IL-6 or LIF administration did not change gp130 protein level in either 
control or gp130 siRNA transfected myotubes (Fig. 2A). Short term IL-6 and LIF exposure 
increased protein synthesis in control siRNA transfected myotubes (Fig. 2B). However, IL-
6 or LIF did not significantly increase protein synthesis in gp130 siRNA transfected 
myotubes (Fig 2B). Consistent with the changes in protein synthesis, short term IL-6 or 
LIF significantly increased p70S6K phosphorylation in control siRNA, transfected 
myotubes, but not in gp130 siRNA transfected myotubes (Fig. 2C). These results 
demonstrate gp130 is necessary for IL-6 or LIF regulation of myotube mTOR signaling 




Time course regulation of IL-6 and LIF on myotube gp130 dependent signaling pathways 
and protein synthesis. 
gp130 signaling induction results in the activation of multiple intracellular signaling 
pathways, including STAT3, ERK1/2 and PI3K/Akt. STAT3 signaling activation then 
induces expression of SOCS3, forming a negative feedback loop to prevent long term 
gp130 signaling induction under physiological conditions. As we have demonstrated gp130 
is necessary for myotube protein synthesis induction by IL-6 or LIF, we then investigated 
the regulation of gp130 dependent signaling pathways by IL-6 and LIF. Myotubes were 
treated with IL-6 (20ng/ml) or LIF (10ng/ml) for 30min, 1h, 2h and 4h. The dosages of IL-
6 and LIF chosen here have demonstrated the maximal protein synthesis induction (Fig. 
1A and B). The phosphorylation of STAT3 was induced as early as 30min after addition of 
either IL-6 or LIF (Fig. 3A). The elevation of STAT3 phosphorylation lasted for 2h under 
IL-6 exposure and for 1h under LIF exposure (Fig. 3A). Long term IL-6/LIF exposure (4h 
for IL-6 and more than 2h for LIF) did not increase the STAT3 phosphorylation (Fig. 3A). 
30min LIF administration elevated ERK1/2 phosphorylation, but ERK1/2 phosphorylation 
did not maintain elevated after 1h, 2h or 4h LIF exposure (Fig. 3A). Neither time period of 
IL-6 exposure was able to induce ERK1/2 phosphorylation. The Akt phosphorylation was 
induced as early as 1h after the addition of either IL-6 or LIF which remained elevated after 
1h to 4h IL-6 or LIF exposure (Fig. 3A).  
 
Role of PI3K-Akt-mTOR signaling in IL-6/LIF regulation of myotube protein synthesis 
Because both IL-6 and LIF were able to induce Akt phosphorylation, we use 
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wortmannin, a PI3K/Akt signaling inhibitor, to examine the role of PI3K/Akt signaling in 
IL-6 or LIF induction of myotube protein synthesis. Myotubes were pretreated with 
wortmannin (1μM) for 1h before the addition of IL-6 or LIF. As expected, wortmannin 
administration blocked the induction of myotube Akt phosphorylation by either IL-6 or LIF 
(Fig. 4A). Furthermore, the wortmannin decreased basal phosphorylation of p70S6K, and 
prevented IL-6 or LIF induction of p70S6K phosphorylation (Fig. 4B). Both IL-6 and LIF 
increased protein synthesis in control (DMSO) condition (Fig. 4C). However, Wortmannin 
decreased basal protein synthesis, and blocked protein synthesis induction by IL-6 or LIF 
(Fig. 4C). These results demonstrate that PI3K/Akt signaling is necessary for myotube 
mTORC1 signaling and protein synthesis induction by either IL-6 or LIF. 
 
Akt signaling is well established and can induce muscle protein synthesis though the 
activation of mTORC1. To examine the role of mTORC1 in myotube protein synthesis 
induction by IL-6 and LIF, we pretreated myotubes with mTORC1specific inhibitor 
rapamycin before the addition of IL-6 or LIF. The presence of rapamycin decreased basal 
p70S6K phosphorylation and blocked the induction of p70S6K phosphorylation by IL-6 or 
LIF (Fig. 4D). Interestingly, although rapamycin decreased basal myotube protein 
synthesis, both IL-6 and LIF were able to significantly increase the protein synthesis in the 
presence of rapamycin (Fig. 4E). These results demonstrate that IL-6 and LIF can induce 
myotube protein synthesis though the mTORC1 independent mechanisms. 
 
Role of STAT3 in IL-6/LIF regulation of myotube protein synthesis 
Induction of STAT3 phosphorylation is a classical hallmark of gp130 dependent 
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cytokine signaling, and we have observed a short term induction of STAT3 phosphorylation 
by both IL-6 and LIF (Fig. 3A). To examine the role of STAT3 signaling in IL-6 and LIF 
regulation of myotube protein synthesis, we use STAT3 specific inhibitor LLL12 to block 
the STAT3 signaling induction by IL-6 and LIF. Pretreatment of LLL12 decreased basal 
STAT3 phosphorylation, and blocked the induction of STAT3 phosphorylation by 2h IL-6 
administration (Fig. 5A). 2h LIF administration alone or in the presence of LLL12 did not 
change the STAT3 phosphorylation (Fig. 5B). Interestingly, LLL12 decreased basal 
myotube protein synthesis, but both IL-6 and LIF administration significantly increased 
protein synthesis in the presence of LLL12 (Fig. 5C). Consistent with the changes in protein 
synthesis, LLL12 also decreased myotube p70S6K phosphorylation, but there was still a 
slight induction of p70S6K phosphorylation by IL-6 or LIF (Fig. 5D). These results 
demonstrate that STAT3 signaling is necessary for maintaining basal myotube protein 
synthesis, but is not involved in IL-6 or LIF induction of myotube mTORC1 signaling and 
protein synthesis. 
 
Role of ERK1/2 in LIF regulation of myotube protein synthesis 
LIF induced transient elevation of ERK1/2 phosphorylation was observed. ERK1/2 
signaling has the potential to activate muscle mTORC1 though the phosphorylation of 
TSC1/2 (16). Therefore, ERK1/2 specific inhibitor, PD98059 was used to examine the role 
of ERK1/2 signaling in LIF induction of myotube protein synthesis. Pretreatment of 
PD98059 inhibited the induction of ERK1/2 phosphorylation by 30min LIF administration 
(Fig. 6A). Consistent with previous observations (Fig. 3A), 2h LIF administration showed 
no induction of ERK1/2 phosphorylation (Fig. 6B). PD98059 pretreated myotubes showed 
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decreased ERK1/2 phosphorylation, which was independent of LIF (Fig. 6B). 2h LIF 
administration increased protein synthesis in control group (Fig. 6C). Interestingly, 
PD98059 alone was able to induce protein synthesis (Fig. 6C). However, combination of 
PD98059 and LIF showed no further induction of protein synthesis (Fig. 6C). These results 
demonstrate ERK1/2 signaling is not involved in LIF induction myotube protein synthesis, 
and suggest potential crosstalk between ERK1/2 signaling and protein synthesis regulation 
in cultured myotubes. 
 
Role of SOCS3 in IL-6/LIF time course regulation of myotube protein synthesis 
We have observed that both IL-6 and LIF only induced short term increase in STAT3 
phosphorylation, suggesting the induction of SOCS dependent feedback inhibition of 
gp130 signaling. Therefore, we examined the IL-6/LIF time course regulation of SOCS3 
expression. The mRNA expression of SOCS3 was induced by both IL-6 and LIF as early 
as 30min exposure, and 1h IL-6 or LIF administration demonstrated the maximum 
induction of SOCS3 expression (Fig. 7A), which demonstrated the induction of SOCS3 
dependent feedback inhibition of gp130 signaling. Because we have demonstrated that 
gp130 is necessary for IL-6/LIF induction of myotube protein synthesis, we further 
examined the time course regulation of myotube protein synthesis by IL-6 or LIF. Both IL-
6 and LIF increased myotube protein synthesis as early as 1h, and 2h IL-6 or LIF exposure 
resulted in further protein synthesis induction (Fig. 7B). Interestingly, 4h exposure of either 
IL-6 or LIF did not further increase myotube protein synthesis, but showed less induction 
compared with 2h IL-6/LIF exposure (Fig.7B). These results demonstrate that IL-6 and LIF 
only results in short term induction of myotube protein synthesis, which coincide with the 
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increased SOCS3 expression.. 
 
To determine whether IL-6 or LIF induced SOCS3 can block their activation of 
myotube protein synthesis, we inhibited SOCS3 expression by siRNA transfection before 
the short term IL-6 and LIF administration. SOCS3 siRNA transfected decreased basal 
SOCS3 mRNA level and attenuated the IL-6/LIF induction of SOCS3 expression (Fig. 7C), 
but SOCS3 siRNA did not fully block the IL-6/LIF induction of SOCS3 expression (Fig. 
7C). We also compared the effect of 4h IL-6 or LIF administration on protein synthesis in 
control or SOCS3 siRNA transfected myotubes. 4h administration of IL-6 and LIF resulted 
a slight induction of protein synthesis (Fig. 7D). SOCS3 siRNA transfection also increased 
basal myotube protein synthesis, IL-6 and LIF treatment resulted in further protein 
synthesis increased in SOCS3 siRNA transfected myotubes (Fig. 7D). These results 
demonstrate that SOCS3 is a suppressor of protein synthesis in myotubes and can prevent 
the long term protein synthesis induction by IL-6 or LIF. 
 
3.5 Discussion 
IL-6 family of cytokines plays a paradoxical role in skeletal muscle mass regulations. 
Under physiological conditions, skeletal muscle production of IL-6 family of cytokines, 
including IL-6 and LIF, are important regulators of skeletal muscle hypertrophy. The 
muscle protein synthesis regulation through Akt-mTOR signaling is an acknowledged 
controller of skeletal muscle mass. However, the regulation of skeletal muscle protein 
synthesis by IL-6 family of cytokines has not been fully investigated. In this study, we 
report the important and novel finding that administration of myotubes with IL-6 family of 
65 
 
cytokines, IL-6 or LIF, resulted in an induction of protein synthesis, which was blocked by 
the inhibition on gp130 or its downstream PI3K-Akt signaling. Interestingly, inhibition of 
Akt downstream target mTORC1 signaling only decreased basal myotube protein synthesis, 
but did not blocked protein synthesis induction by IL-6 or LIF. While STAT3 signaling is 
necessary for maintaining basal protein synthesis, we report that STAT3 signaling 
inhibition did not block thr protein synthesis induction by IL-6 or LIF. Overall, these results 
demonstrate that short term IL-6 family of cytokines, IL-6 or LIF, can transiently increase 
myotube protein synthesis through the activation of gp130-Akt signaling. Both IL-6 and 
LIF are able to induce protein synthesis through mTOR independent mechanisms. 
 
Mechanical stimuli from overload or resistant exercise results in increased muscle 
production of IL-6 and LIF, which can regulate muscle hypertrophic process though 
autocrine/paracrine manner (7, 192, 231). Both LIF and IL-6 knockout mice demonstrated 
an impaired hypertrophy to overloading, (7, 8). It has been well established that IL-6 and 
LIF play a key role in satellite proliferation and differentiation, which is believed to be the 
major mechanisms of IL-6 and LIF regulation of muscle hypertrophy. IL-6 activates murine 
satellite cell proliferation via regulation of cyclin D1 and c-myc (193). The overload 
induced muscle IL-6 expression also plays a key role in satellite cell differentiation when 
cooperated with IL-4 (8, 228). Similarly, exogenous LIF can induce human myoblast 
proliferation via induction of the cell proliferation associated factors c-Myc and JunB (192). 
Although the induction of mTOR signaling plays a key role in satellite cell proliferation 
(230), there is no compelling evidence demonstrating that IL-6 or LIF can regulate protein 
synthesis in skeletal muscle cells. IL-6 and LIF can indirectly stimulate anabolic side 
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muscle protein turnover regulation by sensitizing the insulin/IGF-1 action on Akt signaling 
pathway (232-234), or facility glucose input through Akt-mTORC2 signaling (235, 236), 
but it is still unknown whether IL-6 family of cytokines can regulate protein synthesis in 
differentiated myofibers, thus contributes to the IL-6 and LIF regulation of muscle 
hypertrophy. In the present study, we report both IL-6 and LIF are enough to alter protein 
synthesis in cultured myotubes. The 4-days differentiated myotubes showed no expression 
of myoblasts markers of Cyclin D1, and high expression of myotube marker, Myogenin. 
Most importantly, unlike the upregulation of Cyclin D1 by IL-6 in myoblasts (228), short 
term IL-6 or LIF expression did not induce Cyclin D1 expression in 4-days differentiated 
myotubes, which exclude the possibility that IL-6 and LIF induce protein synthesis in 
residual myoblasts in cell culture. Our results demonstrate that either IL-6 or LIF alone are 
enough to induce protein synthesis in cultured myotubes, which provide another potential 
mechanism underlying the mechanical stimuli regulation of muscle protein synthesis and 
IL-6 family of cytokines regulation of muscle hypertrophy. Interestingly, the overload 
induction of muscle protein synthesis was not attenuated in IL-6 deficient mice, which 
demonstrate the direct protein synthesis induction by IL-6 is not the only mechanism (8). 
Indeed, multiple biochemical events have been identified as mediators of protein synthesis 
induction by mechanical stimulus. Further work is needed to determine whether regulation 
of protein synthesis by IL-6 or LIF contributes to the mechanical stimuli induced muscle 
hypertrophy. 
 
The IL-6 family of cytokines regulate intracellular signal transducers through the 
interaction with their specific cytokine receptors and the gp130 transmembrane protein. 
67 
 
The binding of IL-6 family of cytokine on receptor complex containing its specific receptor 
and gp130 causes the phosphorylation of gp130 intracellular tyrosine residues and STAT3 
by Janus kinases, JAK1 and JAK2 (2). This active receptor complex also leads to activation 
and the Ras-Raf-ERK /MAPK pathway and the PI3K/Akt pathway (2, 237). Intracellular 
signaling pathways initiated by gp130 multiple cellular processes including growth, 
differentiation, and apoptosis (238). However, relatively little is known about its role in 
muscle protein synthesis regulation. Pathological activation of gp130 signaling is a key 
regulator of muscle wasting during LLC induced cancer cachexia, but is not involved in 
muscle protein synthesis suppression (19). Our previous work suggest that gp130 signaling 
may plays an important role in mechanical stretch regulation of myotube protein synthesis, 
even under LLC induced atrophic environment (226). Here, we report that gp130 knock-
down blocked the IL-6/LIF induction of both mTOR signaling and protein synthesis in 
cultured myotubes. This finding further demonstrates that gp130 is required for protein 
synthesis induction by IL-6 and LIF, and further strengthens the anabolic role of gp130 in 
protein synthesis regulation (226).  
 
The PI3K-Akt is the most well defined hypertrophic signaling pathway which leads to 
the anabolic shift of muscle protein turnover regulation (14, 54). Once activated, PI3K-Akt 
signaling can phosphorylate TSC2, thus relieves suppression of TSC1/2 protein complex 
on Ras homolog enriched in brain (Rheb), allowing Rheb to stimulate mTORC1 and 
subsequent protein synthesis (14, 15). Activation of Akt also downregulate the expression 
of MAFbx and MuRF1 by inhibiting the transcriptional activity of FOXO3, which in turn 
suppress the ubiquitin-proteasome system induced muscle protein degradation muscle 
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protein degradation (239). IL-6 family of cytokines have to potential to activate Akt 
signaling, but this regulation seems to be cell-type specific and the mechanism is still 
poorly understood (183-188, 240). We report that both IL-6 and LIF administration 
increased Akt phosphorylation. Most importantly, inhibition of Akt signaling blocked 
protein synthesis induction by IL-6 or LIF. These findings demonstrate that IL-6 family of 
cytokines are able to activate Akt signaling, which plays an important role in IL-6/LIF 
induction in skeletal muscle cells. Our results are similar with previous reports 
demonstrating that Akt signaling is a central mediator of IL-6 and LIF regulation of cardiac 
myocyte survival and hypertrophy (185, 186). Taken together, these results highlight the 
importance of PI3K/Akt signaling activation by gp130 signaling in short term IL-6/LIF 
activation of protein synthesis in culture myotubes. However, future work is still required 
determine the role of gp130-Akt signaling in IL-6/LIF regulation of skeletal muscle 
hypertrophy. 
 
mTOR signaling is known to play a central role in regulating skeletal muscle protein 
synthesis and essential for muscle hypertrophy response to growth factors. mTOR signaling 
activation induces muscle protein synthesis though the phosphorylation of its two 
downstream factors, p70S6K and 4EBP1 (241). Phosphorylation of S6K1 results in hyper-
phosphorylation of the ribosomal protein RPS6, which assists in the translation of mRNA 
encoding proteins of translation apparatus (241, 242). The phosphorylation of 4EBP1 
results its dissociation from eIF4E, allowing the formation of eIF4E-eIF4G protein 
complex, a key step of cap-dependent protein translation initiation (243). Here, we showed 
the induction of phosphorylation of p70S6K by IL-6 and LIF, which can be inhibited by 
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gp130 knock-down or Akt signaling inhibition. These results clearly demonstrate that IL-6 
family of cytokines is able to induce a gp130-PI3K-Akt-mTOR signaling axis in cultured 
myotubes which has been shown in several studies in cardiac myocytes (185, 186). 
Inhibition of mTOR signaling decreased the protein synthesis in both control and IL-6/LIF 
treated myotubes, which further support the central role of mTOR signaling in protein 
synthesis regulation. Surprisingly, mTOR signaling inhibition did not completely block the 
protein synthesis induction by IL-6 or LIF, which highlights the role of mTOR independent 
mechanisms in IL-6/LIF induction of myotube protein synthesis. Interestingly, the IL-6/LIF 
induction of protein synthesis was completely blocked by PI3K inhibitor wortmannin, 
suggesting this mTOR independent mechanisms is still under the control of PI3K/Akt 
signaling. Previous studies have demonstrated that mTOR is not the only mediator of 
muscle protein synthesis induction by nutritional supplementation, including glucose and 
branched chain amino acids (244, 245). Administration of glucose or leucine to diabetic 
rats resulted in the formation of eIF4E-eIF4G protein complex and increased protein 
synthesis in skeletal muscles in the absence of increases in p70S6K or 4E-BP1 
phosphorylation (244, 245), and rapamycin only partially inhibited leucine induced muscle 
protein synthesis (62). A potential mechanism by which leucine stimulates protein 
synthesis independent of mTOR activity is through direct phosphorylation of eIF4G (246, 
247). Interestingly, both IL-6 and LIF can stimulate muscle glucose uptake, which involves 
the activation of PI3K/Akt signaling (235, 236). Therefore, it is possible that the IL-6/LIF 
stimulate myotube uptakeglucose uptake is a key mechanism of mTORC1 independent 
protein synthesis induction. Finally, the ERK1/2 or p38 MAPK signaling cascade can 
induce eIF4E phosphorylation, of rRNA transcription and ribosomal biogenesis 
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independent of mTOR (248-250). However, the role of glucose translocation and MAPK 
signaling in IL-6/LIF induced mTOR independent protein synthesis induction still need to 
be investigated. 
 
STAT3 signaling is a well-defined downstream target of IL-6-gp130 signaling (251). 
Once activated, STAT3 proteins dimerize and translocate to nucleus, where it promotes the 
transcription of downstream genes that are responsible for a variety of cellular functions 
including proliferation, migration and the prevention of apoptosis (36, 252). STAT3 play a 
critical role during development and its deletion lead to early embryonic lethality (253). 
STAT3 activation is also required for hypertrophy under the action of IL-6 requires (36), 
by regulating the transcription of myogenesis genes (229). However, to our knowledge, no 
evidence exists demonstrating a direct regulation of STAT3 on mTOR signaling or protein 
synthesis. Rather, we found that STAT3 inhibition did not block the myotube mTOR 
signaling and protein synthesis induction by IL-6 or LIF, which demonstrate STAT3 is not 
involved in IL-6/LIF regulation of myotube protein synthesis. Interestingly, STAT3 
inhibition resulted in a suppression of mTOR signaling and protein synthesis in both control 
and IL-6/LIF treated myotubes, which suggest that STAT3 is involved in maintaining basal 
protein synthesis in myotubes. These results in conjunction with the previous report and 
demonstrate that STAT3 signaling plays a permissive role in IL-6 induction of PI3K/Akt 
signaling in primary cultured renal proximal tubule cells (254). Several other studies also 
suggest that downregulation of STAT3 signaling may inhibit protein synthesis indirectly, 
by disrupting the glucose metabolism. In cancer cells, STAT3 signaling induction is critical 
for increased glucose uptake and aerobic glycolysis (255), which have been demonstrated 
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a positive regulator mTOR signaling and protein synthesis (245, 256). However, the 
potential cross talk between STAT3 signaling and protein synthesis in skeletal muscle needs 
to be further defined.  
 
ERK1/2 is another downstream effector of gp130 signaling. Previous work has 
demonstrated ERK1/2 can induce muscle proteins synthesis in response to mechanical 
stimulus, through both mTOR dependent and independent mechanisms (16, 257). ERK1/2 
signaling induction is also necessary for LIF and mechanical stretch induced cardiac 
muscle hypertrophy (258). However, our observations did not support that essential role of 
ERK1/2 signaling in IL-6/LIF regulation of protein synthesis in myotubes. Only LIF 
demonstrated a very short induction of ERK1/2 phosphorylation, while both IL-6 and LIF 
were able to induce protein synthesis at the time points when LIF phosphorylation was on 
basal level. Furthermore, ERK1/2 inhibitor had no effect on protein synthesis in LIF treated 
myotubes. Interestingly, ERK1/2 inhibitor alone increased myotube protein synthesis. 
These results suggest that potential crosstalk between ERK1/2 signaling and protein 
synthesis exist, but ERK1/2 seems to be independent from IL-6/LIF regulation of protein 
synthesis in myotubes. 
 
SOCS3, whose expression is induced by STAT3 activation, can inhibit STAT3 
signaling by binding the phosphotyrosines of JAK2, thus physically block binding of 
STAT3 to JAK2 (2), thus prevented the long term induction of gp130 signaling. Several 
previous studies suggest SOCS3 is a potential catabolic factors of skeletal muscle mass 
regulation. Long term in vivo IL-6 overexpression results in muscle protein synthesis 
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suppression and muscle wasting, which is associated with SOCS3 expression. Increased 
SOCS3 expression is observed in wasting skeletal muscles during cancer cachexia and 
sarcopenia (125, 214, 259). Further studies suggest that SOCS3 mays play an indirect role 
in muscle protein synthesis regulation by interacting with IGF-1-PI3K-Akt signaling 
pathways. For example, SOCS3 can target and degrade IRS-1 in inflammation-induced 
insulin resistance possibly via the elongin BC ubiquitin-ligase (260). Consistent with 
previous reports (204, 228), IL-6 and LIF induced a transient increase in STAT3 
phosphorylation, which coincided with the induction of SOCS3 expression by both IL-6 
and LIF. These results demonstrated that both IL-6 and LIF can activate the SOCS3 
dependent negative feedback mechanisms of gp130 signaling. Interestingly, we found 
similar time course regulation of IL-6 and LIF on myotube protein synthesis: it went to 
peak 2h post the addition of IL-6 or LIF and showed a trend to go back to basal level after 
longer IL-6 or LIF exposure. Most importantly, we report that SOCS3 siRNA known-down 
increased basal myotube protein synthesis, and SOCS3 siRNA knock-down resulted in 
longer term induction of IL-6 and LIF on myotube STAT3 phosphorylation and protein 
synthesis. These results demonstrate that the IL-6/LIF induced SOCS3 expression is an 
important negative regulator of myotube protein synthesis and further strengthen the 
catabolic role of SOCS3 in muscle mass regulation. However, it is still unknown whether 
SOCS3 can inhibit myotube protein synthesis through inhibiting gp130 signaling or IRS-
1/Akt signaling. More work is required to investigate the potential interplay of SOCS3 with 
gp130 signaling and anabolic signaling pathways in skeletal muscles. 
 
In summary, we examined the short term regulation of IL-6 family of cytokines, IL-6 
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and LIF, on protein synthesis in cultured myotubes. Both IL-6 and LIF are able to activate 
myotube mTOR signaling and protein synthesis in a time and dose sensitive manner. The 
gp130 receptor and PI3K/Akt signaling pathway is critical for this protein synthesis 
induction, as their inhibition blocked the IL-6 and LIF induction of protein synthesis. 
Interestingly, although IL-6 and LIF induced gp130-Akt signaling axis activated mTORC1 
signaling and can induce protein synthesis through mTORC1 independent mechanisms. 
STAT3 signaling plays a regulatory role in maintaining basal myotube protein synthesis, 
but STAT3 signaling is independent from the protein synthesis induction by IL-6 and LIF. 
Finally, IL-6/LIF induced SOCS3 expression is an inhibitor of protein synthesis, thus 
prevent long term protein synthesis activation by IL-6 or LIF. Our work provide a new 
insights into the involvement of IL-6 family of cytokines in muscle mass regulation, and 
further strengthen the anabolic role of physiological IL-6/gp130 signaling induction in 
muscle mass regulation. Further work is necessary to determine the potential mTOR 
independent mechanisms underlying IL-6/LIF induction of protein synthesis, and the role 
of protein synthesis induction by IL-6 or LIF in muscle regeneration and muscle 
hypertrophy. 
 
3.6 Figure Legends 
Figure 3.1: Myotube protein synthesis and mTOR signaling regulation by short term 
exposure of different cytokines. C2C12 myotubes were treated with different doses (5, 
10, 20, 100ng/ml) of IL-6, LIF and TNF-α for 2h. A. The protein synthesis was determined 
by puromycin incorporation. Dash lines represent different positions on the same gel. B. 
Quantified results of puromycin incorporation in A. *: p < 0.05 vs. control group, #: p < 
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0.05 vs. 5ng/ml and 10ng/ml groups, $: p < 0.05 vs. all other groups, one-way ANOVA. C. 
The phosphorylation of NF-κB in myotubes treated with different doses of TNF-α were 
measured by western blot. *: p < 0.05 vs. control group, one-way ANOVA. D. The 
phosphorylation of p70S6K and 4EBP1 in myotubes treated with different doses of IL-6 or 
LIF were measured by western blot. *: p < 0.05 vs. control group, one-way ANOVA. 
 
Figure 3.2: Role of gp130 in IL-6/LIF regulation of myotubes protein synthesis and 
mTORC1 signaling. C2C12 myotubes were transfected with 100nM control or gp130 
siRNA for 24h, which was followed with 2h exposure of IL-6 (20ng/ml) or LIF (10ng/ml). 
A. gp130 protein level in control or gp130 siRNA transfected myotubes treated 
with/without IL-6/LIF. #: main effect of gp130 siRNA, two-way ANOVA. B. Protein 
synthesis in control or gp130 siRNA transfected myotubes treated with/without IL-6/LIF 
was determined by puromycin incorporation. *: p < 0.05 vs. all other groups, two-way 
ANOVA. C. Phosphorylation of p70S6K in in control or gp130 siRNA transfected 
myotubes treated with/without IL-6/LIF was measured by western blot. *: p < 0.05 vs. all 
other groups, two-way ANOVA. 
 
Figure 3.3: Time course regulation of IL-6 or LIF on myotube gp130 dependent 
signaling pathways. C2C12 myotubes were treated with IL-6 (20ng/ml) or LIF (10ng/ml) 
for different time periods (30min, 1h, 2h or 4h). The phosphorylation of STAT3, ERK1/2 
and Akt were measured by western blot. *: p < 0.05 vs. control group, one-way ANOVA.  
 
Figure 3.4: Role of Akt-mTORC1 signaling in short term IL-6/LIF regulation of 
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myotube protein synthesis. C2C12 myotubes were pre-treated with PI3K/Akt signaling 
inhibitor, wortmannin (1μM) or mTORC1 inhibitor, rapamycin (10nM) for 1h, which was 
followed with 2h exposure of IL-6 (20ng/ml) or LIF (10ng/ml). The equal volume of 
DMSO was added into cell culture medium of control group. A-B. Phosphorylation of Akt 
(A) and p70S6K (B) in myotubes treated with/without IL-6/LIF or wortmannin was 
measured by western blots. Dash lines represent different positions on the same gel. *: p < 
0.05 vs. all other groups, two-way ANOVA. C. The protein synthesis in myotubes treated 
with/without IL-6/LIF or wortmannin was determined by puromycin incorporation. *: p < 
0.05 vs. all other groups, two-way ANOVA. D. Phosphorylation of p70S6K in myotubes 
treated with/without IL-6/LIF or rapamycin was measured by western blots. Dash lines 
represent different positions on the same gel. *: p < 0.05 vs. all other groups, two-way 
ANOVA. E. The protein synthesis in myotubes treated with/without IL-6/LIF or rapamycin 
was determined by puromycin incorporation. #: main effect of rapamycin, $: main effect 
of IL-6/LIF, two-way ANOVA. 
 
Figure 3.5: Role of STAT3 signaling in IL-6/LIF regulation of myotube protein 
synthesis. C2C12 myotubes were pre-treated with STAT3 signaling inhibitor, LLL12 (1μM) 
for 1h, which was followed with 2h exposure of IL-6 (20ng/ml) or LIF (10ng/ml). A. 
Phosphorylation of STAT3 in myotubed treated with/without LLL12 or IL-6 for 2h. *: p < 
0.05 vs. all other groups, two-way ANOVA. B. Phosphorylation of STAT3 in myotubed 
treated with/without LLL12 or LIF for 2h. #: main effect of LLL12, two-way ANOVA. C. 
Protein synthesis in myotubes treated with/without LLL12, IL-6 or LIF was determined by 
puromycin incorporation. Dash lines represent different positions on the same gel. #: main 
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effect of LLL12, $: main effect of IL-6/LIF, two-way ANOVA. D. Phosphorylation of 
p70S6K in myotubes treated with/without LLL12, IL-6 or LIF. Dash lines represent 
different positions on the same gel. #: main effect of LLL12, $: main effect of IL-6/LIF, 
two-way ANOVA.  
 
Figure 3.6: Role of ERK1/2 in LIF regulation of myotube protein synthesis. C2C12 
myotubes were pre-treated with ERK1/2 signaling inhibitor, PD98059 (20μM) for 1h, 
which was followed with 30 min (A) or 2h (B and C) exposure of LIF (10ng/ml). A. The 
phosphorylation of ERK1/2 in myotube with/without 1h PD98059 pretreatment and 30min 
LIF administration was determined by western blot. Dash lines represent different positions 
on the same gel. *: p < 0.05 vs. control group, one-way ANOVA. B. The phosphorylation 
of ERK1/2 in myotube with/without 1h PD98059 pretreatment and 2h LIF administration 
was determined by western blot. Dash lines represent different positions on the same gel. 
#: main effect of PD98059, two-way ANOVA. C. Protein synthesis was determined by 
puromycin incorporation. Dash lines represent different positions on the same gel. *: p < 
0.05 vs. control group, two-way ANOVA. 
 
Figure 3.7: Role of SOCS3 in time course regulation of IL-6/LIF on myotube protein 
synthesis. A. mRNA expression of SOCS3 in myotubes treated with IL-6 (20ng/ml) or LIF 
(10ng/ml) for different time periods (30min, 1h, 2h and 4h) was determined by RT-PCR. *: 
p < 0.05 vs. control group, #: p < 0.05 vs. all other groups, one-way ANOVA. B. The protein 
synthesis in myotubes treated with IL-6 (20ng/ml) or LIF (10ng/ml) for different time 
periods (1h, 2h and 4h) was determined by puromycin incorporation. *: p < 0.05 vs. control 
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group, #: p < 0.05 vs. all other groups, one-way ANOVA. C-D. C2C12 myotubes were 
transfected with control or SOCS3 siRNA for 24h, which was followed with 1h (C) or 4h 
(D) IL-6 (20ng/ml) or LIF (10ng/ml) administration. The SOCS3 mRNA expression (C) 
was measured by RT-PCR, [and puromycin incorporation (E) were measured by western 
blot. *: main effect of IL-6/LIF, #: main effect of SOCS3 siRNA, two-way ANOVA.  
 
Fig. 3.8: The IL-6 or LIF regulation on protein synthesis happens in differentiated 
myotubes. A: The protein expression of Cyclin D1 in myoblasts and 4 days differentiated 
myotubes treated with/without IL-6 (20ng/ml for 2h) or LIF (10ng/ml for 2h). B. Protein 
expression of Myogenein in myoblasts, 4 days and 8 days differentiated myotubes. C. 8 
days differentiated myotubes were treated with IL-6 (20ng/ml) or LIF (10ng/ml) for 2h. 
The protein synthesis was measured by puromycin incorporation. *: p < 0.05, student’s t-
test. D. C2C12 myotubes were incubated in differentiation medium supplemented with cell 
cycle inhibitor Ara-C (50μM) for 24h after 2 days differentiation. After 24h recovery period, 
myotubes were treated with IL-6 (20ng/ml) or LIF (10ng/ml) for 2h after Ara-C incubation. 
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The long term pathological elevation of IL-6 family of cytokines, including IL-6 and 
LIF, play a key role in muscle wasting during cachexia. The cachexia induced muscle 
wasting is caused by disrupted regulation of protein turnover, including both protein 
degradation activation and protein synthesis suppression. Previously work has 
demonstrated that IL-6 and LIF are able to induce muscle protein degradation by activating 
gp130-STAT3 signaling pathways. However, a complete understanding about their role in 
cachexia induced muscle protein synthesis suppression is limited. Therefore, we 
investigated the long term regulation of IL-6 and LIF on protein synthesis in cultured 
myotubes. C2C12 myotubes were treated with different doses of IL-6 or LIF for 24h. The 
role of STAT3 and AMPK signaling were investigated by pharmaceutical inhibition or 
siRNA knockdown. Both long term IL-6 and LIF exposure decreased myotube protein 
synthesis in a dose dependent manner, which is associated with the suppression of Akt-
mTOR signaling and activation of AMPK signaling. STAT3 signaling suppression had no 
effects on IL-6/LIF suppression of myotube protein synthesis. Inhibition of AMPK 
signaling by compound C during IL-6 or LIF treatment rescued the mTORC1 signaling and 
protein synthesis suppression by IL-6 or LIF. However, longer AMPK signaling 
suppression by siRNA knockdown decreased basal myotube protein synthesis. We also 
demonstrated that in vivo IL-6 overexpression can inhibit skeletal muscle mTORC1 
signaling and protein synthesis. These results demonstrate long term IL-6 and LIF exposure 
is enough to suppress protein synthesis in skeletal muscle cells, which is not dependent on 
STAT3 signaling. The different results from two AMPK signaling suppression experiments 
demonstrate that hyper-activation of AMPK signaling by IL-6 and LIF mediates IL-6/LIF 
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suppression mTOR signaling and protein synthesis, but basal AMPK signaling activity still 
play a role in maintaining protein synthesis in myotubes. F 
 
Key words: IL-6, LIF, muscle atrophy, mTOR, protein synthesis, STAT3, AMPK 
 
4.2 Introduction 
Cancer cachexia is metabolic syndrome that occurs in approximately 80% of cancer 
patients and accounts for 22–30% of cancer related death (31, 261). Cancer cachexia is 
characterized by unintentional loss of body weight caused by severe muscle wasting and 
loss of adipose tissue (31). Chronic inflammation is associated with diseases that induce 
muscle wasting, including cancer (6). Several cytokines are chronically up-regulated 
during cachexia in both human cancer and animal models, including IL-6, LIF, TNF-α, IL-
1β, CNTF, IFN-γ and IL-10 (262, 263). It is clear that the pathological elevation of these 
cytokines play a vital role in the development of muscle atrophy in cachexia (18, 125, 264, 
265). However, further research is needed to understand whether inflammatory cytokines 
exert direct or indirect effects on skeletal muscle, in altering protein turnover and inducing 
wasting. 
 
A large body of work has demonstrated the key role of long term elevated IL-6 and 
LIF has a key role in muscle wasting with cancer cachexia (118, 125, 214, 266, 267), and 
inhibition of IL-6 dependent signaling have now been considered as valuable therapeutic 
strategies to combat muscle wasting associated with chronic inflammatory conditions (265). 
The overexpression of IL-6 in transgenic mice and constant in vivo IL-6 infusion are 
enough to induce muscular atrophy (212, 268). A recent study also highlighted the 
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importance of LIF, another member of IL-6 family of cytokine, in cachexia induced muscle 
wasting (204). However, further research is needed to understand whether IL-6 and LIF 
exert direct or indirect effects on muscle wasting and muscle protein turnover in cachexia.  
 
Skeletal muscle mass is regulated by a balance of protein synthesis and protein 
degradation, termed as protein turnover. Altered protein turnover is an established 
regulatory point of both skeletal muscle mass loss and muscle growth. The skeletal muscle 
loss during cancer cachexia is associated with the activation of skeletal muscle protein 
degradation and the suppression of muscle protein synthesis. Whereas several 
inflammatory cytokine and their downstream signaling pathways, including TNF-α/ NF-
κB (143, 269), IL-6-glycoprotein 130-STAT3 (19, 202, 214, 266), and p38 MAPK (146), 
have been identified as important regulators of cachexia induced muscle protein 
degradation, gaps remain in our understanding of the mechanisms underlying the cachexia 
suppression of muscle protein synthesis.  
 
mTOR signaling pathway is the central regulator of muscle protein synthesis and 
muscle mass (14). mTOR, which function as a protein complex mTORC1, is the central 
regulator of protein synthesis can induce muscle protein synthesis through the 
phosphorylation of the p70 ribosomal S6 kinase (p70S6K) and eukaryotic initiation factor 
4E binding protein (4E-BP1), leading to increased ribosomal biogenesis and cap-dependent 
translation initiation (13). mTORC1 integrates multiple upstream signaling pathways 
involved in muscle mass regulation. In cancer cachexia, the dysregulation of protein 
synthesis is tightly associated with suppression mTOR signaling as assessed by decreased 
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phosphorylation of both 4E-BP1 and p70S6K1 (18, 19, 270). mTOR integrates several 
different upstream signaling pathways regulation muscle protein synthesis and muscle 
mass (241). mTOR signaling can be positively regulated by IGF-PI3K-Akt signaling (14, 
15), and negatively regulated by AMPK signaling (17). Suppression of muscle mTOR 
signaling has been demonstrated in cachexia patients and different animal models of cancer 
cachexia (118). The muscular atrophy induced by IL-6 infusion is associated with the 
reduction in p70S6K phosphorylation (212, 268). But the upstream signaling pathways 
regulating mTOR signaling during cancer cachexia still need to be determined.  
 
The IL-6 family of cytokines signals through gp130 by forming either a heterodimer 
or homodimer with the cytokine, its receptor, and gp130. Gp130 dimerization leads to 
activation of several intracellular signaling pathways (238). STAT3 signaling is a typical 
molecular hallmark IL-6/gp130 signaling induction. The role STAT3 signaling in cachexia 
induced muscle wasting has been well established (202, 214, 267). Present data 
demonstrate that STAT3 activation is necessary and sufficient for muscle wasting by cancer 
cachexia (202, 214). Induction of caspase-3, myostatin, and the ubiquitin-proteasome 
system are key mechanisms of STAT3 signaling regulation of muscle wasting during 
cachexia (202, 214, 215). However, no compelling evidence exist demonstrating the direct 
regulation of IL-6/STAT3 on muscle protein synthesis, and the role of IL-6 or STAT3 
signaling in muscle protein synthesis suppression during cancer cachexia is poorly 
understood. In addition to the classical gp130 dependent signaling cascades, Long term IL-
6 exposure also results in AMPK signaling activation in skeletal muscle cells (20). AMPK 
signaling can inhibit mTORC1 via the phosphorylation of different sites of TSC2 and 
95 
 
mTORC1 protein Raptor (17). Induction of muscle AMPK signaling was also observed in 
severe cachectic APCMIN/+ mice, a well-established IL-6 dependent cancer cachexia 
animal model, which manifested decreased muscle protein synthesis and suppression of 
mTOR signaling activity (18, 19). These results suggest that AMPK is a potential mediator 
of IL-6 suppression of protein synthesis in skeletal muscle.  
 
The purpose of this study is to determine if long term IL-6 or LIF administration can 
regulate myotube protein synthesis in skeletal muscle cells. We hypothesized that long term 
IL-6 or LIF would suppress protein synthesis in skeletal muscle cells by activating STAT3 
or AMPK signaling pathways. We examined the effects of different doses of IL-6 and LIF 
on mTOR signaling and protein synthesis in cultured myotubes. The role of STAT3 





C2C12 myoblasts (American Type Culture Collection, Manassas, VA) were cultured 
in DMEM supplemented with 10% FBS, 50 U/ml penicillin, and 50 μg/ml streptomycin. 
To induce C2C12 myoblast differentiation, C2C12 myoblasts were incubated in DMEM 
supplemented with 2% horse serum, 50 U/ml penicillin, and 50 μg/ml streptomycin for 4 





Differentiated C2C12 myotubes were treated with different doses (20 or 100ng/ml) of 
IL-6 (Sigma-Aldrich, St. Louis, MO) or LIF (Thermo Scientific, Waltham, MA) for 24h. 
To exclude the potential effects of cytokines in serum, myotubes were maintained in serum-
free condition during cytokine treatment. 
 
RNA interference: 
Three days after the onset of differentiation, C2C12 myotubes were transfected with 
scramble siRNA (GE Dharmacon, Lafayette, CO, USA) or siRNA targeting to STAT3 or 
AMPK (Santa Cruz Biotech, Santa Cruz, CA, USA) using Dharmafect 3 transfection 
reagent (GE Dharmacon) according to the manufacturer’s instructions. Briefly, siRNA and 
transfection reagent were separately diluted in serum-free and antibiotics-free DMEM and 
incubated at RT for 5min. The diluted transfection reagent was then added to the siRNA 
mixture and allowed to complex with siRNA for 20 min. siRNA-transfection reagent 
complexes were then added to the antibiotics-free differentiation medium, and myotubes 
were incubated for 24 h in the medium containing the transfection mixture. The final 
concentration of siRNA was set at 100 nM. 
 
STAT3 and AMPK signaling inhibition 
To inhibit myotube STAT3 signaling, STAT3 specific inhibitor C-188-9 (10μM, 
Sigma-Aldrich) was added to cell culture medium 2h before the IL-6/LIF administration. 
After 2h incubation, the culture media containing C-188-9 was changed into fresh culture 
medium containing IL-6 or LIF. To inhibit myotube AMPK signaling, AMPK specific 
inhibitor compound C (10μM, Sigma-Aldrich) was added into cell culture medium during 
97 
 
the 24h of IL-6 and LIF treatment. For both C-188-9 and compound C experiments, equal 
volume of DMSO was added to the culture medium of control groups.  
 
Animals 
The original C57BL/6 mice used in this study were purchased from Jackson 
Laboratories (Bar Harbor, ME) and bred at the University of South Carolina's Animal 
Resource Facility. All mice used in the present study were obtained from the investigator's 
breeding colony within the Center for Colon Cancer Research Mouse Core. Mice were kept 
on a 12:12-h light-dark cycle, and had access to standard rodent chow (no. 8604 Rodent 
Diet; Harlan Teklad, Madison, WI) and water ad libitum.  The University of South 
Carolina's Institutional Animal Care and Use Committee approved all animal 
experimentation in this study. 
 
In vivo IL-6 overexpression by electroporation 
In vivo intramuscular electroporation of an IL-6 plasmid was used to increase 
circulating IL-6 levels in mice as previously described (271). Mice (Male C57BL/6, ~10 
weeks old) were anesthetized with a 2% mixture of isoflurane (IsoSol, VEDCO, St. Joseph, 
MO) and oxygen (1 L/min). The quadriceps muscle was used to synthesize and secrete 
exogenous IL-6 into circulation from the injected expression plasmid, and was not used for 
any analyses in the study. Briefly, mice were injected with 40 μg of IL-6 plasmid driven by 
the CMV promoter, or control plasmid (pV1J), into the right quadriceps muscle. The leg 
was shaved, and a small incision was made over the quadriceps muscle. Fat was dissected 
away from the muscle, and the plasmid was injected in a 50 μl volume of sterile phosphate-
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buffered saline (PBS). A series of eight 50 ms, 100 V pulses was used to promote uptake 
of the plasmid into myonuclei, and the incision was closed with a wound clip.  
 
Tissue Collection 
All mice were sacrificed 5 days post intramuscular plasmid electroporation. After 5h 
fasting, mice were anesthetized with a subcutaneous injection of ketamine-xylazine-
acepromazine cocktail (1.4 ml/kg body wt) at the time of death. Hindlimb muscles were 
rapidly excised, cleared of excess connective tissue, rinsed in PBS, weighed, and snap 
frozen in liquid nitrogen. The TA muscle was frozen in liquid nitrogen. Blood was collected 
before muscle collection via retro-orbital eye bleed with heparinized capillary tubes, placed 
on ice, and centrifuged (10,000 g for 10 min at 4°C). The supernatant was removed and 




Western blot analysis was performed as previously described (226). Briefly, cells were 
washed by ice-cold PBS and then scraped into ice-cold RIPA buffer [50 mM Tris, 150 mM 
NaCl, 1% Triton X-100, 1 mM EDTA, 0.5% sodium deoxycholate, 0.1% SDS, 5 mM NaF, 
1 mM NaVO4, 1 mM β-glycerophosphate, and 1% protease inhibitor cocktail (Sigma-
Aldrich)]. Cell lysates were homogenized on ice and centrifuged at 4°C, and supernatants 
were collected. Protein concentrations were determined by the Bradford reagent (Bio-Rad) 
following the manufacturer’s instructions. Protein were fractionated in SDS-
polyacrylamide gels and transferred to polyvinylidene fluoride membranes. After the 
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membranes were blocked, antibodies for phosphorylated/total ERK1/2, STAT3, NF-κB p65, 
Akt, p70S6K, 4EBP1, GAPDH (Cell Signaling Technology), gp130 (Santa Cruz 
Biotechnology), and puromycin (Millipore, Billerica, MA) were incubated at dilutions 
from 1:2,000 to 1:8,000 overnight at 4°C in 2% Tris-buffered saline-Tween 20 milk. Anti-
rabbit or anti-mouse IgG-conjugated secondary antibodies (Cell Signaling Technology) 
were incubated with the membranes at 1:2,000 to 1:5,000 dilutions for 2 h in 2% Tris-
buffered saline-Tween 20 milk. Enhanced chemiluminescence (Advansta, Menlo Park, CA) 
developed by autoradiography was used to visualize the antibody-antigen interactions. 
Blots were analyzed by measuring the integrated optical density (IOD) of each band with 
ImageJ software (National Institutes of Health, Bethesda, MD). 
 
RNA isolation, cDNA synthesis, and real-time PCR 
RNA isolation was performed using Trizol Reagent (Thermo scientific) according to 
the manufacturer’s instructions. cDNA synthesis, and real-time PCR were performed as 
previously described, using reagents from Applied Biosystems (Foster City, CA, USA). 
Quantitative real-time PCR analysis was carried out in 20-ul reactions consisting of 2 × 
SYBR Green PCR buffer (AmpliTaq Gold DNA Polymerase, Buffer, dNTP mix, AmpErase 
UNG, MgCl2), 0.1ul of cDNA, RNase-free water, and 60 nM of each primer. The 
sequences of SOCS3 primers set are5’-TGCAGGAGAGCTGATTCTAC-3’ (forward) and 
5’-TGACGCTCAACGTGAAGAAG (reverse). The sequence of GAPDH primers were 
published elsewhere (19). Data were analyzed by ABI software using the cycle threshold 
(CT), which is the cycle number at which the fluorescence emission is midway between 
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detection and saturation of the reaction. The SOCS3 data of each sample was normalized 
by its GAPDH results.  
 
Protein synthesis measurement 
The myotube protein synthesis was determined by puromycin incorporation as 
previously described (227). In brief, puromycin (EMD Chemicals, San Diego, CA) was 
added into cell culture media (1 μM final concentration) 30 min before protein collection. 
To determine protein synthesis in mouse skeletal muscle, 0.04 mmol/g BW puromycin 
(solved in PBS) was given to mouse by i.p. injection 30 min before sacrifice. The amount 
of puromycin incorporated into newly synthesized protein was determined by Western blots. 
The protein samples from myotubes without puromycin labelling were used as negative 
control. 
 
Plasma IL-6 level 
For each mouse, blood samples were taken at the time of electroporation (D-0), 4 days 
post electroporation (D-5) and time of sacrifice (5 days post electroporation, D-5) by eye 
bleeding. Mice were fasted for at least 5h before blood sample collection. Blood samples 
were centrifuged by 10000 rpm for 10min at 4°C, and the supernatant were collected and 
kept frozen at -80°C before assay. Plasma IL-6 was determined by mouse ELISA kid 
purchased from BD Bioscience (Franklin Lakes, NJ) following manufacturer’s instructions. 
In brief, 96-well plate was coated with capture antibody (1:250, solved in 0.1M sodium 
carbonate, pH 9.5, 100 μl/well) overnight at 4°C. The plate was then blocked by assay 
diluent (10% FBS in PBS, 100μl/well) for 1h at RT, incubated with IL-6 standards (range 
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from 16pg/ml to 1000 pg/ml, solved in assay diluent, 100 μl/well) or plasma samples 
(100μl/well) for 2h at RT, incubated with working detector (1: 250 detection antibody and 
1:500 Sav-HRP reagent, solved in assay diluent), incubated in Tetramethybenzidine 
(TMB)-H2O2 substrate (100μl/well) for 30min in dark. Plates were washed by PBS with 
0.05% tween 3-7 time between steps. The reaction was stopped by adding 2N H2SO4 (100 




Student's t-test, one-way ANOVA, and two-way ANOVA (indicated in figure legends) 
were used to examine the effects of cytokines and signaling inhibition. For all comparisons, 




Long term IL-6 and LIF exposure inhibited myotube mTORC1 signaling and protein 
synthesis 
To determine the regulation of myotube protein synthesis by long term exposure of IL-6 
family of cytokines, myotubes were incubated with different doses of IL-6 or LIF for 24h. 
24h exposure of 20 ng/ml IL-6 significantly decreased myotube protein synthesis, and 100 
ng/ml IL-6 showed further suppression (Fig. 4.1A). Both 20 ng/ml and 100 ng/ml LIF 
showed similar inhibitory effects on myotube protein synthesis (Fig. 4.1A). We also 
measured the phosphorylation of p70S6K and 4EBP1, which are downstream targets of 
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mTORC1. Both 20 ng/ml and 100 ng/ml IL-6 decreased p70S6K phosphorylation, while 
only 100ng/ml LIF suppressed p70S6K phosphorylation (Fig. 4.1B). IL-6 and LIF also 
suppressed 4EBP1 phosphorylation in a dose dependent manner (Fig. 4.1B). These results 
demonstrate that long term IL-6 or LIF exposure can negatively regulate mTORC1 
signaling and protein synthesis in cultured myotubes. 
 
Long term IL-6 and LIF regulation on myotube signaling pathways. 
To understand the potential mechanisms underlying the long term IL-6 and LIF suppression 
of myotube protein synthesis, we investigated the effects of IL-6 and LIF on gp130 
dependent signaling pathways, including STAT3, ERK1/2 and Akt. Long term IL-6 
administrated increased STAT3 phosphorylation in a dose dependent manner (Fig. 4.2A). 
However, none of LIF dosages demonstrate the induction STAT3 phosphorylation (Fig. 
4.2A). Similar with STAT3 results, IL-6, but not LIF, increased ERK1/2 phosphorylation 
(Fig. 4.2A). Interestingly, both IL-6 and LIF decreased Akt phosphorylation in a dose 
dependent manner (Fig. 4.2A). The SOCS3 mRNA level was elevated in myotube treated 
with LIF, but not IL-6 (Fig. 4.2B). Both IL-6 and LIF increased AMPK phosphorylation in 
a dose dependent manner (Fig. 4.2C).  
 
Role of STAT3 in IL-6/LIF regulation of myotube protein synthesis 
STAT3 is a classical downstream effector of gp130 signaling and pathological activation 
of STAT3 signaling plays a pivotal role in dysregulation of muscle protein turnover and 
muscle wasting in cachexia. To determine the role of STAT3 signaling in protein synthesis 
suppression by long term IL-6 or LIF, we inhibited STAT3 signaling by STAT3 specific 
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inhibitor, C-188-9 and STAT3 siRNA knock-down. In C-188-9 experiment, myotubes were 
pre-treated with C-188-9 for 2h prior to the addition of IL-6 or LIF (Fig. 4.3A). In STAT3 
siRNA experiment, myotubes were transfected with control or STAT3 siRNA for 24h, 
followed with 24h IL-6 or LIF treatment (Fig. 4.3A). C-188-9 decreased basal STAT3 
phosphorylation (Fig. 4.3B, C), also blocked the IL-6 induction of STAT3 phosphorylation 
(Fig. 4.3B). LIF did not change the STAT3 phosphorylation in either control or C-188-9 
treated myotubes (Fig. 4.3C). Long term IL-6 or LIF exposure suppressed p70S6K 
phosphorylation (Fig. 3C) and protein synthesis (Fig. 4.3D) in control myotubes. 
Interestingly, C-188-9 alone decreased basal myotube p70S6K phosphorylation (Fig. 4.3C) 
and protein synthesis (Fig. 4.3D). IL-6 or LIF did not result in further decrease in p70S6K 
phosphorylation (Fig. 4.3C) or protein synthesis (Fig. 4.3C) in C-188-9 pretreated 
myotubes. In STAT3 siRNA experiment, STAT3 siRNA transfection decreased myotube 
STAT3 protein level, which was independent of IL-6 or LIF (Fig. 4.3E). STAT3 siRNA 
transfection also decreased basal STAT3 phosphorylation, and blocked the induction of 
STAT3 phosphorylation by IL-6 (Fig. 4.3E). Similar with the results of C-188-9 
experiments, long term IL-6 or LIF exposure decreased protein synthesis in control siRNA 
transfected myotubes (Fig. 4.3F). STAT3 siRNA transfection decreased protein synthesis 
in both control and IL-6/LIF treated myotubes (Fig. 4.3F), but long term IL-6 or LIF 
exposure did not change protein synthesis in STAT3 siRNA transfected myotubes (Fig. 
4.3F). These results demonstrate STAT3 signaling is not necessary for myotube protein 
synthesis suppression by long term IL-6 or LIF exposure.  
 
Role of AMPK signaling in IL-6 and LIF regulation of myotube protein synthesis 
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AMPK is an important upstream suppressor of mTORC1 signaling and the induction of 
AMPK is involved in muscle protein synthesis suppression in different models of cancer 
cachexia. We observed both IL-6 and LIF induced AMPK signaling (Fig. 4.2C). To 
examine the role of AMPK signaling in myotube protein synthesis suppression by long 
term IL-6 or LIF, myotube AMPK signaling was inhibited by AMPK inhibitor, compound 
C or AMPK siRNA transfection. Myotubes were pretreated with compound C (10μM) 2h 
before IL-6/LIF treatment, or transfected with control or AMPK siRNA for 24h before IL-
6/LIF treatment (Fig. 4.4A). As previously reported, compound C decreased basal AMPK 
phosphorylation and blocked the induction of AMPK phosphorylation by IL-6 or LIF (Fig. 
4.4B). Compound C increased basal p70S6K phosphorylation (Fig. 4.4C), and rescued the 
IL-6 and LIF suppression of p70S6K phosphorylation (Fig. 4.4C). Most importantly, 
compound C alone showed a dramatic protein synthesis induction (Fig. 4.4D). Compound 
C also dramatically induced protein synthesis in the presence of IL-6 or LIF (Fig. 4.4D). 
AMPK siRNA transfections decreased basal AMPK protein level, which was independent 
of IL-6 or LIF (Fig. 4.4E). Similar with the inhibitory effects of compound C, AMPK 
siRNA decreased basal AMPK phosphorylation, and prevented IL-6 or LIF induction of 
AMPK phosphorylation (Fig. 4.4E). Surprisingly, AMPK siRNA transfection decreased, 
but not increased, basal protein synthesis and p70S6K phosphorylation (Fig. 4.4F). Long 
term IL-6 and LIF treatment showed no further protein synthesis suppression in AMPK 
siRNA transfected myotubes (Fig. 4.4F). These results demonstrate a complex role of 
AMPK signaling in IL-6/LIF regulation of myotube protein synthesis: AMPK signaling 
activation by long term IL-6 and LIF exposure is a key mediator of myotube protein 
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synthesis suppression, but basal AMPK signaling is still required for maintaining protein 
synthesis in myotubes. 
 
Regulation of in vivo IL-6 overexpression on skeletal muscle protein synthesis 
To further determine if long term exposure of IL-6 family of cytokines can regulate skeletal 
muscle protein synthesis in vivo, we overexpressed IL-6 in C57BL6 mice by transfecting 
the IL-6 overexpression plasmid driven by the CMV promoter into quadriceps muscles. 
The plasma IL-6 levels of both control and IL-6 overexpressing mice were below the 
detection level at the time of plasmid transfection (Table. 4.1). We found the elevation of 
plasma IL-6 4-days and 5-days post transfection in IL-6 overexpressing mice (135.4 ± 
42.3pg/ml on day 4 and 423.7 ± 115.2pg/ml on day 5), but not in control mice (Table. 4.1). 
5 days IL-6 overexpression did not the body weight or the hind limb muscle weights (Table. 
4.1). Consistent with the elevation of plasma IL-6, the STAT3 phosphorylation in TA 
muscle was also elevated in IL-6 overexpressing mice (Fig. 4.5A). Most importantly, IL-6 
overexpression decreased the phosphorylation of p70S6K (Fig. 4.5B) and protein synthesis 
(Fig. 4.5C) in TA muscles. These results demonstrate long term plasma IL-6 elevation can 
inhibit mTORC1 signaling and decrease protein synthesis in skeletal muscles. 
 
4.5 Discussion 
Skeletal muscle wasting in cancer cachexia involves the disrupted homeostatic 
regulation of muscle protein turnover, including the protein degradation activation and 
protein synthesis suppression (118). However, our understanding of protein degradation 
regulation during the wasting process exceeds our understanding of protein synthesis. Long 
106 
 
term elevation of IL-6 family of cytokines, IL-6 and LIF, have acknowledged role in muscle 
proteolysis and muscle wasting in cancer cachexia, but their role in cachexia induced 
muscle protein synthesis suppression is poorly understood. Here, we report important and 
novel finding that long term exposure of IL-6 or LIF can negatively regulate mTOR 
signaling and protein synthesis in myotubes, and long term plasma IL-6 elevation also 
decreased muscle protein synthesis in vivo. IL-6 and LIF suppression of myotube protein 
synthesis is associated with the induction of gp130 and AMPK signaling. Inhibition of 
STAT3 signaling pathway did not rescue the protein synthesis suppression by IL-6 or LIF. 
AMPK signaling inhibition during IL-6/LIF exposure rescued their inhibition of protein 
synthesis. However, long term AMPK signaling inhibition before IL-6 and LIF treatment 
suppressed myotube protein synthesis. These results demonstrated that IL-6 or LIF alone 
are enough to suppress protein synthesis in skeletal muscle cells by the hyper-activation of 
AMPK signaling. However, basal AMPK signaling may play a role in maintaining protein 
synthesis. 
 
IL-6 family of cytokine induces STAT3 phosphorylation and transcriptional activation 
though gp130 signaling. Activated STAT3 signaling induces expression of SOCS3, which 
block the signaling transduction from gp130 to STAT3 and prevent the constant gp130 
signaling inductions under physiological conditions. Here, we investigated the long term 
IL-6/LIF regulation on myotube gp130 signaling. Long term IL-6 and LIF exposure 
demonstrated differential regulation of gp130 signaling: 24h IL-6 exposure increased 
phosphorylation of STAT3 and ERK1/2 in a dose dependent manner, but LIF did not change 
their phosphorylation. Interestingly, the SOCS3 expression is only induced in myotube 
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treated with LIF, but not IL-6, suggesting the IL-6 induced STAT3 and ERK1/2 signaling 
is caused by disrupted SOCS3 dependent negative feedback mechanisms. Both IL-6 and 
LIF decreased Akt phosphorylation, which is a potential contributor to IL-6/LIF 
suppression of mTOR and protein synthesis. Taken together, these results demonstrate the 
differential regulation of gp130 signaling between short term and long term IL-6/LIF 
exposure.  
 
STAT3 is a well-established downstream effector of IL-6 family of cytokines (238). 
Once activated, STAT3 translocate into nucleus and regulate the transcription to target 
genes, which involved in a large variety of cellular processes. STAT3 signaling activation 
also induces the expression of SOCS3, which inhibits signal transduction from gp130 to its 
downstream effector, and ensures a transient pattern of gp130 dependent signaling under 
physiological conditions (193, 238). Constant elevation of IL-6 family of cytokines in 
cachexia induces pathological activation of muscle gp130/STAT3 signaling, which plays a 
key role in muscle proteolysis genes transcription and muscle wasting (18, 202, 214). 
However, the potential regulation of STAT3 on muscle protein synthesis in cachectic 
muscles has not been proposed yet. Here, we report that long term IL-6 administration 
induced STAT3 signaling in myotubes, however, this induction was not observed in LIF 
treated myotubes. We have shown short term administration of both IL-6 and LIF induced 
a transient STAT3 phosphorylation, which was associated with the induction of SOCS3 
expression. Interestingly, we observed increased SOCS3 expression in myotubes under the 
long term exposure of LIF but not IL-6, suggesting the disrupted SOCS3 dependent 
negative feedback loop may account for the IL-6 induction STAT3 signaling. Unlike the 
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differential regulation of STAT3 signaling, both IL-6 and LIF demonstrate suppression of 
myotube protein synthesis. Furthermore, we reported either STAT3 pharmaceutical 
inhibitor C-188-9 or STAT3 siRNA knockdown was not able to rescue the IL-6/LIF 
suppression of myotube protein synthesis. These result further support our previous 
findings that STAT3 signaling inhibition did not rescue the LLC induced myotube protein 
synthesis suppression (272), and demonstrate STAT3 signaling is not necessary for IL-
6/LIF suppression of muscle protein synthesis in cancer cachexia. Similar with the effects 
of LLL12, long term STAT3 signaling inhibition by C-188-9 or STAT3 siRNA suppressed 
myotube mTOR signaling and protein synthesis, which suggests that STAT3 signaling may 
play a role in maintaining basal protein synthesis in skeletal muscle cells.  
 
An energy deficiency or cachectic environment can induce the induction AMPK 
signaling, which plays a role in catabolic shift of muscle protein turnover regulation, 
through mTOR signaling inhibition (17), induction of FOXO-dependent E3 ubiquitin 
ligase transcription (273), and increased autophagy processes (274). Muscle AMPK 
signaling is chronically activated in severe cachectic ApcMIN/+ mice, an IL-6 dependent 
cachexia animal model (18). Consistent with previous findings (20), long term IL-6 and 
LIF induced AMPK phosphorylation in myotubes was observed. Most notable the 
inhibition of myotube AMPK activity during IL-6/LIF treatment can rescue IL-6/LIF 
suppression of protein synthesis. These results further strengthen the well-established 
inhibitory role of AMPK signaling on protein synthesis regulation (68), and further 
strengthen the role of pathological AMPK signaling induction as a key mediator of muscle 
protein synthesis suppression in cancer cachexia (20). These results also demonstrate that 
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AMPK is an important mediator of IL-6 and LIF suppression of myotube protein synthesis. 
Surprisingly, long term AMPK signaling inhibition by siRNA transfection before IL-6/LIF 
administration decreased basal protein synthesis, and showed no rescue effects on protein 
synthesis suppression by IL-6 or LIF. One possible reason is that the induction of protein 
synthesis by compound C is caused by its off-target effects (275). However, previously 
reported was that compound C can block Akt/mTOR signaling independent of AMPK 
suppression, which is opposite to our observations (272). Notably, unlike the AMPK 
suppression by compound C during the IL-6/LIF administration, siRNA transfection was 
conducted 24h prior to the addition of IL-6 or LIF. One potential possibility is that the 
different duration of AMPK signaling inhibition opposite effects of two AMPK signaling 
inhibitors. Previously studies also reported different duration of AMPK signaling showed 
differential regulation of protein synthesis: AMPK signaling inhibition by compound C 
during 24h palmitate treatment rescued palmitate suppression of p70S6K phosphorylation 
in cultured myotubes (276). However, over 24h AMPK signaling inhibition by siRNA 
knockdown resulted in induction (277) or suppression (278) of mTOR signaling in different 
cell types. These results suggest a complicated, cell type specific, role of basal AMPK 
signaling in protein synthesis regulation, and basal AMPK signaling may play a role in 
maintaining myotube protein synthesis. In addition to the direct inhibitory effects on mTOR 
signaling, AMPK is a documented signaling nexus controlling energy metabolism, 
including glucose transportation, oxidative metabolism, mitochondrial biogenesis, fatty 
acid oxidation and autophagy process (279). AMPK can sensitize the insulin action on 
PI3K/Akt signaling by the inhibition of the insulin-induced negative feedback loop (272). 
Another possibility is that long term inhibition of AMPK signaling by siRNA knock-down 
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may inhibit protein synthesis indirectly by the dysregulation of metabolic homeostasis. 
More work is still needed to determine the potential indirect regulation of AMPK signaling 
on muscle protein synthesis regulation. 
 
In summary, we examined the long term regulation of IL-6 related cytokines, IL-6 and 
LIF on protein synthesis in cultured myotubes and skeletal muscles. Long term exposure 
of IL-6 or LIF suppressed mTOR signaling and protein synthesis, which is not dependent 
on STAT3 signaling. Interestingly, different duration of AMPK signaling inhibition 
demonstrated a very complicated role in myotube protein synthesis regulation: activation 
of AMPK signaling mediates the IL-6/LIF suppression of myotube protein synthesis, while 
basal AMPK signaling is still necessary for maintaining protein synthesis. Furthermore, we 
also demonstrated long term IL-6 elevation is enough to suppress skeletal muscle protein 
synthesis in vivo. These results provide new insights of the role of IL-6 family of cytokines 
on muscle mass regulation under pathological conditions and further extend the 
understanding of the mechanism underlying skeletal muscle wasting in cancer cachexia. 
However, due to the potential disruption of myotube protein synthesis by long term AMPK 
signaling inhibition, targeting AMPK signaling may not be the optimal therapy to attenuate 
muscle protein synthesis in cachexia. Further work is still needed to determine the 




4.6 Figure Legend 
Figure 4.1: Regulation of long term IL-6 and LIF on myotube protein synthesis and 
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mTOR signaling. C2C12 myotubes were treated with difference doses (20ng/ml and 
100ng/ml) of IL-6 or LIF for 24h. A. Protein synthesis was determined by puromycin 
incorporation. B. The phosphorylation of p70S6K and 4EBP1 were measured by western 
blot. For A and B, *: p < 0.05 vs. control group, #: p < 0.05 vs. 20ng/ml group, one-way 
ANOVA. 
 
Figure 4.2: Regulation of long term IL-6 and LIF on myotube gp130 dependent 
signaling and AMPK signaling. C2C12 myotubes were treated with difference doses 
(20ng/ml and 100ng/ml) of IL-6 or LIF for 24h. A. The phosphorylation of STAT3, ERK1/2, 
Akt were measured by western blot. *: p < 0.05 vs. control group, #: p < 0.05 vs. 20ng/ml 
group, one-way ANOVA. B. The SOCS3 mRNA expression was measured by RT-PCR. *: 
p < 0.05 vs. control group, one-way ANOVA. C. The phosphorylation of AMPK were 
measured by western blot. *: p < 0.05 vs. control group, #: p < 0.05 vs. 20ng/ml group, one-
way ANOVA. 
 
Figure 4.3: Role of STAT3 signaling in long term IL-6 and LIF regulation of myotube 
protein synthesis. A. Experiment design. B. Phosphorylation of STAT3 in myotubes 
treated with/without IL-6, LIF or C-188-9, Dash lines represent different parts on the same 
gel. *: p < 0.05 vs. all other groups, #: p < 0.05, main effect of C-188-9, two-way ANOVA. 
C. Phosphorylation of p70S6K in myotubes treated with/without IL-6, LIF or C-188-9, 
Dash lines represent different parts on the same gel. *: p < 0.05 vs. control group, #: p < 
0.05, vs. IL-6 group, two-way ANOVA. D. Protein synthesis in myotubes treated 
with/without IL-6, LIF or C-188-9 was determined by puromycin incorporation. Dash lines 
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represent different parts on the same gel. *: p < 0.05 vs. control group, #: p < 0.05, vs. IL-
6/LIF group, two-way ANOVA. E. Phosphorylation of STAT3 and total STAT3 in control 
or STAT3 siRNA transfected myotubes treated with/without IL-6 or LIF. *: p < 0.05 vs. all 
other groups, #: p < 0.05 vs. control groups, $: p < 0.05, main effect of STAT3 siRNA, two-
way ANOVA. F. Protein synthesis in control or STAT3 siRNA transfected myotubes treated 
with/without IL-6 or LIF was determined by puromycin incorporation. Dash lines represent 
different parts on the same gel. *: p < 0.05 vs. control group, #: p < 0.05, vs. IL-6/LIF group, 
two-way ANOVA. 
 
Figure 4.4: Role of AMPK signaling in long term IL-6 and LIF regulation of myotube 
protein synthesis. A. Experiment design. B. Phosphorylation of AMPK in myotubes 
treated with/without IL-6, LIF or compound C, Dash lines represent different parts on the 
same gel. *: p < 0.05 vs. all other groups, #: p < 0.05 vs. control groups, two-way ANOVA. 
C. Phosphorylation of p70S6K in myotubes treated with/without IL-6, LIF or compound 
C, Dash lines represent different parts on the same gel. *: p < 0.05 vs. control group, #: p 
< 0.05 vs. IL-6/LIF group, two-way ANOVA. D. Protein synthesis in myotubes treated 
with/without IL-6, LIF or compound C was determined by puromycin incorporation. Dash 
lines represent different parts on the same gel. *: p < 0.05 vs. control group, #: p < 0.05, vs. 
IL-6/LIF group, two-way ANOVA. E. Phosphorylation of AMPK and total AMPK in 
control or AMPK siRNA transfected myotubes treated with/without IL-6 or LIF. *: p < 0.05 
vs. all other groups, #: p < 0.05 vs. control groups, $: p < 0.05, main effect of AMPK siRNA, 
two-way ANOVA. F. Protein synthesis in control or AMPK siRNA transfected myotubes 
treated with/without IL-6 or LIF was determined by puromycin incorporation. Dash lines 
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represent different parts on the same gel. *: p < 0.05 vs. control group, #: p < 0.05, vs. IL-
6/LIF group, two-way ANOVA. 
 
Figure 4.5: Regulation of in vivo IL-6 over-expression on muscle mTORC1 signaling 
and protein synthesis. IL-6 was overexpressed in male C57BL/6 mice (~10 weeks old) by 
transfecting 40 μg of IL-6 plasmid driven by the CMV promoter into quadriceps muscles. 
All mice were sacrificed after 5 days overexpression. A-B. Phosphorylation of STAT3 (A) 
and p70S6K (B) in TA muscles were measured by western blot. C. Protein synthesis in TA 






    Control (n=7) IL-6 OE (n=8) 
Plasma IL-6 (pg/ml) D-0 N.D. N.D. 
 D-4 N.D. 135.4±42.3* 
 D-5 (Sac) N.D. 423.7±115.2* 
Body Weight   25.4 ±1.4 24.9±1.1 
Muscle Weight Solues 7.3±1.3 6.9±1.0 
 Plantaris 17.3±1.4 17.0±1.7 
 Gastroc 124.2±6.5 120.6±6.4 
 EDL 8.1±1.2 8.1±1.2 
  T.A. 43.5±3.2 44.8±3.3 
Tibia Length   17.1±0.1 17.0±0.1 
 
  
Table 4.1: Phenotype of IL-6 overexpression mice. Plasma IL-6 levels in 
control or IL-6 overexpressing mice at the time of transfection (D-0), 4-days (D-
4) and 5 days (D-5) post transfection. Muscle wet weights were recorded during 
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Figure 4.2: Regulation of long term IL-6 and LIF on myotube gp130 







Figure 4.3: Role of STAT3 signaling in long term IL-6 and LIF regulation of 







Figure 4.3: Role of STAT3 signaling in long term IL-6 and LIF regulation of 








Figure 4.4: Role of AMPK signaling in long term IL-6 and LIF regulation 







Figure 4.4: Role of AMPK signaling in long term IL-6 and LIF regulation of 







  Figure 4.5: Regulation of in vivo IL-6 over-expression on muscle mTORC1 




IL-6 AND LIF REGULATION OF MECHANICAL STIMULI 
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Mechanical stimulus from stretch or contractions can activate muscle and myotube 
protein synthesis through the induction of mTOR signaling. Short term, physiological 
elevation IL-6 and LIF plays a key role in mechanical stimulus induced muscle hypertrophy. 
While long term, pathological elevation of IL-6 and LIF are key players in cachexia 
induced atrophic environment, which also has a potential to disrupt muscle mechanical 
signaling. IL-6 and LIF role in muscle hypertrophy and atrophy has been established, but 
the effect of this cytokines on mechanical signaling in skeletal muscle has not been 
determined. We investigated whether IL-6 or LIF can regulate the stretch or eccentric 
contraction induction of protein synthesis in myotubes or skeletal muscles, respectively. To 
determine short term IL-6 or LIF regulation on myotube mechanical signaling, C2C12 
myotubes were stretched for 4h in the presence of IL-6 or LIF. To determine the long term 
IL-6 or LIF regulation on myotube mechanical signaling, C2C12 myotube were 
preincubated in IL-6 or LIF for 24h and stretched in last 4h. To determine the IL-6 
regulation of muscle protein synthesis induction by eccentric contractions, High Frequency 
Electrical Stimulation (HFES) induced eccentric contractions of the left tibialis anterior 
muscle the control and IL-6 overexpressing mice was conducted. Protein synthesis and 
mTOR signaling regulation were examined in each experiment. Short term IL-6 and LIF 
administration increased basal mTOR signaling activity and protein synthesis, but stretch 
in the presence of IL-6 or LIF decreased mTOR signaling activity and protein synthesis in 
IL-6/LIF treated myotubes. Long term IL-6 or LIF treatment decreased mTOR signaling 
activity and protein synthesis and attenuated the stretch induction of protein synthesis. 
However, HFES increased mTOR signaling activity and protein synthesis in both control 
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and IL-6 overexpressing mice. These results demonstrate that IL-6 and LIF can dissociate 
stretch-induced signaling from protein from protein synthesis in cultured myotubes. But 
IL-6 had no influence on muscle protein synthesis regulation by eccentric contraction 
induced mechanical signaling.  
 
Key words: IL-6, LIF, mTOR, protein synthesis, mechanical signaling, cachexia 
 
5.2 Introduction 
Skeletal muscle mass has a well-documented role in health and quality of life. The 
skeletal muscle mass is sensitive to large variety of systemic changes including the physical 
activity level and inflammatory cytokines, which can regulate multiple cellular processes 
involved in protein synthesis and protein degradation in skeletal muscle fibers (1). IL-6 
family of cytokines have a pleiotropic functions in different tissues and organs, and plays 
a role in both skeletal muscle hypertrophy and atrophy (5). In response to contractions or 
overload, skeletal muscle produces and releases significant levels of IL‐6, which has been 
associated with stimulation of hypertrophic muscle growth and myogenesis through 
regulation of the proliferative capacity of muscle stem cells. Paradoxically, chronic 
elevation of IL-6 and LIF can promote muscle wasting in cancer cachexia. Until now, no 
clear explanation about contradictory role of IL-6 family of cytokines in muscle mass 
regulation exists. 
 
Mechanical stimuli such as loading or stretch induce an anabolic response in skeletal 
muscle that is important for the maintenance of mass and function (23). Cultured myotubes 
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respond to chronic or intermittent stretch through increased protein synthesis, 
morphological maturation, and development of the contractile apparatus (280, 281). 
Eccentric contractions induced by high frequency electrical stimulation (HFES) in vivo is 
also a strong inducer of muscle signaling associated with hypertrophy (90, 95, 282), and 
demonstrated a therapeutic effects to attenuating muscle mass loss in tumor bearing mice 
(283, 284). The signaling pathways induced by mechanical stimulation, known as 
mechanical signaling, can regulate skeletal muscle hypertrophy via the induction of mTOR 
signaling and subsequent muscle protein synthesis (22, 101). The subsequent 
phosphorylation of p70S6K, S6RP and 4EBP1 by mTOR signaling activation are key 
inducer of molecular processes involved in muscle protein synthesis, including ribosomal 
RNA and protein transcription, ribosomal biogenesis, translation initiation, and the 
induction of protein synthesis (46). Until now, multiple signaling pathways including 
phospholipase D/ phosphatidic acid (285, 286) and ERK1/2 (16) are involved in the process. 
Exercise or muscle overload also induce a short term elevation of plasma IL-6 and muscle 
expression of IL-6 and LIF (8, 237), and both IL-6 and LIF are necessary for overload-
induced muscle hypertrophy (7, 8). IL-6 and LIF dependent signaling has been associated 
with stimulation of hypertrophic muscle growth through regulation of the proliferative 
capacity of muscle stem cells, but their role in mechanical stimuli induction of muscle 
protein synthesis still need to be determined. 
 
Unlike their positive role of mechanical stimuli induced skeletal muscle hypertrophy, 
chronic elevation of systematic IL-6 and LIF plays a key role in muscle wasting under some 
pathological conditions, include cancer cachexia. Disruption of protein turnover 
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homeostasis is a major reason of cachexia induced muscle wasting. IL-6 and LIF can 
upregulate genes involved protein degradation by activating gp130/STAT3 signaling axis 
is well established, but the direct IL-6/LIF regulation on muscle mTOR signaling or protein 
synthesis during cachexia has not been proposed yet. Chronic systemic inflammation has 
the potential to inhibit muscle protein synthesis dissociating muscle mTOR signaling from 
anabolic stimuli, including IGF-1 (287), leucine (288) and resistant exercise (175), which 
is known as anabolic resistance. Our previous work has demonstrated that the catabolic 
factors from cancer cells can disrupt protein synthesis induction by mechanical stimuli. 
Severely cachectic ApcMin/+ mice demonstrated impaired mTOR signaling induction by 
muscle contractions, which was restored by NF-κB and STAT3 inhibitor, PDTC (25). LLC 
derived cachectic factors can dissociate stretch-induced signaling from protein synthesis 
through ERK1/2 and p38 signaling induction (226). However, not known is whether long 
term pathological elevated IL-6 or LIF are involved in disruption of muscle protein 
synthesis by mechanical signaling.   
 
Clearly both mechanical stimuli and cachexia can induce IL-6 and LIF elevation in 
skeletal muscle microenvironment (219, 231), but little evidence supporting the direct 
regulation of IL-6 or LIF on muscle protein synthesis exists. Regulating the muscle 
sensitivity to the mechanical stimuli has the potential to contribute to the muscle protein 
synthesis and muscle mass regulation (25, 226), but the ability of the physiological or 
pathological elevated IL-6 and LIF to interact with muscle mechanical signaling still need 
of further investigation. The purpose of this study was to examine if IL-6/LIF would 
regulate protein synthesis induction by stretch in cultured myotubes or eccentric 
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contractions in skeletal muscles. We hypothesized that short term administration of IL-6 or 
LIF would strengthen the stretch induction of myotube protein synthesis, while long term 
exposure of IL-6 or LIF would attenuate stretch induction of protein synthesis and eccentric 
contraction induced protein synthesis in skeletal muscle. The effects of different duration 
of IL-6 and LIF exposure on stretch induction of myotube protein synthesis were examined. 
We also investigated the high-frequency stimulation induced muscle protein synthesis in 




C2C12 myoblasts (American Type Culture Collection, Manassas, VA) were cultured 
in DMEM supplemented with 10% FBS, 50 U/ml penicillin, and 50 μg/ml streptomycin. 
To induce C2C12 myoblast differentiation, C2C12 myoblasts were incubated in DMEM 
supplemented with 2% horse serum, 50 U/ml penicillin, and 50 μg/ml streptomycin for 4 
days after they reached ∼95% confluence. 
 
Cell Stretch 
Cell stretch experiment was conducted as previously described with small 
modifications (226). The representative image of cell stretching device was shown in 
Figure 1A. Static stretching device consists of a small frame with two axles (part 1) 
separated by lateral supports (part 2). The axles were threaded to accept screw nuts (part 
3). Silastic membranes (GLOSS/GLOSS, 0.02 in., Speciality Manufacturing, Saginaw, MI, 
part 5) were mounted onto the devices by two friction-fit C-clamps (part 4). The assembled 
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stretching device was then immersed into distilled H2O, autoclaved, and transferred into a 
sterile 100-mm petri dish. The screw nuts were set to 30 cycles from baseline when the 
stretching device was assembled (left). Approximately 175 μl type I collagen solution 
(Advanced Biomatrix, San Diego, CA; diluted into 1 mg/ml by PBS, pH 7-8, adjusted by 
sterile 10N NaOH) was applied onto one edge of Silastic membrane on each stretching 
device. The collagen solution was then drawn across the substrate with a sterile cell scraper. 
Excess collagen was aspirated, and the culture dish containing the stretching device was 
transferred to a 37°C incubator for 1 h. After the incubation period, stretching device was 
washed by sterile distilled H2O twice and air dried under UV overnight. C2C12 myoblasts 
were suspended (∼1 × 106 cells/ml) and plated onto Silastic membrane mounted in a 
stretching device (∼1.5–2 × 105 cells/stretching device). The cells were grown to ∼95% 
confluence and differentiated into myotubes. To induced 5% stretch, screw nuts on both 
axles were rotated by 1.5 cycles using sterile forceps (right side). Myotubes were constantly 
stretched by for 4h. 
 
Cytokine treatment 
To determine the regulation of short term IL-6 or LIF exposure on stretch induction of 
protein synthesis, C2C12 myotubes were stretched by 5% for 4h in the presence of IL-6 
(20ng/ml, Sigma-Aldrich, St. Louis, MO) or LIF (10 ng/ml, Thermo Scientific, Waltham, 
MA). To determine the regulation of long term IL-6 or LIF exposure on stretch induction 
of protein synthesis, C2C12 myotubes were incubated in IL-6 (100ng/ml) or LIF (100ng/ml) 
for 24h. The stretch (5%) was conduction in last 4h of IL-6/LIF incubation. The myotube 





The original C57BL/6 mice used in this study were purchased from Jackson 
Laboratories (Bar Harbor, ME) and bred at the University of South Carolina's Animal 
Resource Facility. All mice used in the present study were obtained from the investigator's 
breeding colony within the Center for Colon Cancer Research Mouse Core. Mice were kept 
on a 12:12-h light-dark cycle, and had access to standard rodent chow (no. 8604 Rodent 
Diet; Harlan Teklad, Madison, WI) and water ad libitum.  The University of South 
Carolina's Institutional Animal Care and Use Committee approved all animal 
experimentation in this study. 
 
In vivo IL-6 overexpression by electroporation 
In vivo intramuscular electroporation of an IL-6 plasmid was used to increase 
circulating IL-6 levels in mice as previously described (271). Mice were anesthetized with 
a 2% mixture of isoflurane (IsoSol, VEDCO, St. Joseph, MO) and oxygen (1 L/min). The 
quadriceps muscle was used to synthesize and secrete exogenous IL-6 into circulation from 
the injected expression plasmid, and was not used for any analyses in the study. Briefly, 
mice were injected with 40 μg of IL-6 plasmid driven by the CMV promoter, or control 
plasmid (pV1J), into the right quadriceps muscle. The leg was shaved, and a small incision 
was made over the quadriceps muscle. Fat was dissected away from the muscle, and the 
plasmid was injected in a 50 μl volume of sterile phosphate-buffered saline (PBS). A series 
of eight 50 ms, 100 V pulses was used to promote uptake of the plasmid into myonuclei, 





After 5 days IL-6 overexpression, mice were subjected to HFES. HFES of the left 
hindlimb was performed as previously described (90), with slight modifications. Mice were 
anesthetized via isoflurane (2% in O2 with 1.5% maintenance), the left leg/hip region was 
shaved, and two needle electrodes were placed on the left leg subcutaneously posterior to 
the femur to stimulate the sciatic nerve. Tetanic muscle contractions were generated using 
a Grass Stimulator (Grass Instruments, Quincy, MA) for 10 sets of 6 repetitions (100 Hz, 
6–12 V, 1-ms duration, 3-s repetition duration). Ten seconds of rest were given between 
repetitions, and 50 s of rest were given between sets. The stimulation protocol recruits all 
motor units of the hindlimb. The maximal force production of the plantar flexors 
(gastrocnemius, soleus, and plantaris) are greater than the dorsiflexors (TA and EDL) (61, 
62), which results in net plantar flexion of the ankle (90). Therefore, the dorsiflexors 
undergo lengthening eccentric muscle contractions against the shortening concentric 
plantar flexors. Each session lasted ∼25 min in duration. Following each stimulation 
procedure, mice were given an intraperitoneal injection of warm saline and returned to 
cages upon complete recovery. 
 
Tissue Collection 
All mice were sacrificed 3h post HFES. Mice were anesthetized with a subcutaneous 
injection of ketamine-xylazine-acepromazine cocktail (1.4 ml/kg body wt) at the time of 
death. Hindlimb muscles were rapidly excised, cleared of excess connective tissue, rinsed 
in PBS, weighed, and snap frozen in liquid nitrogen. The TA muscle was frozen in liquid 
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nitrogen. Blood was collected before muscle collection via retro-orbital eye bleed with 
heparinized capillary tubes, placed on ice, and centrifuged (10,000 g for 10 min at 4°C). 
The supernatant was removed and stored for plasma IL-6 analysis. Plasma and tissue 
samples were stored at −80°C until further analysis. 
 
Plasma IL-6 level 
For each mouse, blood samples were taken at the time of electroporation (D-0), 4 days 
post electroporation (D-5) and time of sacrifice (5 days post electroporation, D-5) by eye 
bleeding. Mice were fasted for at least 5h before blood sample collection. Blood samples 
were centrifuged by 10000 rpm for 10min at 4°C, and the supernatant were collected and 
kept frozen at -80°C before assay. Plasma IL-6 was determined by mouse ELISA kid 
purchased from BD Bioscience (Franklin Lakes, NJ) following manufacturer’s instructions. 
In brief, 96-well plate was coated with capture antibody (1:250, solved in 0.1M sodium 
carbonate, pH 9.5, 100 μl/well) overnight at 4°C. The plate was then blocked by assay 
diluent (10% FBS in PBS, 100μl/well) for 1h at RT, incubated with IL-6 standards (range 
from 16pg/ml to 1000 pg/ml, solved in assay diluent, 100 μl/well) or plasma samples 
(100μl/well) for 2h at RT, incubated with working detector (1: 250 detection antibody and 
1:500 Sav-HRP reagent, solved in assay diluent), incubated in Tetramethybenzidine 
(TMB)-H2O2 substrate (100μl/well) for 30min in dark. Plates were washed by PBS with 
0.05% tween 3-7 time between steps. The reaction was stopped by adding 2N H2SO4 (100 





Protein synthesis measurement 
The myotube protein synthesis was determined by puromycin incorporation as 
previously described (227). In brief, puromycin (EMD Chemicals, San Diego, CA) was 
added into cell culture media (1 μM final concentration) 30 min before protein collection. 
To determine protein synthesis in mouse skeletal muscle, 0.04 mmol/g BW puromycin 
(solved in PBS) was given to mouse by i.p. injection 30 min before sacrifice. The amount 
of puromycin incorporated into newly synthesized protein was determined by Western blots. 




Western blot analysis of protein samples from cultured myotubes and TA muscles was 
performed as previously described (19). Frozen TA muscle was homogenized in ice-cold 
Mueller buffer, and cells were washed by ice-cold PBS and then scraped into ice-cold RIPA 
buffer. The protein concentration was determined by the Bradford method. Protein were 
fractionated in SDS-polyacrylamide gels and transferred to polyvinylidene fluoride 
membranes. After the membranes were blocked, antibodies for phosphorylated/total 
p70S6K (Cell Signaling Technology, Danvers, MA) and puromycin (Millipore, Billerica, 
MA) were incubated at dilutions from 1:2,000 to 1:8,000 overnight at 4°C in 2% Tris-
buffered saline-Tween 20 milk. Anti-rabbit or anti-mouse IgG-conjugated secondary 
antibodies (Cell Signaling Technology) were incubated with the membranes at 1:2,000 to 
1:5,000 dilutions for 2 h in 2% Tris-buffered saline-Tween 20 milk. Enhanced 
chemiluminescence (Advansta, Menlo Park, CA) developed by autoradiography was used 
133 
 
to visualize the antibody-antigen interactions. Blots were analyzed by measuring the 
integrated optical density (IOD) of each band with ImageJ software (National Institutes of 
Health, Bethesda, MD). 
 
Statistical Analysis 
Two-way ANOVA were used to examine the effects of stretch and cytokine treatment. 
Two-way repeated measures were used to examine the effects of IL-6 overexpression and 
HFES in animal experiments. P values < 0.05 were considered significant. 
 
5.4 Results: 
Short term IL-6 or LIF administration disrupted stretch induction of myotube protein 
synthesis 
To determine if short term IL-6 and LIF will regulate stretch induction of myotube 
protein synthesis, we stretched myotubes for 4h in the presence of either IL-6 or LIF. 
Consistent with our previous finding, 4h stretch in control condition increased myotube 
proteins synthesis (Fig. 5.1B). 4h administration of IL-6 and LIF significantly increased 
basal myotube protein synthesis. However, 4h stretch in the presence of either IL-6 or LIF 
resulted in a decrease, but not further increased in myotube protein synthesis (Fig. 5.1B). 
Consistent with the changes in protein synthesis, 4h stretch increased the phosphorylation 
of p70S6K (Fig. 5.1C). Either IL-6 or LIF alone also increased p70S6K phosphorylation, 
but stretch decreased p70S6K phosphorylation of p70S6K in IL-6 or LIF treated myotubes 
(Fig. 5.1C). These results demonstrate that although short term IL-6 or LIF alone is an 
positive regulator of myotube protein synthesis, both IL-6 and LIF reversed the stretch 




Long term IL-6 or LIF administration attenuated stretch induction of myotube protein 
synthesis 
To determine if long term IL-6 and LIF will regulate stretch induction of myotube 
protein synthesis, we pre-incubated myotubes for 24h and stretched for in last 4h of IL-
6/LIF incubation. Stretch in absence of IL-6 or LIF increased myotube protein synthesis 
(Fig. 5.2A). Long term exposure of both IL-6 and LIF resulted in protein synthesis 
suppression (Fig. 5.2A). Most importantly, 4h stretch was not able to increase myotube 
protein synthesis in the presence of either IL-6 or LIF (Fig. 5.2A). Consistent with the 
changes in protein synthesis, long term exposure of IL-6 or LIF decreased p70S6K 
phosphorylation (Fig. 5.2B). Stretch increased p70S6K phosphorylation in control 
myotubes, but not in IL-6 or LIF treated myotubes (Fig. 5.2B). These results demonstrate 
long term IL-6 or LIF exposure was able to attenuate stretch induction of protein synthesis 
and mTOR signaling in cultured myotubes. 
 
IL-6 overexpression had no effect on eccentric contraction induced muscle protein 
synthesis 
To determine the regulation of IL-6 on muscle protein synthesis inductions by eccentric 
contractions, we conducted high frequency electrical stimulation (HFES) in control and IL-
6 overexpressing mice. In control mice, plasma IL-6 level was below the detection level at 
the time of at the time of electroporation (D-0) and 4 days post electroporation (D-4). The 
plasma IL-6 level of control mice increased to 139.8 ± 84.1 pg/ml at the time of sacrifice 
(D-5, 3h post electrical stimulation). In mice transfected with IL-6 plasmids, the plasma 
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IL-6 was not detected at the time of electroporation (D-0), but rises as early as 4 days post 
electroporation (148.6 ± 34.2 pg/ml). The plasma IL-6 level in IL-6 overexpressing mice 
reached to 769.9 ± 217.2 pg/ml at the time of sacrifice, which was significantly higher than 
control mice (Fig. 5.3A). We also examined the effects of HEFS on muscle STAT3 and 
p70S6K phosphorylation in control and IL-6 overexpressed mice. The HFES induced 
eccentric contraction significantly increased muscle p70S6K phosphorylation in both 
control and IL-6 overexpressing mice and IL-6 overexpression showed no effects on 
p70S6K phosphorylation in either control or contracted muscles (Fig 5.3B). IL-6 
overexpressing increased STAT3 phosphorylation (Fig. 5.3C). Interestingly, the HFES 
increased STAT3 phosphorylation in control mice, but did not further increase muscle 
STAT3 phosphorylation in IL-6 overexpressing mice (Fig. 5.3C). Similar with the changes 
in p70S6K phosphorylation, HFES induced eccentric contraction increased muscle protein 
synthesis both control and IL-6 overexpressing mice (Fig. 5.3D). These results 
demonstrated that 5 days IL-6 overexpression had no effect on muscle protein synthesis 
induction by eccentric contractions. 
 
5.5 Discussion 
The IL-6 family of cytokines IL-6 and LIF play a critical and enigmatic roles in local 
regulation of the inflammatory process and skeletal muscle mass during physiological and 
pathological conditions (5). Low levels of IL-6 can promote activation of satellite cells, 
muscle regeneration and muscle growth while chronically elevated production of IL-6 
promote skeletal muscle wasting (5, 237, 289). The sensitivity of muscle protein synthesis 
regulation to mechanical stimulus is a potential regulator of muscle mass. But there is very 
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limited understanding about the potential interaction of IL-6/LIF with skeletal muscle 
mechanical signaling. Here, we reported that both short term and long term IL-6 and LIF 
exposure disrupted the stretch induction of myotube protein synthesis. These results 
suggest IL-6 and LIF may indirectly contribute to muscle protein synthesis suppression by 
dissociating protein synthesis regulation from mechanical stimulation. However, IL-6 had 
no influence of muscle mechanical signaling induced by eccentric contractions, which 
demonstrate the 5-day did not change the muscle plasticity to eccentric contraction induced 
protein synthesis. 
 
The role of IL-6 and LIF in skeletal muscle hypertrophy is tightly associated with 
muscle mechanical signaling (290). IL-6 and LIF are secreted by muscle fibers during 
exercise or overload. The muscle production of IL-6 and LIF are necessary for overload 
induced muscle hypertrophy (7, 8). However, potential regulation of IL-6 and LIF on 
overload induced muscle protein synthesis has not been proposed yet. Here we report that 
although short term exposure of IL-6 or LIF itself stimulated myotube mTORC1 signaling 
and protein synthesis, stretch resulted in the presence of IL-6 or LIF resulted in suppression 
and not further activation of myotube protein synthesis which is completely opposite to our 
hypothesis. These results, as well as previous findings that overload induced muscle protein 
synthesis was not attenuated in IL-6 deficient mice (8), suggest that muscle produced IL-6 
may not be a positive regulator of mechanical stimuli induction of muscle protein synthesis. 
However, these results go against our previous work which demonstrated that LIF-gp130 
signaling play an important role in myotube mechanical signaling regulation of protein 
synthesis, even in the LLC derived atrophic conditions (226). Notably, the LIF level in 
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LLC conditional medium was ~1000 fold lower than that in our current experiment (226). 
One potential explanation is that the effects of LIF on myotube mechanical signaling is 
dose sensitive, or the LIF dose used in our current experiment is at supra-physiological 
level. Nonetheless, further work in this area is required to explain the seeming 
contradictory role of IL-6/LIF in stretch induction of myotube protein synthesis. 
 
Increased mechanical signaling has been theorized to have potential for attenuating 
cancer-induced muscle mass loss by activating muscle protein synthesis. However, under 
pathological conditions, such as sarcopenia, diabetes and cancer cachexia, skeletal muscle 
protein synthesis regulation show a resistance to multiple anabolic stimulus (175, 256, 288), 
including mechanical signaling (25, 226), which would have the potential to accelerate the 
wasting process and negatively impact the therapeutic potential of exercise and physical 
activity interventions. However, present understanding concerning the potential mediators 
of cachexia induced muscle mechanical signaling disruption is lacking. Here we reported 
in addition to their direct inhibitory effects on basal myotube protein synthesis, long term 
IL-6/LIF exposure also attenuated myotube protein synthesis induction by stretch. These 
results clearly demonstrated that the pathological long term exposure of IL-6 and LIF are 
enough to dissociate stretch induced mechanical signaling from myotube protein synthesis. 
In addition, these results also provide some clues to further mechanistic studies of cachexia 
induced muscle anabolic resistance (25, 226), by highlighting the importance of IL-6 
family of cytokines in muscle mechanical signaling disruption. However, there is little 
understanding about the potential signaling pathways in involved in mechanical signaling 
disruption during cachexia. Our previous work suggest that STAT3, NFκB, ERK1/2 and 
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p38 MAPK signaling may play a role in attenuated mechanical induction of muscle or 
myotube mTOR signaling and protein synthesis in atrophic environment derived from 
cancer cells (25, 226). However, the mechanisms underlying the cachexia induced muscle 
mechanical signaling disruption and muscle anabolic resistance is far from fully understood. 
 
HFES of the sciatic nerve produces eccentric contractions of the rodent TA and EDL 
muscles is a widely used mechanical stimuli model inducing muscle protein synthesis and 
hypertrophy. HFES induced eccentric contractions are also able to attenuate muscle protein 
and muscle mass loss in tumor-bearing mice (283, 284). Here we report that the IL-6 
overexpression did not change the protein synthesis induction by HFES induced eccentric 
contractions. However, our current results cannot clearly explain the different regulation of 
IL-6/LIF on protein synthesis induction between in vitro and in vivo mechanical stimuli 
models. The difference in IL-6 level between two different models is a potential reason. 
Previously reported that plasma IL-6 concentrations did reach ~22 pg/ml after strenuous 
exercise (291), which is ~1000 fold less than the IL-6 doses used in our in vitro experiment 
(20ng/ml). The plasma IL-6 level of our IL-6 over-expressing mice is also ~200 fold lower. 
Although mechanical stimuli also induced muscle production of IL-6, which results in 
higher IL-6 level in muscle microenvironment than its plasma level (289), it is possible that 
the doses of IL-6 used in cell stretch experiment (20ng/ml) is supra-physiological level, 
although it showed beneficial effects on basal myotube mTOR signaling and protein 
synthesis regulation. The different IL-6 effects on proteins synthesis induction in different 
models of mechanical stimuli may also due to the different mechanical signaling induced 
by passive stretch and eccentric contractions. Although both stretch and eccentric 
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contraction are able to induce mTOR signaling and protein synthesis in vitro and in vivo, 
there is limited understanding about the upstream regulators mTOR signaling in these 
mechanical stimuli models. The work here do demonstrate that the induction of mTOR 
signaling, protein synthesis, as well as some stress and inflammatory signaling pathways 
including PI3K/Akt, p38 MAPK, ERK1/2, NFκB and AMPK signaling in our myotube 
stretch model (226, 292, 293). But the potential role of these signaling pathways in stretch 
induction in stretch induction of myotube protein synthesis is far from fully understood. 
Mechanical stretch can induce muscle mTOR signaling through growth factor/Akt 
independent mechanisms (52). Further studies demonstrated that the induction of muscle 
DGKζ kinase activity and subsequent accumulation of phosphatidic acid, a direct activator 
of mTORC1 independent of TSC1/2 complex, is the key mechanism of stretch induced 
mTOR signaling and protein synthesis in skeletal muscles (294). However, the role of this 
signaling pathway has not been proposed in eccentric contraction model. Instead, the 
phosphorylation of RxRxxS/T consensus motif on TSC2 (24) and S696, T706, and S863 
site Raptor (295) play a key role in muscle mTOR signaling induction by eccentric 
contractions. But the upstream regulators of these phosphorylation sites are still need to be 
determined. One possibility is that IL-6 and LIF disrupt the mechanical signaling pathways 
specific to stretch but not eccentric contractions. In addition of direct activation of mTOR 
signaling in Akt independent mechanisms (16), eccentric contraction or stretch can also 
induce muscle expression of growth factors IGF-1, and subsequent induction of Akt/mTOR 
signaling pathway (296, 297). Interestingly, even pathological long term IL-6 exposure did 
not block the insulin induction of Akt/mTOR signaling in cultured myotubes (20), which 
suggest that eccentric contraction induced muscle secretion of IGF-1 is a redundant 
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mechanism to induce muscle mTOR signaling and protein synthesis in the presence of IL-
6. Unlike the in vivo muscle eccentric contraction model, the potential myotube secreted 
IGF-1 was diluted in culture medium and unable to induce myotube protein synthesis in 
cell stretch model. However, much more work is still required to investigate the potential 
difference in mechanical signaling pathways induced by stretch and eccentric contractions. 
 
Taken together, our results are a starting point for future studies concerning the 
potential importance for crosstalk between IL-6/LIF and myotube and skeletal muscle 
mechanical signaling regulation of protein synthesis. Our results demonstrate that long 
term pathological exposure of IL-6 can dissociate the stretch induced mechanical signaling 
from mTORC1 signaling and protein synthesis in cultured myotubes. These results provide 
new insights for IL-6/LIF regulation of muscle protein synthesis suppression under 
pathological conditions, and suggest that long term pathological elevated IL-6/LIF may 
contribute muscle protein synthesis suppression indirectly by attenuating protein synthesis 
induction by mechanical stimulation. However, in vivo IL-6 overexpression mice did not 
change the muscle protein synthesis induction by high-frequency eccentric contractions, 
which demonstrate IL-6 alone cannot disrupt the mechanical signaling induced by muscle 
eccentric contractions, and suggest that HFES induced muscle eccentric contractions is a 
promising therapy to induce muscle protein synthesis and attenuate muscle wasting under 
pathological conditions. 
 
5.6 Figure Legends 
Figure 5.1: Short term IL-6 or LIF regulation on stretch induced myotube protein 
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synthesis and mTOR signaling. C2C12 myotubes were stretched for 4h in the presence 
of IL-6 or LIF. A. Representative figure of cell stretch. The screw nuts were set to 30 cycles 
from the baseline when stretch device was assembled (left) and were rotated by another 1.5 
cycles when cells were stretched (right). B. Protein synthesis in myotubes stretched in the 
presence of IL-6 or LIF was determined by puromycin incorporation. Dash lines represent 
different parts on the same gel. *: p < 0.05 vs. control group, #: p < 0.05 vs. IL-6/LIF treated 
non-stretched group, two-way ANOVA. C. Phosphorylation of p70S6K in myotubes 
stretched in the presence of IL-6 or LIF was determined by western blot. Dash lines 
represent different parts on the same gel. *: p < 0.05 vs. control group, #: p < 0.05 vs. IL-
6/LIF treated non-stretched group, two-way ANOVA. 
 
Figure 5.2: Long term IL-6 or LIF regulation on stretch induced myotube protein 
synthesis and mTOR signaling. C2C12 myotubes were incubated in IL-6 or LIF for 24h 
and stretched in last 4h of IL-6/LIF incubation. A. Protein synthesis in myotubes stretched 
in the presence of IL-6 or LIF was determined by puromycin incorporation. Dash lines 
represent different parts on the same gel. *: p < 0.05 vs. all other groups, #: p < 0.05 vs. 
control group, two-way ANOVA. B. Phosphorylation of p70S6K in myotubes stretched in 
the presence of IL-6 or LIF was determined by western blot. Dash lines represent different 
parts on the same gel. *: p < 0.05 vs. all other groups, #: p < 0.05 vs. control group, two-
way ANOVA. 
 
Figure 5.3: Regulation of IL-6 overexpression on eccentric contraction induced 
muscle mTOR signaling and protein synthesis. A. Plasma IL-6 level of control and IL-
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6 overexpressing mice at the time of electroporation (D-0), 4 days post electroporation (D-
4) and sacrifice (Sac), *: p < 0.05 vs. D-4 of IL-6 group, #: p < 0.05 vs. D-5 of control 
group, two-way repeated measures. B. The phosphorylation of STAT3 in TA muscles of 
non-stimulated control leg (Right, R) and HFES induced contracted leg (Left, L) was 
measure by western blot. *: significant different from control group, #: significant different 
from control-ECC group, two-way repeated measures. C. The phosphorylation of p70S6K 
in TA muscles of non-stimulated control leg (Right, R) and HFES induced contracted leg 
(Left, L) was measure by western blot. *: p < 0.05, main effect of HFES, two-way repeated 
measures. D. The protein synthesis in TA muscles of non-stimulated control leg (Right, R) 
and HFES induced contracted leg (Left, L) was determined by puromycin incorporation. *: 
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IL-6 family of cytokines have the pleiotropic functions in different tissues and organs, 
including skeletal muscles. Skeletal muscle serves as both a biological target and source of 
the IL-6 family of cytokines. Short term systematic elevation and muscle production of IL-
6 and LIF is required for mechanical stimuli induced muscle hypertrophy. However, the 
long term systematic elevation of IL-6 and LIF are key regulator of muscle wasting in 
cachexia. Regulation of muscle protein synthesis plays a key role in both mechanical 
stimuli induced muscle hypertrophy and cachexia induced muscle atrophy, but the IL-6 and 
LIF regulation of muscle protein synthesis under physiological or pathological conditions 
has not been proposed yet. Finally, mechanical stimuli from passive stretch and eccentric 
contractions is a strong hypertrophic stimulator on skeletal muscle by inducing muscle 
protein synthesis pathways, but the mechanical stimuli induced muscle protein synthesis 
pathways can be attenuated in cachexia induced catabolic environment. The overall 
purpose of this dissertation is to determine if physiological short term or pathological long 
term exposure of IL-6 and LIF will regulate protein synthesis and interact with mechanical 
signaling in myotubes and skeletal muscles. We hypothesized that physiological, short term 
inflammatory cytokine exposure would induce basal muscle protein synthesis through 
gp130 activation of Akt-mTOR signaling, while pathological, long term cytokine exposure 
would suppress basal muscle protein synthesis through gp130 activation of AMPK 
signaling. Furthermore, physiological or pathological cytokine exposure would either 
amplify or suppress mechanical regulation of muscle protein synthesis, respectively.  
 
The data presented in this dissertation support our hypothesis that short term IL-6/LIF 
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exposure increased protein synthesis, while long term IL-6/LIF suppression decreased 
basal myotube protein synthesis. gp130 siRNA knockdown and Akt signaling inhibition 
blocked myotube protein synthesis induction by IL-6 and LIF, which support our 
hypothesis that gp130/Akt signaling plays a key role in myotube protein synthesis 
induction by short term IL-6 and LIF. However, mTOR signaling inhibition did not 
completely block the IL-6/LIF induction of myotube protein synthesis, which highlighted 
the mTOR independent mechanisms. As we expected, AMPK signaling inhibition during 
long term IL-6/LIF exposure rescued IL-6/LIF suppression on protein synthesis, which 
goes with our hypothesis that AMPK is a key mediator of protein synthesis suppression by 
long term IL-6/LIF exposure. Unexpectedly, the IL-6/LIF regulation of mechanical 
signaling differs in different models mechanical stimuli models: Regardless of their 
differential effects on basal myotube protein synthesis regulation, both short term and long 
term IL-6/LIF exposure attenuated stretch induction of myotubes protein synthesis, but in 
vivo IL-6 overexpression had no effect on muscle protein synthesis induction by eccentric 
contractions.  
 
Myotube protein synthesis regulation by IL-6 and LIF. 
The current understanding of the mechanical stimuli induced IL-6/LIF’s role in 
skeletal muscle hypertrophy focuses on their regulation on proliferation and differentiation 
of satellite cells, while the induction of protein degradation related genes though 
gp130/STAT3 signaling is considered as the major mechanisms of IL-6 regulation of 
muscle wasting in cachexia. The muscle protein mTOR signaling is plays a key role in 
muscle mass regulation. The results in this dissertation demonstrate both IL-6 and LIF have 
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the capability to stimulate and suppress mTOR signaling and protein synthesis in culture 
myotubes, and the duration of IL-6/LIF exposure is a key determinant of their differential 
effects. These results further strengthen the dual role of IL-6 family of cytokines in muscle 
mass regulation, and suggest that differential regulation of protein synthesis, at least, 
contribute to the IL-6/LIF regulation on muscle hypertrophy and atrophy in physiological 
and pathological conditions, respectively.  
 
gp130 dependent signaling regulation by IL-6/LIF. 
All IL-6 family of cytokines induce intracellular signaling pathways though their 
functional receptor complex which is composed by their specific receptor and gp130. 
Regardless of different compositions of protein subunits, the functional receptor complexes 
of all IL-6 family of cytokines require at least one copy of gp130 protein. The formation of 
ligand-receptor protein complex leads to the phosphorylation tyrosine residues in the distal 
cytoplasmic domains of gp130 by activating constitutively bound Janus family kinases, or 
Tyk2. Phosphorylated gp130 can recruit and phosphorylate its downstream effectors, 
including STAT3. Not surprisingly, we reported the siRNA knock-down of gp130 
attenuated IL-6/LIF induction of myotube protein synthesis. These results demonstrated 
gp130 is necessary for short term IL-6/LIF induction of myotube protein synthesis and 
further support the central role of gp130 in biological processes regulated by IL-6 family 
of cytokines. We also measured the IL-6/LIF time course regulation of gp130 dependent 
signaling pathways. Both IL-6 and LIF induced a transient induction of STAT3 
phosphorylation, which went back to basal level after 4h IL-6/LIF exposure. The transient 
pattern of STAT3 phosphorylation is associated with the increased expression of SOCS3, 
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which can inhibit gp130 signaling pathways by competitively binding with JAK1 and 
JAK2. These results showed the induction of classical SOCS3 dependent negative feedback 
loop of gp130 signaling. Interestingly, the IL-6/LIF induced myotube protein synthesis 
showed a similar time course pattern as STAT3: the IL-6/LIF induction of myotube protein 
synthesis peaks at 2h, then showed a trend to go back to basal level. Due to the importance 
of gp130 in IL-6/LIF induction of protein synthesis, these results suggest IL-6/LIF induced 
SOCS3 dependent negative feedback loop may also suppress the IL-6/LIF induction of 
protein synthesis. Indeed, previous report which showed SOCS3 is a potential regulator of 
muscle protein synthesis suppression in IL-6 overexpressing mice (268). However, more 
work is required to determine the role of IL-6/LIF induced STAT3-SOCS3 dependent 
negative feedback loop in time course regulation of myotube protein synthesis. 
 
We also investigated the long term IL-6/LIF regulation on myotube gp130 signaling. 
Long term IL-6 and LIF exposure demonstrated differential regulation of gp130 signaling: 
24h IL-6 exposure increased phosphorylation of STAT3 and ERK1/2 in a dose dependent 
manner, but LIF did not change their phosphorylation. Interestingly, the SOCS3 expression 
is only induced in myotube treated with LIF, but not IL-6. Suggesting the IL-6 induced 
STAT3 and ERK1/2 signaling is caused by disrupted SOCS3 dependent negative feedback 
mechanisms. Both IL-6 and LIF decreased Akt phosphorylation, which is a potential 
contributor to IL-6/LIF suppression of mTOR and protein synthesis. However, more work 
is required to determine the upstream regulators of Akt signaling induced by long term IL-
6/LIF exposure. Taken together, these results demonstrated the differential regulation of 




Role of Akt signaling in short term IL-6/LIF regulation of myotube protein synthesis 
The Akt signaling has emerged as a key intermediary in the response of muscle to 
activity, nutrients growth factors, and cytokines. The activation of PI3K/Akt signaling 
results in anabolic shift of muscle protein turnover. It can stimulate muscle protein 
synthesis though the classical mTOR signaling, and suppress muscle protein degradation 
by the phosphorylation of FOXO3, thus inhibit its transcriptional induction of genes 
involved in ubiquitin proteasome system: MuRF-1 and Atrogin-1. The gp130 activation by 
IL-6 family of cytokines also has the potential to induce PI3K/Akt signaling, but the precise 
mechanisms still remain to be determined and this regulation seems to be cell specific. In 
cardiac myocyte, both IL-6 and LIF can induce the gp130-PI3K-Akt signaling axis and 
subsequent protein synthesis, which plays a key role in IL-6/LIF induced cardiac muscle 
hypertrophy. We have found that short term IL-6 and LIF exposure increased Akt 
phosphorylation in cultured myotubes, which established the IL-6/LIF regulation on 
PI3K/Akt signaling in skeletal muscle cells. Most, importantly, inhibition of PI3K/Akt 
signaling by PI3K inhibitor wortmannin completely blocked the IL-6/LIF induction of 
protein synthesis. These results demonstrated the central role of PI3K/Akt signaling 
induction in IL-6/LIF regulation of myotube protein synthesis. Interestingly, long term IL-
6 or LIF exposure decreased Akt phosphorylation, suggesting the disrupted signaling 
transduction from gp130 to Akt, or the presence of other PI3K/Akt suppressor. Mice 
overexpressing IL-6 showed decreased plasma IGF-1 level (268). and IL-6 is able to induce 
muscle expression of SOCS3 (260) and myostatin (298), which can negatively regulate of 
PI3K/Akt signaling by the degradation of IRS-1 (299), These results suggest the IL-6 and 
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LIF may suppress myotubes Akt signaling by transcriptional regulation of upstream 
regulators of Akt. Suppressed Akt signaling is an obvious negative regulator of mTOR 
signaling and protein synthesis, which showed significant decreased in long term IL-6/LIF 
treated myotubes. However, IL-6 and LIF suppression of myotube mTOR signaling and 
protein synthesis was completely restored by the inhibition of AMPK, which is an 
independent upstream regulator mTOR signaling. Our previous work also reported that 
insulin induction of myotube mTOR signaling was not attenuated by long term IL-6 
exposure. However, future work is still needed to determine the role of Akt signaling in 
muscle protein synthesis regulation by long term exposure of IL-6 family of cytokines. 
 
Role of mTOR signaling in short term IL-6/LIF regulation of myotube protein synthesis  
The mTOR signaling plays a pivotal role in the regulation of skeletal muscle protein 
synthesis, and mTOR signaling activation is necessary for muscle hypertrophic process in 
response to multiple anabolic stimulus, such as growth factors, energy status, amino acids 
and mechanical stimuli. Akt is considered an important upstream regulator of mTOR 
signaling, therefore, we further investigated the role of mTOR signaling in short term IL-
6/LIF induction of myotube protein synthesis. As we expected, mTOR signaling inhibition 
by rapamycin decreased basal protein synthesis. Surprisingly, we found mTOR inhibition 
did not completely block the protein synthesis induction by either IL-6 or LIF. These results 
clearly demonstrate short term IL-6 and LIF can induce myotube protein synthesis through 
mTOR independent mechanisms, and unravel a novel aspect of protein synthesis regulation 
in muscle cells. Although it has been repeatedly demonstrated that mTOR signaling plays 
a central role in muscle protein synthesis induction by large varieties of anabolic stimulus, 
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several studies reported the mTOR independent muscle protein synthesis induction by 
glucose or leucine supplementation. The direct phosphorylation eIF4G, which leads to 
increased protein translation initiation, is a key mechanism of mTOR independent protein 
synthesis induction by leucine, but the potential upstream regulator still need to be 
determined. In cancer cells, the ERK1/2-MNK signaling cascade can also bypass mTORC1 
and activate protein synthesis in by phosphorylating eIF4E. Future work is still needed to 
identify the mTOR independent signaling pathways mediating IL-6/LIF induction of 
myotube protein synthesis. Our results showed Akt signaling inhibition blocked myotubes 
protein synthesis induction, suggesting this IL-6/LIF induced mTOR independent activator 
is still dependent on Akt signaling. But more work is still needed to determine the mTOR 
independent myotube protein synthesis activators induced by IL-6/LIF. 
 
Role of STAT3 signaling in IL-6/LIF regulation of myotube protein synthesis 
STAT3 signaling is an important downstream effects of gp130. Once phosphorylated 
and activated , STAT3 proteins dimerize and translocate into nucleus to induce 
transcriptions of its target genes. STAT3 induction has a documented role in IL-6 regulation 
of muscle hypertrophy and atrophy.  STAT3 pathway was shown to be necessary for 
myoblast proliferation based on its capacity to regulate the expression of cell cycle 
associated genes (197). STAT3 signaling is also involved in myogenessis by regulation 
MyoD gene expression (196). The pathological induction of STAT3 also play a key role in 
regulation expression of genes involved in protein degradation during cancer cachexia. 
However, no study demonstrated the role of STAT3 signaling in muscle protein synthesis 
regulation during IL-6 family of cytokines induced muscle hypertrophy or atrophy. Here, 
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we report inhibition of STAT3 signaling by siRNA knock or different pharmaceutical 
inhibitors did not influence the myotube protein synthesis regulation by short term or long 
term exposure of IL-6 and LIF. This findings also go with our previous reports that STAT3 
signaling inhibition did not the rescue the cachexia suppression of muscle protein synthesis 
in vitro and in vivo. These results demonstrate STAT3 signaling is not necessary for 
myotube protein synthesis regulation by either short term or long term IL-6 and LIF 
exposure, and suggests that STAT3 is not directly involved in muscle protein synthesis 
regulation. 
 
Role of AMPK signaling in IL-6/LIF regulation of AMPK signaling 
An energy deficiency or cachectic environment can induce the induction AMPK 
signaling, which plays a role in catabolic shift of muscle protein turnover regulation, 
through mTOR signaling inhibition (17), induction of FOXO-dependent E3 ubiquitin 
ligase transcription (273), and increased autophagy processes (274). The severe cachectic 
ApcMin/+ mice showed increased muscle AMPK signaling activity, which may contribute 
to muscle protein synthesis regulation.  
We reported the long term exposure of IL-6 or LIF induced AMPK signaling in 
myotubes. Most importantly, AMPK inhibition by compound C during the IL-6/LIF 
administration rescued the myotube protein synthesis suppression by IL-6/LIF. These 
results, consistent with our previously findings (20), clearly demonstrate induction of 
pathological AMPK signaling activation is a key mediator of IL-6/LIF suppression of 
protein synthesis under pathological conditions. However, long term inhibition of AMPK 
signaling by siRNA knockdown decreased basal myotube protein synthesis and showed no 
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rescue effects on protein synthesis suppression by IL-6/LIF, which demonstrate the basal 
AMPK signaling is required still required for maintaining basal protein synthesis in 
myotubes. It is possible that basal AMPK signaling contributes protein synthesis 
maintenance by maintaining metabolic homeostasis (279). Further work is the required to 
determine the mechanisms underlying the AMPK signaling induction by long term 
elevation of IL-6 family of cytokines. 
 
Interaction of IL-6/LIF with mechanical signaling induced by stretch and eccentric 
contractions. 
Mechanical stimuli is an important anabolic regulator of muscle protein synthesis and 
muscle hypertrophy (21). Therefore, it is theorized that regulating the sensitivity of muscle 
proteins synthesis can contribute to muscle mass regulation. However, there is quite limited 
understanding about the potential regulation of IL-6 and LIF in muscle mechanical 
signaling which regulate protein synthesis. In this dissertation we reported the regulation 
of IL-6 and LIF on mechanical signaling in myotube stretch models. Unlike what we 
hypothesized they disrupted stretch regulation of myotubes protein synthesis. These results 
suggest the potential role of IL-6 family of cytokines in muscle anabolic resistance, which 
is observed in many pathological conditions including cancer cachexia (25, 300). It is 
possible that suppression of protein synthesis induction by mechanical stimuli from daily 
activities contribute the protein synthesis suppression under IL-6/LIF involved 
pathological conditions. However, we did not observe similar attenuation effects in HEFS 
induced muscle eccentric contraction model. It is possible muscle eccentric contraction can 
induce different anabolic signaling pathways which is independent from IL-6 regulations. 
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However, lots of work is still needed to determine the potential interactions of downstream 
signaling pathways regulated by IL-6/LIF and mechanical stimulus. 
 
Conclusions and Future Directions 
In summary, we demonstrated that short term exposure of IL-6 family of cytokines IL-
6 and LIF can induce myotube proteins synthesis by inducing gp130-Akt signaling axis, 
while the long term exposure of IL-6 or LIF decreased myotube protein synthesis by 
activation of AMPK signaling. Finally, the IL-6 and LIF showed differential regulation on 
mechanical signaling in different experimental models mechanical stimuli: IL-6 or LIF 
administration blocked the myotube protein synthesis induction by mechanical stretch, but 
in vivo IL-6 overexpression had no effect on eccentric contraction induced muscle protein 
synthesis. These findings suggest that IL-6 family of cytokines have the potential to 
activate and suppress protein synthesis as well as interact with mechanical signaling in 
skeletal muscle cells. Our work provides a new insight of the mechanism of the IL-6 family 
of cytokines’ role in muscle mass regulation under physiological and pathological 
conditions.  
 
Although the data presented in this dissertation push forward our understanding about 
the role of IL-6 and LIF in muscle mass regulation, there are still a lot of gaps of our 
understanding. We have demonstrated the IL-6 and LIF have the ability to positively and 
negatively regulation protein synthesis in cultured myotubes, but the relative importance 
of protein synthesis activation or suppression in IL-6/LIF regulation of muscle mass still 
need to be determined. Our current results also exclude the potential crosstalk of IL-6/LIF 
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with other cytokines under physiological and pathological conditions. The molecular 
mechanism underlying the IL-6/LIF activation or suppression of myotube protein synthesis 
is also far from fully understood. Finally, we still need to determine the potential 
interactions of IL-6/LIF induced intracellular signaling pathways on mechanical signaling 
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C2C12 Cell Culture 
Materials and Reagents 
 C2C12 Myoblast (ATCC, Catalog #: CRL-1772) 
Dulbecco's Modified Eagle's Medium (DMEM) (ATCC, Catalog #: 30-2002) 
Fetal Bovine Serum (FBS) (ATCC, Catalog #: 30-2020) 
Horse Serum (ATCC, Catalog #: 30-2020) 
100 × Penicillin/Streptmycin Solution (10,000 U/mL) (Thermo Scientific, Catalog #: 
15140122) 
Trypsin-EDTA (Thermo Scientific, Catalog #: 25200056) 
Cell culture flasks 
6-well plates 
Cell culture hood 
CO2 incubator (37°C, 5% CO2) 
Culture Mdium: 
 Growth Media: DMEM with 10% FBS, 100U/ml Penicillin/Streptmycin 
 Differentiation Media: DMEM with 2% FBS, 100U/ml Penicillin/Streptmycin 
Revive Cells 
1. Pre-warm growth media in 37°C water bath for ~20min 
2. Transfer ~10ml warm growth medium into a 15ml falcon tube. 
3. Thaw frozen cells in 37°C water bath, keep the lower part of cryogenic vial into the 
water, swirl and shake gently. 
4. When the ice chunk disappears, transfer cells suspend in cryogenic vial into warm 
growth media in 15ml falcon tube immediately. 
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5. Centrifuge cell suspend 1500rpm for 5min at 37°C. 
6. Remove supernatant, re-suspend cells with ~10ml growth medium. 
7. Transfer cell suspend into a cell culture flasks, keep cells in 37°C, 5% CO2 incubator. 
Divide Cells (Keep the coverage of C2C12 myoblasts less than 80% to maintain their 
differentiation ability) 
1. Pre-warm growth medium in 37°C water bath for ~20min 
2. Remove old cell culture medium. 
3. Wash cells with sterile PBS once (~6ml per 75cm2 cell culture flask) 
4. Add Trypsin-EDTA onto cells (1ml per 75cm2 cell culture flask), put cell culture flask 
into 37°C, 5% CO2 incubator. Incubate for 3-5min. 
5. When most cells are detached from the flask, add warm growth medium (at least 3ml 
per 75cm2 cell culture flask). 
6. Add more growth medium to the desired volume (8-10ml per 75cm2 cell culture flask, 
2 ml for one well of 6-well plate). 
7. Transfer cell suspend to new cell culture flask/6-well plats, keep cells in 37°C, 5% CO2 
incubator 
Freeze Cells 
1. Trypsin digestion of cells grown in cell culture flask (step 1-5 in ‘Divide Cells’ section). 
2. Transfer cell suspend to 15ml or 50ml falcon tubes, centrifuge cell suspend 1500rpm 
for 5min at 37°C. 
3. Remove supernatant, re-suspend cells with growth medium containing 5% DMSO. 
4. Aliquot cells suspend into cryogenic vials. 
5. Put cryogenic vials into isopropanol bath, and transfer vials into -80°C. 
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6. For longer storage, transfer cells into liquid nitrogen when cells are frozen in -80°C 
fridge. 
Differentiation 
1. Trypsin digestion of cells grown in cell culture flask (step 1-5 in ‘Divide Cells’ section). 
2. Transfer cell suspend to 6-well plates, keep cells in 37°C, 5% CO2 incubator. 
3. When cells reach 95%-100% coverage, switch old growth media into differentiation 
medium, keep cells in 37°C, 5% CO2 incubator. 
4. Change differentiation medium every 2 days during differentiation. 
5. Myotubes forms after 4-5 days of differentiation. 
 
siRNA Transfection 
Materials and Reagents 
 5 × siRNA Buffer (GE Healthcare-Dharmacon, Catalog #: 002000) 
 RNase-free H2O (GE Healthcare-Dharmacon, Catalog #: 002000) 
 siRNA  
 DMEM (no serum or antibiotics) 
 Complete cell culture medium (without antibody) 
 Dharmafect III Transfection Reagent (GE Healthcare-Dharmacon, Catalog #: T-2003) 
1. Make 1 × siRNA buffer using 5 × siRNA Buffer and RNase-free H2O. Dilute siRNA 
to 20μM stock solution by 1 × siRNA buffer, store siRNA aliquot into -20°C. 
2. Calculate the volume of siRNA stock concentration and Dharmafect III Transfection 
Reagent required for experiment. One well of 6-well plate requires 2ml culture medium, 
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in which the final concentration of siRNA is 20-100nM, and the volume of transfection 
reagent is 1-10μl. 
3. Prepare two sets of 15ml falcon tubes, termed as Tube 1 and Tube 2. 
4. In Tube 1, dilute siRNA stock solution using serum free DMEM up to 200μl/each well 
(for cell culture of 6-well plates), mix by pipetting gently. 
5. In Tube 2, dilute Dharmafect III Transfection Reagent stock solution using serum free 
DMEM up to 200μl/each well (for cell culture of 6-well plates), mix by pipetting gently. 
6. Let Tube 1 and Tube 2 sit at room temperature for 5min. 
7. Transfer contents of Tube 1 to Tubes 2, mix by pipetting gently. Let the mixture sit at 
room temperature for 20min. 
8. Add complete cell culture medium without antibiotics to the mixture of step 7, volume 
up to 2ml/well (for 6-well plate culture). This is transfection medium. 
9. Wash cells by sterile PBS twice, add transfection medium to cell culture. 
10. Incubate cells in transfection medium for 24-48h. 
Protein Sample Collection from Cultured Cells 
Materials and Reagents 
RIPA Buffer: 50 mM Tris, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 0.5% 
sodium deoxycholate, 0.1% SDS, 5 mM NaF, 1 mM NaVO4, 1 mM β-
glycerophosphate, and 1% protease inhibitor cocktail (added bofore use) 
1. Remove cell culture medium. 
2. Wash cells with ice-cold PBS. 
3. Add ice-cold RIPA buffer onto the cells (~100-150μl/well of 6-well plate). 
4. Scrape cells off using rubber scraper. 
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5. Transfer RIPA buffer containing cell lysate into an ependorf tube, keep samples on ice. 
6. Ultra-sound sonicate cell lysate on ice (3-5 time, 5s each time with 5-10s interval 
between 2 sonications). 
7. Centrifuge samples 13000rpm for 10min at 4°C. 
8. Transfer supernatant to a new ependorf tube, discard pellets. 
9. Run protein assay (Bradford). 
10. Store samples in -80°C. 
Protein Sample Collection from Tissues 







Volume of stock 
needed(ul) 
HEPES 500mM 50mM 600 
Triton-X100 100% 0.10% 6 
EGTA (pH 8.0) 500mM 4mM 48 
EDTA (pH 8.0) 500mM 10mM 120 




2M 100mM 300 
NaF 500mM 25mM 300 
NaVO4 1M 5mM 50 
dH2O - - 3585 
Protease 
Inhibitor 











Volume of stock 
needed(ul) 
Glycerol 100% 50% 1500 
Na4P2O7 100mM 50mM 1500 




500mM 1mM 6 
Protease 
Inhibitor 
- - 30 
1. Weigh out the samples to be used and place weighted portion into an ependorf tube 
labeled with the sample and M. 
2. Add 10ul/mg tissue of Mueller buffer to the homogenization tube and add sample. 
3. Homogenize in glass on glass tissue homogenizer keeping the sample in ice while 
homogenizing. (homogenize ~30s check sample repeat if needed) 
4. Wash glass tissue homogenizer 3 times by dH2O between two samples. 
5. Transfer tissue homogenate back to ependorf tube. 
6. Spin samples at 13,000rpm for 10min at 4°C. 
7. Transfer supernatant to clean ependorf tube labeled with sample and D, discard the 
pellet. 
8. Add 5ul/mg tissue of Diluent buffer to the D tube and vortex. 
9. Run protein assay (Bradford). 
10. Dilute samples down to a working concentration in a new tube labeled with the sample 
and the working concentration. Keep both D tube and diluted samples in -80°C. 
Protein Assay (Bradford Assay) 
Materials and Reagents 
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 Bradford Reagent (Bio-Rad, Catalog #: 5000006) 
1. Make a stock of 1mg/ml BSA in PBS, store aliquot in -20°C. 
2. In a clear flat bottom 96 well plate create a standard curve with the 1ug/ul BSA solution 
from 0-14ug in duplicate or triplicate 
3. Dilute samples 1:5 in a new tube with water (5ul sample: 20ul dH20) 
4. Add 5ul of the diluted samples to the wells of the plate being sure to run them in duplicate 
or triplicate 
5. Make a 1:5 dilution of Bradford reagent. You will need enough for 300ul/well. Be sure 
to clean the glassware well before you use it with soap and water. 
6. Add 300ul of diluted Bradford reagent to each well. 
7. Let sit in dark drawer for 15 minutes 
8. Read in plate reader at 595nm 
9. Calculate protein concentration based on standard curve 
a. Create curve being sure to subtract out the zero value from both curve and samples. 
b. Calculate protein concentration using y=mx+b equation 
(sample=con*slope+intercept -> con=(sample-intercept)/slope) 
 
SDS Page/Western Blot 
Materials and Reagents 
 For SDS-PAGE gel 
Acrylamide Solution (38.5% Acrylamide + 1% Bis-Acrylamide) 
  1.5M Tris-HCL, pH 8.8 
  1.0M Tris-HCL, pH 6.8 
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  10% SDS 
  10% APS. 
  TEMED 
4×SDS Loading Buffer: 200 mM Tris-Cl (pH 6.8), 400 mM DTT, 8% SDS, 0.4% 
bromophenol blue, 40% glycerol 
SDS Running Buffer: 25mM Tris, 200mM Glycine, 0.1% SDS 
Protein Ladder (Bio-Rad, Catalog #: 1610373) 
Transfer Buffer: 25mM Tris, 200mM Glycine, 20% Methanol 
1×TBST: 50 mM Tris-Cl, 150 mM NaCl, 0.1% Tween-20 
5% milk (solved in 1×TBST) 
ECL plus (Thermo Scientific, Catalog #: 1610373) 
SDS Page 
1. Make gel. Base the % off of what molecular weight the protein of interest is. 
2. Prepare samples 
a. Pipette desired amount of protein into ependorf tube 
b. Add correct volume of 4 × SDS loading dye 
c. Vortex and do a quick spin 
d. Heat in heat block at 100°C or in boiling water for 5 minutes 
e. Quick spin 
3. Load 4ul of protein ladder to the 1st lane in the gel 
4. Load all of sample on gel 




6. Prepare 750ml of transfer buffer 
7. Prepare membrane by placing in a small amount of methanol for 1 minute 
8. Pour methanol into the transfer buffer and wash membranes with the transfer buffer 
9. Set up the transfer with the black side of the holder facing down, sponge, blotting paper, 
gel, membrane (be sure there are absolutely no bubbles between the gel and the membrane), 
blotting paper, sponge, white/clear side. 
10. Carefully close the sandwich and place in the transfer box black side to black side and 
clear side facing the red side of the transfer box. 
11. Place ice pack in the box and pour remaining transfer buffer into the box. 
12. Transfer either overnight at 70mA or for 200min at 200mA making sure to pack well 
with ice. 
Probing 
13. Prepare 5% milk in 1×TBST solution 
14. Remove membrane from transfer and place in ponceau solution for 3-5 minutes 
15. Rinse off excess ponceau with dH2O and place membrane in plastic sheet and scan into 
computer 
16. Wash off ponceau with 1×TBST 
17. Block the membrane for 1h in 5% TBST milk solution (made in step 13) 
18. Incubate in primary antibody in milk solution 
19. Wash membranes 3× with 1×TBST for 5 minutes each 
20. Incubate in secondary antibody in milk solution for 1 hour 
21. Wash membranes 3× with 1×TBST for 5 minutes each 




RNA Isolation (from cell culture) 
Materials and Reagents 
 RNase AWAY (Thermo Scientific, Catalog #: 10328011)  
 Trizol Reagents (Thermo Scientific, Catalog #: 15596026) 
 Chloroform 
 Isopropanol Alcohol 
 DEPC H2O 
 75% ethanol in DEPC H2O 
1. Clean work area thoroughly with alcohol 
2. Label 3 sets of sterile RNAase free 1.5mL eppendorf tubes 
3. Remove cell culture medium, and wash cells once by ice-cold PBS 
4. Remove PBS, add Trizol reagent onto the cell (1ml Trizol for each well of 6-well plate). 
5. Scrape cell off from cell culture plate gently with rubber scraper, pipette cell suspended 
in Trizol up and down several times with 1ml pipette to brake cell thoroughly. 
6. Transfer cell homogenate to a sterile 1.5mL tube. 
7. Let samples sit at RT for ~5 minutes. 
8. Add 200ul of chloroform to each tube 
9. Shake tubes (DO NOT VORTEX) for 15-30s (should be the color of pepto bismal). 
10. Let samples sit at RT for 2-3min. 
11. Spin samples at 12000rpm for 15 minutes at 4°C. 
12. Clean gloves and pipette with RNAase AWAY. 
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13. Transfer clear supernatant to new tube carefully, Do NOT disturb the protein interface 
(white layer) or organic phase (red/pink colored). 
14. Add 500ul of isopropanol and invert to mix. 
15. Incubate for 20-30 minutes at RT. 
16. Spin samples at 12000rpm for 10 minutes at 4°C, gel like pellet can be visualized at the 
bottom of tube. 
17. Dump the supernatant being careful not to lose the pellet. 
18. Add 1mL 75% EtOH in DEPC to RNA pellet invert to break loose. 
19. Spin at 9500rpm for 5 min at 4°C. 
20. Repeat steps 18-20 once. 
21. Air dry tubes upside down in hood for 10-20 minutes (on towel of Kimwipes). 
22. Add ~20-40ul of DEPC water to dissolve pellet, pipette to solve RNA (Keep track of 
the amount of DEPC added). 
23. Read on spec (1-2ul RNA+800ul dH2O) in quartz cuvette/NANO DROP and record 
260/280/and 230 measurements. (Good quality of RNA samples should have 260/280 
ratio > 1.8 and 260/230 > 1.8. Do not use samples with 260/280 below 1.6) 
24. Calculate and Record RNA concentration: RNA= (OD260*40*0.8)/ volume RNA 
added to cuvette.  
25. Store RNA samples in -80°C. 
 
cDNA synthesis 
Materials and Reagents: 




1. Prepare reverse transcriptase cocktail as follows and keep on ice. 
Reagent  ul/sample  
DEPC  4.2  
10X RT buffer  2.0  







Total  10.0  
2. In a cold block add 3ug of RNA in a 200ul PCR tube and volume to 10ul with DEPC 
water. 
3. Add 10ul of reverse transcriptase cocktail to each tube. 
4. Put in thermocycler on program as follows: 
a. 25°C for 10 min 
b. 42°C for 50 min 
c. 70°C for 15 min 
d. 4°C Hold 
5. Store all samples in -20°C. 
RT PCR 
Materials and Reagents: 
iTaq™ Universal SYBR® Green Supermix (Bio-Rad, Catalog #: 1725121) 
ddH2O 
1. Dilute cDNA samples 1:10 and 1:100 (serial dilution) with ddH2O, keep samples on 
cold block.  
2. Fill out plate template, all samples are in duplicate. 
3. Prepare master mix solutions as follows, keep master mix on ice. 
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Reagent  ul/sample  
Syber Green Mix  10.0  
Forward Primer (20uM)  1.0  
Reverse Primer (20uM)  1.0  
  
Total  12.0  
4. Load 8ul of cDNA to each well as per template. 
5. Load 12ul of master mix solution into each well, DO NOT introduce bubbles. 
6. Cover plate with plate cover sheet 
7. Spin plate in centrifuge in environmental genomics core 
8. Put plate onto Applied Biosystems 7300 Real-Time PCR System 
9. Add dissociation step and set volume to 20ul. 
10. Start analysis. 
11. Turn OFF machine when finished. 
 
IL-6 Electroporation 
1. Prepare plasmids. They are typically at a concentration of 2-3 ug/ul. Dilute to 1 ug/ul in 
sterile saline. Need 40 ug of plasmid per injection. 
2. Start anesthesia with Isoflurane at 1-2%/1L O2. (Change percentage of isoflurane based 
on the level of consciousness of the mice.) 
3. Add mice to the anesthesia box. 
4. Place mouse under nose cone. Shave top of quad. Alcohol off skin and betadyne. 
5. Sterilize Scissors with bead sterilizer and alcohol. Make a small vertical snip with 
scissors over quad. 




7. Electroporate with default setting. 100 mV; 50 ms; 8 pulses. Make sure electrodes are 
under the skin, next to the quad. Touch foot pedal once to start the electrical current. 
8. Close the incision with a wound clip. 
9. Return mouse to cage. 
10. Remove wound clip in 7-10 days. 
 
IL-6 ELISA 
Materials and Reagents: 
 Coating Buffer: 100mM Sodium Carbonate, pH 9.5. 
 Assay Diluent: PBS with 10% FBS 
 Wash Buffer: PBS with 0.05% Tween-20 
 TMB-ELISA Substrate Solution (Thermo Scientific, Catalog #: 34028) 
Stop Solution: 2N H2SO4 
 Mouse IL-6 ELISA Kit (BD Bioscience, Catalog #: 555240) 
  IL-6 Standard (Reconstitute by dH2O to 1ng/ml) 
Capture Antibody (Anti-Mouse IL-6 monoclonal antibody, 1:250) 
Detection Antibody (Biotinylated Anti-Mouse IL-6 monoclonal antibody,1:500) 
Enzyme Reagent (Streptavidin-horseradish peroxidase conjugate (SAv-
HRP)1:250) 
1. Coat microwells with 100 μL per well of Capture Antibody diluted 1:250 in Coating 
Buffer. Seal plate and incubate overnight at 4° C. 
2. Aspirate wells and wash 3 times with ≥ 300 μL/well Wash Buffer. After last wash, 
invert plate and blot on absorbent paper to remove any residual buffer. 
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3. Block plates with ≥ 200 μL/well Assay Diluent. Incubate at RT for 1 hour. 
4. Prepare the IL-6 standards. 
a) Prepare a 1000 pg/mL standard from the stock standard. Vortex to mix. 
b) Add 300 μL Assay Diluent to 6 tubes. Label as 500 pg/mL, 250 pg/mL, 125pg/mL, 
62.5 pg/mL, 31.3 pg/mL, and 15.6 pg/mL. 
c) Perform serial dilutions by adding 300 μL of each standard to the next tube and 
vortexing between each transfer. Assay Diluent serves as the zero standard (0 
pg/mL). 
5. Aspirate/wash as in step 2. 
6. Pipette 100 μL of each standard, sample, and control into appropriate wells. Seal plate 
and incubate for 2 hours at RT. 
7. Aspirate/ wash as in step 2, but with 5 total washes. 
8. Add 100 μL of Working Detector (1:500 Detection Antibody + 1:250 SAv-HRP 
reagent, solved in Assay Diluent) to each well. Seal plate and incubate for 1 hour at RT. 
9. Aspirate/ wash as in step 2, but with 7 total washes. 
10. Add 100 μL of TMB-ELISA Substrate Solution to each well. Incubate plate (without 
plate sealer) for 30 minutes at room temperature in the dark. 
11. Add 50 μL of Stop Solution to each well. 
12. Read absorbance at 450 nm within 30 minutes of stopping reaction. 
13. Calculate protein concentration based on standard curve 
a) Create curve being sure to subtract out the zero value from both curve and samples. 
b) Calculate protein concentration using y=mx+b equation 





Materials and Reagents: 
 Uniaxle Stretch Device (See schematic picture below). 
 
 Silastic Sheet (GLOSS/GLOSS, 0.02’’, Speciality Manufacturing Inc.) 
 Type I Collagen from rat tail (Advanced Biomatrix, Catalog #: 34028) 
 10N NaOH (Sterile filtered) 
 pH paper. 
1. Assemble cell stretch device. 
a) Cut silastic sheet into 1.5’×2’ squares. 
b) Adjust screw nuts (part 3) on two side arms (part 1) 30 cycles from baseline (part 
2) 
c) Fix the silastic sheet (part 5) with two C-shaped rings (part 4). 
2. Immerse cell stretch devices into a beaker of dH2O, seal the beaker with foil and 
autoclave (liquid program). 
3. Autoclave a pair of twizzles. 
4. Pick out cell stretch devices out of dH2O inside cell culture hood, transfer cell stretch 




5. Dilute Type I collagen solution by ice-cold sterile PBS to 200μg/ml, use 10N NaOH to 
adjust pH to ~7.0-8.0 (estimate pH by pH paper). 
6. Carefully pipette ~1ml diluted Type I collagen solution onto the silastic sheet of 
stretching device. Use pipette to spread out the solution throughout the sheet carefully. 
7. Leave stretching device in RT overnight, the collagen can polymerize into fibers to 
make gel-like solution. 
8. Air dry the collagen solution on the stretching device in the cell culture hood. 
9. Wash off the crystalized salt on the silastic sheet of stretching device by dH2O. 
10. Prepare C2C12 myoblasts suspend by trypsin digestion (see step 1-5 in ‘Divide Cell’ 
section of C2C12 cell culture). 
11. Pipette ~1ml C2C12 myoblasts suspend on to the silastic sheet of stretching device. 
Use pipette to spread out the cell suspend throughout the sheet carefully. 
12. Shake the petri dish containing stretching device very gently to help cells attach onto 
the silastic sheet evenly. 
13. Transfer petri dish containing stretching device into 37°C, 5% CO2 incubator. 
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14. After ~2h, add more growth medium to cover the cells on silastic sheet of stretching 
devices. 
15. Induce differentiation when C2C12 myoblast reach over 95% coverage on stretching 
devices. 
16. After 4-5 days differentiation, rotate screw nuts (part 3) on two side arms (part 1) by 
sterile twizzles to induce stretch (1.5 cycles to induce 5% stretch). 
High Frequency Electrical Stimulation (HFES) 
1. Start anesthesia with Isoflurane at 1-2%/1L O2. (Change percentage of isoflurane based 
on the level of consciousness of the mice). 
2. Add mice to the anesthesia box. 
3. Place mouse under nose cone. Shave top of left quad. Alcohol off skin and betadyne. 
4. Place two needle electrodes on the left leg subcutaneously posterior to the femur to 
stimulate the sciatic nerve. Use tape to fix the electrodes and make sure the electrodes 
can attach the skin. 
5. Start electrical stimulation 
6. Electrical stimulation parameters: 
a) 10 sets of 6 repetitions  
b) Each repetition: 100 Hz, 6–12 V, 1-ms duration, 3-s repetition duration. 
c) 10s interval between 2 repetitions. 
d) 50s interval between 2 sets. 
7. Use twizzles to help the hindlimb back to basal position after each repetition. 
8. Give mouse an intraperitoneal injection of warm saline (~1ml) and put mouse back to 




DOCTORAL DISSERTATION PROPOSAL 
 
The Role of Glycoprotein130 in Inflammatory cytokines and Mechanical 









Introduction and Aims 
Skeletal muscle provides a fundamental basis for human function, including 
locomotion, respiration and homeostasis of metabolism. Maintaining skeletal muscle mass 
is critical for physical activity level, quality of life and decreased mortality. The skeletal 
muscle mass is sensitive to multiple systematic changes related to nutritional status, 
physical activity level, inflammatory cytokines and muscle wasting diseases. The 
regulation of skeletal muscle mass involves the balance between protein synthesis and 
degradation, which is termed as protein turnover (1). However, significant gaps remain in 
our understanding of skeletal muscle protein turnover regulation by hypertrophic or 
atrophic stimuli in health and disease. 
Glycoprotein 130 (gp130) is signal-transducing receptor that forms part of the receptor 
complex for IL-6 family of cytokines (3). Formation of functional ligand-receptor complex 
results in gp130 activation of multiple downstream signaling pathways, including STAT3, 
ERK1/2 and PI3K-Akt, which regulate many physiological and pathophysiological 
processes including immune system regulation, inflammation, wound healing and cell 
survival (4). Two members of IL-6 family of cytokines, IL-6 and Leukemia Inhibitory 
Factor (LIF), have recognized roles in skeletal muscle mass regulation (5) (7, 8). Skeletal 
muscle undergoing repeated contractions or overload can produce IL-6 and LIF, which is 
thought to initiate important autocrine and paracrine signaling that contributes to metabolic 
adaptations and muscle hypertrophy through, at least in part, the activation of satellite cell 
proliferation and fusion to myofibers (7, 8). Physiological elevation of IL-6 family of 
cytokines by exercise or muscle contractions under physiological conditions is transient, 
and goes back to basal level 3-4h post exercise (6). However, long-lasting elevated 
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systemic levels of IL-6 family of cytokines is associated with the pathological 
inflammatory conditions in some types of cancer and other chronic disease states. It has 
been well demonstrated that constant elevation of IL-6 has been demonstrated as a key 
mediator of different muscle wasting diseases such as rheumatoid arthritis, chronic kidney 
disease and cancer cachexia (9-11). Currently, there is not a clear understanding of this 
complex dichotomy involving the effects LIF and IL-6 on muscle mass regulation. 
The muscle protein synthesis regulation is a key determinant of muscle mass (12).  
The integration of muscle protein synthesis through mTOR signaling is an acknowledged 
control point of skeletal muscle mass (12). Activation of mTOR signaling plays a central 
role in muscle hypertrophic response to multiple hypertrophic stimulus, including growth 
factors, hormones, nutrition and mechanical stimuli (16), while the muscle mTOR 
signaling and protein synthesis suppression is associated with muscle wasting (17-19). 
Once activated, mTOR can induce muscle protein synthesis through the phosphorylation 
of the p70S6K and 4E-BP1 (13). Multiple upstream signaling pathways, including PI3K-
Akt, ERK1/2 and AMPK, regulate mTORC1 by phosphorylating different sites of tuberous 
sclerosis 1/2 (TSC1/2). TSC2 phosphorylation by PI3K-Akt or ERK1/2 can relieve TSC1/2 
suppression on Ras homolog enriched in brain (Rheb), allowing Rheb to stimulate mTOR 
signaling (14-16), while AMPK suppress mTOR signaling by phosphorylation of TSC2 
and subsequent enhancement of the inhibition of TSC1/2 on mTOR (17).  
Although gp130 signaling is involved in both muscle hypertrophy and atrophy, the 
potential gp130 signaling regulation of muscle protein synthesis in physiological or 
pathological conditions still needs to be determined. gp130 induction can activate 
PI3K/Akt and ERK1/2 signaling, two upstream stimulator of mTOR, through JAK and Ras 
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dependent mechanisms, respectively (3). Short term IL-6 or LIF exposure can stimulate 
Akt-mTOR signaling in cardiomyocytes, which is a key mechanism of IL-6 and LIF 
induced cardiac hypertrophy (18, 25). However, the specific interaction between these 
cytokines and the PI3K/Akt-mTORC1 or gp130-ERK1/2-mTORC1 signaling axis within 
skeletal muscle fibers needs further investigation. Unlike the potential anabolic effects of 
short term IL-6/gp130 signaling action, pathological long term activation of IL-6-gp130 
dependent signaling is associated with suppression of muscle protein synthesis (18, 19). 
Chronic in vivo systemic IL-6 overexpression or in vitro IL-6 administration can decrease 
mTOR and p70S6K phosphorylation in skeletal muscles or cultured myotubes (20). The 
induction of AMPK signaling is a potential mediator of IL-6 suppression of muscle mTOR 
(20), but the mechanisms of IL-6 induction of muscle AMPK signaling is not well 
understood. 
Mechanical stimuli such as loading, stretch or muscle contractions can induce skeletal 
muscle hypertrophy by stimulating muscle protein synthesis (21, 22), that is important for 
the maintenance of mass and function (23). The induction of mTOR signaling through 
TSC2 dependent mechanisms plays a key role (24), but the biochemical events connecting 
the mechanical stimuli and mTOR activation still need to be determined. Physiological 
elevation of IL-6 family of cytokines during exercise or overload have a documented role 
in muscle metabolic adaptations and muscle hypertrophy (4-6). Pathological induction of 
muscle inflammatory or stress signaling pathways has the potential to inhibit muscle 
anabolic signaling induced by mechanical stimuli. Muscle contraction-induced mTOR 
signaling is attenuated in severely cachectic ApcMin/+ mice, which is associated with 
muscle STAT3 and NF-κB signaling activation (25). AMPK activation is also sufficient to 
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prevent mTOR induction by electrically-stimulated muscle contractions (26). However, the 
role of physiological or pathological IL-6/gp130 signaling in mechanical stimuli induced 
muscle protein synthesis have not been investigated.  
 
The overall goal of this dissertation is to examine gp130 regulation of anabolic 
signaling in skeletal muscle during physiological and pathological conditions. 
Specifically, we will investigate the role of gp130 signaling in basal muscle protein 
synthesis regulation during either physiological short term or pathological long term 
exposure to inflammatory cytokines. Additionally, we will investigate if physiological or 
pathological gp130 signaling regulates the induction of protein synthesis by mechanical 
stimuli. We hypothesize that physiological, short term inflammatory cytokine exposure will 
induce basal muscle protein synthesis through gp130 activation of Akt-mTOR signaling, 
while pathological, long term cytokine exposure will suppress basal muscle protein 
synthesis through gp130 activation of AMPK signaling. Furthermore, physiological or 
pathological cytokine exposure will either amplify or suppress mechanical regulation of 
muscle protein synthesis, respectively. 
In this study, we propose to address the following specific aims. 
Aim. 1: Determine if physiological, short term exposure of inflammatory cytokines 
IL-6 or LIF can stimulate muscle protein synthesis through gp130 regulation of Akt-
mTOR signaling. 
Aim 1.1: Determine if short term IL-6 or LIF exposure will stimulate myotube protein 
synthesis. 
Aim 1.2: Determine if gp130 or Akt-mTOR signaling is necessary for myotube protein 
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synthesis regulation by short term IL-6 or LIF exposure. 
Aim 1.3: Determine if in vivo short term IL-6 infusion will stimulate muscle protein 
synthesis. 
Aim. 2: Determine if pathological, long term IL-6 and LIF exposure can suppress 
muscle protein synthesis through AMPK signaling. 
Aim 2.1: Determine if long term IL-6 or LIF exposure will suppress myotube protein 
synthesis.  
Aim 2.2: Determine if gp130 regulation of AMPK signaling is necessary for long term 
IL-6 or LIF regulation of myotube protein synthesis. 
Aim 2.3: Determine if in vivo long term IL-6 overexpression will suppress skeletal 
muscle protein synthesis. 
Aim 3: Determine if physiological or pathological administration of IL-6 or LIF 
cytokines can regulate the induction of muscle protein synthesis by mechanical stimuli. 
Aim 3.1 Determine if short term IL-6 or LIF exposure will potentiate stretch induction 
of myotube protein synthesis through gp130 regulation of Akt signaling. 
Aim 3.2 Determine if long term IL-6 or LIF exposure will disrupt stretch induction of 
myotube protein synthesis though gp130 or AMPK dependent mechanisms. 
Aim 3.3 Determine if in vivo short term IL-6 infusion or long term IL-6 overexpression 





Overall working model 
 
IL-6 and LIF can activate or suppress skeletal muscle mTOR signaling and protein 
synthesis, which is determined by the duration of cytokine exposure. Short term IL-6 or 
LIF can induce mTOR signaling and subsequent protein synthesis through gp130-
PI3K/Akt signaling axis under physiological conditions, while pathological long term IL-
6 or LIF exposure can suppress muscle mTOR signaling and protein synthesis, which is 
dependent on gp130 and AMPK signaling. Furthermore, short term or long term IL-6/LIF 
exposure can potentiate or suppress muscle protein synthesis induction by mechanical 
stimuli, including stretch and eccentric contractions. The phosphorylation of TSC1/2 on 
different sites is a converging regulatory point of protein synthesis regulation by IL-6/LIF 
and mechanical stimuli. 
 
Preliminary Data 
1. gp130 siRNA knock-down decreased basal myotube protein synthesis. C2C12 
myotubes were transfected with gp130 siRNA for 24h. gp130 siRNA knockdown 
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significantly decreased myotube gp130 protein, as well as gp130 downstream STAT3 
phosphorylation (Fig. B1A). gp130 siRNA knockdown also significantly decreased 







Figure B1: Effect of gp130 siRNA knock-down on myotube mTOR signaling 
and protein synthesis. C2C12 myotubes were tranfected with control or gp130 siRNA  
for 24h. A. gp130, p-STAT3, total STAT3, p-p70S6K (T389), total p70S6K were measured  
by western blot. B. protein synthesis was measured by puromycin incorporation. *:p < 0.05,  
student’s t-test  
 
2. Long term IL-6 administration increased AMPK phosphorylation and 
suppressed mTOR signaling in C2C12 myotubes. C2C12 myotubes were treated with 
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different doses (5ng/ml and 20ng/ml) of IL-6 for 24h. 20ng/ml IL-6 significantly increased 
AMPK phosphorylation (Fig. B2A) and decreased mTOR and its downstream target 








3. Cell stretch induction of myotube hypertrophy, mTOR signaling and protein 
synthesis. Differentiated C2C12 myotubes were subjected to 5% stretch for either 4h or 
Figure B2: Effect of long term (24h) IL-6 administration on AMPK and  
mTOR signaling in C2C12 myotubes. A. representative Western blot and 
quantification of total and phosphorylated AMPK. B. representative Western blot 
and quantification of total and phosphorylated Akt, mTOR and 4EBP1. *: 




24h. Stretch for 24h significantly increased C2C12 myotube mean diameter (Fig. B3A). 
Related to growth signaling, both 4h and 24h stretch induced p70S6K and S6RP 
phosphorylation (Fig. B3B). However, neither stretch time point demonstrated an increase 
4EBP1 phosphorylation (Fig. B3B). Myotube protein synthesis rate was also significantly 
increased by both 4h and 24h stretch (Fig. B3C). These results demonstrate stretch can 









Figure B3: Effect of mechanical stretch on myotube mTOR signaling pathway and 
protein synthesis. C2C12 myotubes were stretched for 4h and 24h. A. Mean diameter of 
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myotubes after 4h and 24h stretch. B. Phosphorylation (ratio between phospho and total) 
of p70S6K, S6RP and 4EBP1 was measured by western blot. C: Protein synthesis rate was 
measured by western blot against puromycin. NC: Negative Control, the protein sample 
from C2C12 myotubes without puromycin treatment. For A and B, bar graphs represent 
fold changes relative to control group. All values are means ± SE. * p < 0.05 vs. Control, 
one-way ANOVA.  
 
4. Skeletal muscle mTOR signaling and protein synthesis induction by eccentric 
contractions. ~13 weeks of C57BL/6 mice were subjected to high frequency electrical 
stimulation (HFES) to induced eccentric contractions in TA and EDL muscles of their left 
legs, while the right legs were used as intra-animal control. Mice were sacrificed 3h post 
electrical stimulation. The eccentric contractions activated mTOR signaling in TA muscle, 
which was reflected by the induction of p70S6K and its downstream target, S6RP 
phsophorylation (Fig. B4A). Consistent with the changes in p70S6K and S6RP, eccentric 
contractions also increased protein synthesis (measured by puromycin incorporation) in TA 













Research Design and Methods 
Overall Research Design 
The overall purpose of this study is to monitor the regulation of physiological short 
term and pathological long term gp130 cytokines, IL-6 and LIF, on basal mechanical 
stimuli induced muscle protein synthesis. We will use in vitro and in vivo approaches in all 
three aims. In vitro myotubes model will be treated with different level of IL-6 or LIF for 
different time periods to model the short term or long term exposure of inflammatory 
Figure B4: Eccentric contractions induction of skeletal muscle mTOR 
signaling and protein synthesis. ~13 week of control B6 were subjected to 
high frequency electric stimulation to induce eccentric contractions on their 
left TA muscles. A. Phosphorylation of p70S6K and S6RP were measured 




cytokines under physiological or pathological conditions, respectively. The role of gp130 
receptor or gp130 downstream signaling pathways will be investigated by RNA 
interference or specific pharmaceutical inhibitors. In aim 3, cultured myotubes will be 
stretched to apply mechanical stimuli in vitro. The regulation of short term and long term 
IL-6 on muscle protein synthesis will also investigated in vivo by IL-6 infusion and long 
term IL-6 over-expression, respectively. To investigate the regulation of short term or long 
term IL-6 exposure on muscle mechanical signaling, muscle eccentric contractions will be 
induced by electrical stimulation. The primary outcomes includes Akt-mTOR signaling 
(phosphorylation of Akt, TSC2 and p70S6K) and protein synthesis (measured by 
puromycin incorporation) in myotubes or skeletal muscles. 
 
Aim. 1: Determine if physiological, short term exposure of inflammatory cytokines 
IL-6 or LIF can stimulate muscle protein synthesis through gp130 regulation of Akt-
mTOR signaling.  
Aim 1.1: Determine if short term IL-6 or LIF exposure will stimulate myotube protein 
synthesis.  
Aim 1.2: Determine if gp130 or Akt-mTOR signaling is necessary for myotube protein 
synthesis regulation by short term IL-6 or LIF exposure. 
Aim 1.3: Determine if in vivo short term IL-6 infusion will stimulate muscle protein 
synthesis through gp130 dependent mechanisms. 
 
Overview: We will use both in vitro and in vivo approaches in this aim. Myotubes will 
be treated with IL-6 or LIF for 1-4 hours, which mimics physiological elevation of 
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inflammatory cytokines. The role of gp130 regulation of Akt-mTOR signaling will be 
investigated. The primary outcomes include protein synthesis regulation and gp130 
downstream signaling pathways. We will further examine this regulation in vivo using short 
term IL-6 administration. Muscle specific gp130 knock-out mice will be used to examine 
the role of gp130 in short term IL-6 regulation of muscle protein synthesis. 
In this aim, we will conduct four experiments. In experiment 1.1, we will determine if short 
term (1-4h) IL-6 or LIF exposure will stimulate Akt-mTOR signaling and protein synthesis 
in cultured myotubes. In experiment 1.2, we will knock-down myotube gp130 by siRNA 
transfection before short term IL-6 or LIF exposure to determine if gp130 is necessary for 
short term IL-6 or LIF regulation of myotube protein synthesis. In experiment 1.3, we will 
inhibit myotube Akt-mTOR signaling by wortmannin (PI3K inhibitor) or rapamycin 
(mTORC1 inhibitor) during IL-6 or LIF treatment to determine if Akt-mTOR signaling is 
necessary for short term IL-6 or LIF regulation of myotube protein synthesis. In experiment 
1.4, we will inject IL-6 into control or skm-gp130-/- mice to determine if short term (1-2h) 
in vivo IL-6 infusion will stimulate muscle mTOR signaling or protein synthesis through 
gp130 dependent mechanisms. 
 
Experiment 1.1 will determine if short term (1-4h) IL-6 or LIF exposure will 
stimulate Akt-mTOR signaling and increase protein synthesis in cultured myotubes. 
Hypothesis 1.1: Short term IL-6 or LIF exposure will activate Akt-mTOR signaling 
and increase protein synthesis in cultured myotubes. 
Design:  
This experiment will determine the effect of different doses and duration of IL-6/LIF 
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administration on myotube protein synthesis regulation. In dose response study, C2C12 
myotube will be treated with different level (5, 10, 20 or 100ng/ml) of IL-6 family of 
cytokines (IL-6 and LIF) or control cytokines (TNF-α and IL-1β) for 2h. In time response 
study, C2C12 myotube will be treated with IL-6 (20ng/ml) or LIF (10ng/ml) for different 
time periods (30min, 1h, 2h and 4h). All inflammatory cytokines will be solved in serum-
free DMEM to exclude the potential influence of cytokines or growth factors in serum. To 
measure protein synthesis, puromycin (1μM) will be added to cell culture medium 30min 
before protein sample collection. The treatment groups are listed in table 1. All groups 
contains at least 6 replicates from 2 independent experiments. 
Study Cytokine Dose (ng/ml) Duration (h) 
Cytokine Dose Response study 





















IL-6/LIF Time course study 















Protein synthesis: Protein synthesis will be determined by puromycin incorporation as 
previously described.  
Akt-mTOR signaling: The activity of mTORC1 will be determined by the phosphorylation 
of p70S6K (T389) and 4EBP1 (T37/46), which are two downstream targets of mTORC1 
and central mediators of mTOR activation of protein synthesis. The Akt signaling will be 
examined by measuring the phosphorylation of Akt (T308). The phosphorylation of Akt 
downstream target, TSC2 (T1462), which mediates the mTOR signaling activation by Akt, 
will also be examined. The total level of p70S6K, 4EBP1, Akt and TSC2 will also be 
measured. The phosphorylated or total proteins will be measured by western blot 
Secondary Outcomes: 
gp130 downstream signaling pathways: The gp130 protein and the phosphorylation of 
STAT3 (Y705), ERK1/2 (T402/Y404), two other gp130 downstream targets, will be 
measured by western blot to determine the regulation of IL-6 or LIF on gp130 dependent 
signaling. To further examine STAT3 signaling activity and potential negative feedback of 
gp130 signaling induction (see literature review), the mRNA expression of SOCS3 will be 
measured by RT-PCR. 
Other upstream regulator of mTOR signaling: The phosphorylation of AMPK, which is a 
suppressor of mTOR signaling and associated with long term IL-6 elevation, will be 
measured by western blot. The mRNA expression of REDD1, which can suppress mTOR 
signaling, will be measured by RT-PCR. 
 
Experiment 1.2 will determine if gp130 siRNA knock-down will block myotube 
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protein synthesis regulation by short term IL-6 or LIF exposure. 
Hypothesis 1.2: gp130 knock-down will block myotube protein synthesis induction by 
short term IL-6 or LIF exposure. 
Design: 
This experiment will determine if inhibition of gp130 dependent signaling pathways 
by gp130 siRNA knock-down will affect myotube protein synthesis regulation by short 
term IL-6 or LIF exposure. C2C12 myotubes will be transfected with control (scramble) 
siRNA or gp130 siRNA for 24h before short term IL-6 or LIF exposure. The control or 
gp130 siRNA transfected myotubes will be treated with IL-6 (20ng/ml) or LIF (10ng/ml) 
for 1h or 2h as described in experiment 1.1. To measure protein synthesis, puromycin (1μM) 
will be added to cell culture medium 30min before protein sample collection. The treatment 
groups are listed in table 2. All groups contains at least 6 replicates from 2 independent 
experiments. 
Group Cytokine siRNA 
1 - Control 
2 IL-6 Control 
3 LIF Control 
4 - gp130 
5 IL-6 gp130 
6 LIF gp130 
 
Primary Outcomes: 
Protein synthesis: see experiment 1.1 




gp130 downstream signaling pathways: see experiment 1.1. 
Other upstream regulator of mTOR signaling: see experiment 1.1. 
 
Experiment 1.3 will determine if inhibition of Akt-mTOR signaling will block 
myotube protein synthesis regulation by short term IL-6 or LIF exposure. 
Hypothesis 1.3: Pharmaceutical inhibition of Akt -mTOR signaling will block myotube 
protein synthesis induction by short term IL-6 or LIF exposure. 
Design: 
This experiment will determine if inhibition of PI3K-Akt signaling by wortmannin 
(PI3K inhibitor) or inhibition of mTOR signaling by rapamycin (mTORC1 inhibitor) will 
block the myotube protein synthesis regulation by short term IL-6 or LIF exposure. The 
C2C12 myotubes will be pretreated with DMSO (vehicle control), wortmannin (1μM, 
solved in DMSO) or rapamycin (10nM, solved in DMSO) for 1h before the short term IL-
6 or LIF administration (20ng/ml IL-6 for 2h or 10ng/ml LIF for 2h as described in 
experiment 1.1). The DMSO, wortmannin or rapamycin will be kept in culture medium 
during IL-6 of LIF administration. To measure protein synthesis, puromycin (1μM) will be 
added to cell culture medium 30min before protein sample collection. The treatment groups 





Group Cytokine Inhibitor 
1 - DMSO 
2 IL-6 DMSO 
3 LIF DMSO 
4 - Wortmannin 
5 IL-6 Wortmannin 
6 LIF Wortmannin 
7 - Rapamycin 
8 IL-6 Rapamycin 
9 LIF Rapamycin 
 
Primary Outcomes: 
Protein synthesis: see experiment 1.1 
Akt-mTOR signaling: see experiment 1.1 
Secondary Outcomes: 
gp130 downstream signaling pathways: see experiment 1.1. 
Other upstream regulator of mTOR signaling: see experiment 1.1. 
 
Experiment 1.4 will determine if in vivo short term IL-6 infusion will stimulate 
muscle Akt-mTOR signaling and protein synthesis. 
Hypothesis 1.4: In vivo short term IL-6 infusion will stimulate muscle Akt-mTOR 
signaling and increase muscle protein synthesis. 
Design: 
This experiment will examine the effect of short term IL-6 infusion on muscle Akt-
mTOR signaling and protein synthesis in vivo. Male C57BL/6 mice (~8 week old) will be 
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fasted for 5h, followed with intraperitoneal (i.p.) injection of PBS or IL-6 (3ng/kg BW, 
solved in PBS) as previously described (301). Mice will be sacrificed 30min or 1h post IL-
6 injection. A pilot study will be conducted to determine the optimal duration of IL-6 
exposure, which demonstrate the significant difference in protein synthesis between PBS 
and IL-6 treated group.  To measure protein synthesis, 0.04mmol/g body weight 
puromycin will be injected into mice (I.P. injection) 30min before sacrifice. The experiment 
groups and mouse calculation are listed in table 4. At least 8 mice will be included in each 
experiment group, see table 4 for experiment groups and mice number calculations. 
 
Genotype C57BL/6 
Cytokine PBS IL-6 PBS IL-6 PBS IL-6 





1h 1h 30min or 1h# 30min or 1h# 
Number of Mice 3* 3* 3* 3* 5 5 
Total 22 (22 C57BL/6) 
 
Primary Outcomes:  
Protein synthesis: Protein synthesis in TA muscle will be determined by western blot 
analysis of incorporated puromycin as previously described. 
Akt-mTOR signaling: To measure muscle PI3K-Akt signaling activity, the phosphorylation 
of Akt (T308) and TSC2 (T1462) in TA muscle will be examined. The phosphorylation of 
p70S6K (T389), S6 Ribosomal Protein and 4EBP1 (T37/46) will be examined to determine 




gp130 signaling pathways: The phosphorylation of STAT3 (Y705), ERK1/2 (T402/Y404) 
in TA muscle will be measured by western blot. The mRNA expression of SOCS3 in gastroc 
muscle will be measured by RT-PCR. 
AMPK signaling: The phosphorylation of AMPKα (T172) and Acetyl-CoA Carboxylase 
(S79) and total AMPKα in TA muscle will be measured by western blot. 
Plasma IL-6 level:  Plasma IL-6 levels of blood samples taken from the retroorbital eye 
sinus at sacrifice to ensure validity of in vivo IL-6 infusion. The plasma IL-6 will be 
measured by ELISA using specific mouse IL-6 kit. 
Muscle weight: the wet weight of hindlimb muscles (soleus, plantaris, gastroc, EDL, TA 
and quadceps) will be recorded during sacrifice. 
 
Experiment 1.5 (alternative) will determine if short term IL-6 infusion will 
stimulate muscle mTOR signaling or protein synthesis in muscle specific gp130 knock 
out mice.  
Hypothesis 1.5: Short term IL-6 administration will not induce muscle mTOR 
signaling or protein synthesis in skm-gp130-/- mice. 
Design:  
This experiment will be conducted if short term IL-6 exposure can regulate muscle 
mTOR signaling or protein synthesis (significant difference between control (PBS) and IL-
6 treated mice). Skeletal muscle gp130 knock-out mice (skm-gp130-/- mice, C57BL/6 
background) will be administrated by short term IL-6 in these experiment to examine if 
gp130 is necessary for short term IL-6 regulation of muscle protein synthesis.  Skm-
gp130-/- mice will be generated by crossing gp130 fl/fl mice with cre-expressing mice 
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driven by myosin light chain, and will be genotyped to validate homozygous for the gp130-
flox and mlc-Cre genes as previously described (19). skm-gp130-/- mice will be injected 
with PBS (control) or IL-6 (3ng/g BW) as described in experiment 1.4. All mice will be 
sacrifice 30min or 1h post injection (the same cytokine treatment time as experiment 1.4). 
To measure protein synthesis, 0.04mmol/g body weight puromycin will be injected into 
mice (I.P. injection) 30min before sacrifice. See table 5 for experiment groups and mice 
number calculations. 
Genotype skm-gp130-/- 
Cytokines PBS IL-6 





Number of Mice 8 8 
Total 16 (16 skm-gp130-/-) 
 
Primary Outcomes:  
Protein synthesis: see experiment 1.4. 
Akt-mTOR signaling: see experiment 1.4 
Secondary Outcomes: 
Genotyping: The muscle specific gp130 knock-out of each skm-gp130-/- mouse will be 
further validated by genotyping PCR using DNA samples collected by its quadceps muscle, 
liver heart and spleen. 
Muscle gp130 level: The loss of skeletal muscle gp130 protein in skm-gp130-/- mice will 
be validated by examining gp130 protein in membrane fraction of quadceps muscle. 
gp130 signaling pathways: see experiment 1.4 
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AMPK signaling: see experiment 1.4. 
Plasma IL-6 level:  see experiment 1.4. 
Muscle weight: see experiment 1.4. 
 
Overall Aim 1 Interpretation: 
In experiment 1.1: 
Increased myotube Akt or TSC2 phsophorylation by short term IL-6 or LIF 
administration will indicate that physiological, short term IL-6 or LIF exposure can 
activate myotube Akt signaling. 
Increased myotube p70S6K or 4EBP1 phsophorylation by short term IL-6 or LIF 
administration will indicate that physiological, short term IL-6 or LIF exposure can 
activate myotube mTOR signaling. 
Increased myotube puromycin incorporation by short term IL-6 or LIF 
administration will indicate that physiological, short term IL-6 or LIF exposure can 
increased myotube protein synthesis. 
In experiment 1.2: 
Attenuated increase of Akt or p70S6K phosphorylation by short term IL-6 or LIF 
administration in gp130 siRNA transfected myotubes will indicate that gp130 is 
necessary for myotube Akt-mTOR signaling activation by short term IL-6 or LIF 
exposure. 
Attenuated increase of puromycin incorporation by short term IL-6 or LIF 
administration in gp130 siRNA transfected myotubes will indicate that gp130 is 




In experiment 1.3: 
Attenuated increase of protein synthesis by short term IL-6 or LIF administration 
in the presence of wortmannin will indicate that Akt signaling is necessary for 
myotube protein synthesis induction by short term IL-6 or LIF exposure. 
Attenuated increase of protein synthesis by short term IL-6 or LIF administration 
in the presence of rapamycin will indicate that mTOR signaling is necessary for 
myotube protein synthesis induction by short term IL-6 or LIF exposure. 
In experiment 1.4: 
Increased muscle Akt, p70S6K, S6RP or 4EBP1 phsophorylation by IL-6 infusion 
in WT mice will indicate that in vivo short term IL-6 elevation can activate muscle 
Akt-mTOR signaling pathway. 
Increased muscle protein synthesis by IL-6 infusion in WT mice will indicate that 
in vivo short term IL-6 elevation can induce muscle protein synthesis. 
In experiment 1.5: 
Attenuated Akt, p70S6K, S6RP or 4EBP1 phsophorylation induction by IL-6 
infusion in skm-gp130-/- mice will indicate that gp130 is necessary for muscle Akt-
mTOR signaling activation by short term IL-6 exposure. 
Attenuated protein synthesis induction by IL-6 infusion in skm-gp130-/- mice will 
indicate that gp130 is necessary for muscle protein synthesis induction by short 
term IL-6 exposure. 
 
Methods of Aim 1: 
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C2C12 cell culture:  
All cells are kept in 37°C, 5% CO2, humidified incubator. C2C12 myoblasts (from 
American Type Culture Collection, Manassas, VA, USA) are cultured in DMEM, 
supplemented with 10% FBS, 50 U/ml penicillin, and 50 µg/ml streptomycin. To maintain 
the myoblasts phenotype of C2C12 cells, the cells will be digested by trypsin and divided 
into more cell culture flasks before they reach 80% confluence.  To induce C2C12 
myoblasts differentiation, C2C12 myoblasts will be allowed to reach ~95% confluence, 
then incubate in differentiation medium (DMEM supplemented with 2% horse serum, 50 
U/ml penicillin, and 50 µg/ml) for 4-5 days. The differentiation medium will be switched 
every 2 days.  
RNA interference:  
Scramble siRNA (GE Healthcare, Pittsburgh, PA, USA, 100nM final concentration) or 
siRNAs specifically targeting gp130, p38α, STAT3 and AMPK (Santa Cruz Biotechnology, 
100nM final concentration) will be transfected into cultured myotubes (3 days 
differentiation) by Dharmafect 3 transfection reagent (GE Healthcare, 5μl in each well of 
6-well plate) following manufacturer’s instructions.  
Akt-mTOR downstream signaling inhibition:  
To inhibit gp130 downstream STAT3 signaling, myotubes will be STAT3 specific 
inhibitor, LLL12 (100nM, BioVision, Milpitas, CA, USA) will be added to cell culture 
media during stretch. Similarly, ERK1/2 signaling will be inhibited by adding PD98059 
(20µM, Cell Signaling Technology) during stretch. 
skm-gp130 knock-out mice:  
Male mice on a C57BL/6 background were bred with the gp130 fl/fl mice provided by 
248 
 
Dr. Colin Stewart’s lab in collaboration with Dr. Hennighausen (NCI) (302). Gp130 fl/fl 
mice will be bred with cre-expressing mice driven by myosin light chain from Dr. Steven 
Burden (NYU) (303). The resulting fl/fl cre/cre (skm-gp130) will have a skeletal muscle 
deletion of the gp130 protein. Offspring were genotyped  (described in detail below) for 
cre recombinase (forward 5’ AAG CCC TGA CCC TTT AGA TTC CAT TT 3’, reverse 5’ 
AAA ACG CCT GGC GAT CCC TGA AC 3’, wild type 5’ GCG GGC TTC TTC ACG 
TCT TTC TTT 3’), floxed gp130 (forward 5’ ACG TCA CAG AGC TGA GTG ATG CAC 
3’, reverse 5’ GGC TTT TCC TCT GGT TCT TG 3’), by taking tail snips at the time of 
weaning. All mice are group housed and provided standard rodent chow (Harlan Teklad 
Rodent Diet, #8604) and water ad libitum. The room are maintained on a 12:12 light:dark 
cycle with the light period starting at 07:00. Mice will be killed by injecting ketamine 
cocktail (90 mg/kg BW Ketamine, 7 mg/kg BW Xylazine and 1 mg/kg BW Acepromazine, 
solved in PBS, IP injection 15min before sacrifice), and hindlimb muscles (Soleus, 
Plantaris, Gastroc, EDL, TA and Quadceps) on both sides and important organs will be 
quickly isolated and frozen in liquid nitrogen during sacrifice. All animal experimentation 
protocols are approved by the University of South Carolina’s Institutional Animal Care and 
Use Committee. 
Genotyping:  
All animals will be genotyped using a tail snip. At 4-5 weeks of age animals a weaned, 
numbered, and a small tail snip (~1-2mm) collected. The tail snip is digested in 200ul of 
tail digest buffer and 5ul of proteinase K. Tails are incubated overnight in a water bath set 
at 37°C. After incubation samples are heat shocked at 95°C in a dri-bath for 10 minutes. 
DNA Extraction and Genotyping:  
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To screen the genotypes of mouse colony, a small snip of tail from each mouse will be 
in ~50-100μl tailing buffer (25mM NaOH, 0.2mM EDTA, PH 8.0) at 50°C overnight to 
degrade mouse tissues and expose genomic DNA. The digestion process will then be 
stopped by incubating on 90°C hotplate for 10min, and samples will be stored at 4°C. The 
DNA in organs/tissues (~20mg) frozen in -80°C will be collected using DNAzol Reagent 
(Invitrogen) following manufacturer’s instructions. Genotyping PCR will be conducted 
using GO-Taq Green Mater Mix (Promega). Each PCR reaction mix will contain 12.5μl 
GO-Taq Green Mater Mix, 9.5μl dH2O, 0.5μl forward primer, 0.5μl reverse primer and 2μl 
DNA sample. The amplified DNA fragment will be stained by Midori Green Florescence 
dye and separated in agarose gel (1% agarose,), and visualized under UV light.  
RNA Extraction and RT-PCR:  
The RNA extraction, cDNA synthesis and RealTime PCR (RT-PCR) will be conducted 
as previously described (18, 19). RNA in cultured myotubes and mouse muscles will be 
collected using Trizol Reagent (Invitrogen). Myotubes cultured will be scraped into Trizol 
(1ml for each cell stretching device or 1 well of 6-well plate) by cell scraper. Frozen tissues 
will be homogenized in 1 ml of Trizol on ice (Use new 14 ml Polyproplylen tube, rinse 
polytrone with EtOH, then dH2O each homogenization). After homogenization, samples 
will be spinned at 14000rpm for 10min at 4°C and supernatant will be kept. The RNA 
samples in Trizol will then be phase-seperated by chloroform, precipitated by isopropanol, 
washed by 75% EtOH (solved in DEPC H2O) and air dried following the manufacturer’s 
instructions. RNA sample will the solved in DEPC H2O and the OD260 and 260/280 ratio 
of each RNA sample will be measured by Nanodrop 2000 spectrometer (Thermo Fisher 
Scientific, Waltham, MA, USA) to determine their concentration and quality. The RNA 
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samples whose 260/280 ratio larger than 1.8 will be used to make cDNA. The cDNA 
samples will be synthesized using High Capacity cDNA Reverse Transcript Kit (Applied 
Biosystems, Foster City, CA, USA) following the manufacturer’s instructions. 2μg RNA 
sample will be included in 20μl reaction mix. cDNA sample will be further diluted either 
1:10 or 1:100 with sdH2O and analyzed by RT-PCR using SYBR Green Master mix 
(Applied Biosystems). The 20ul reaction mix contains 9.0μl of diluted cDNA, 10μl 2x 
SYBR Master mix, 0.08μl forward primer (20μM), 0.08μl reverse primer (20μM) and 
0.84μl sdH2O. The sequence of each primer is listed below. 
 
Protein Extraction and Western Blot:  
The protein extraction from cultured cells and mouse tissues and western blot analysis 
will be performed as previously described (19). To collect proteins from cultured cells, cell 
will be washed twice by ice-cold PBS, and scraped into ice-cold RIPA buffer [50mM Tris, 
150mM NaCl, 1% Triton X100, 1mM EDTA, 0.5% Sodium Deoxycholate, 0.1% SDS, 
5mM NaF, 1mM NaVO4 , 1mM β- glycerophosphate and 1% Protease Inhibitor Cocktail 
(Sigma-Aldrich)]. Cell lysates will be homogenized on ice by ultrasound sonication, 
centrifuged (12000rpm, 10min) at 4°C and supernatants will be collected. To collect 
proteins from mouse tissue, the frozen tissues will be homogenized in ice-cold Mueller 
Buffer (50mM HEPES, 4mM EGTA, 10mM EDTA, 15mM NaP2O7, 10mM β-
glycerophosphate, 25mM NaF, 5mM NaVO4, 0.1% Triton X-100, 1% Protease Inhibitor 
Cocktail, pH 7.4), centrifuged (12000rpm for 10min) at 4°C and supernatants will be 
collected and mixed with Diluent Buffer (50mM NaP2O7, 2.5mM EGTA, 1mM β-
mercaptoethanol, 50% glycerol, 1% Protease Inhibitor Cocktail, pH 7.4).  The volume of 
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Mueller Buffer will be determined by tissue weight (Mueller Buffer: 20µl/mg tissue; 
Diluent Buffer: 10µl/mg tissue). Protein concentrations will be determined by the Bradford 
reagent (BioRad). Homogenates were fractionated in SDS-polyacrylamide gels and 
transferred to PVDF membranes. After the membranes were blocked, antibodies for 
Phosphorylated/ total ERK1/2, Akt, STAT3, NF-κB p65, AMPK, MAPKAPK-2, p70S6K, 
S6RP, 4EBP1, GAPDH (Cell Signaling Technology), p38 MAPK (Santa Cruz 
Biotechnology), and puromycin (Millipore, Billerica, MA, USA) were incubated at 
dilutions from 1:2000 to 1:8000 overnight at 4°C in 2% TBST milk. Anti-rabbit or anti-
mouse IgG-conjugated secondary antibodies (Cell Signaling Technology) were incubated 
with the membranes at 1:2000 to 1:5000 dilutions for 2h in 2% TBST milk. Enhanced 
chemiluminescence (Advansta, Menlo Park, CA, USA) developed by autoradiography was 
used to visualize the antibody–antigen interactions. Blots were analyzed by measuring the 
integrated optical density (IOD) of each band with ImageJ software (NIH, Bethesda, MD, 
USA). 
Protein Synthesis Measurement:  
Protein synthesis measurement will be conducted as previously described (19). Briefly, 
to measure protein synthesis in mouse tissues, 0.04mmol/g body weight puromycin (EMD 
Chemicals, San Diego, CA, USA, solved in 300µl PBS) will be injected into mice (IP 
injection) 30min before sacrifice. To measure protein synthesis in cultured cells, puromycin 
stock solution (1mM, solved in sterile PBS) will be added to cell culture media (1µM final 
concentration) 30min before protein collection. The puromycin integrated into peptides 
will be monitored by western blot using mouse puromycin primary antibody (Millipore, 
Billerica, MA, USA) and HRP-Rabbit anti-Mouse IgG2a secondary antibody (Invitrogen). 
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The gel or PVDF membranes will be stained by commassie blue or ponceau to validate the 
protein integrity and equal loading of each protein sample. 
Statistical Analysis:  
All statistical analysis will be conducted by Prism Software. In experiment 1.1, 1.2 and 
1.3, the main effect of short term IL-6/LIF administration, main effect of gp130 
antibody/siRNA/inhibitor and their interactions will be determined by two-way ANOVA. 
In experiment 1.4, the effect of in vivo short term IL-6 administration will be determined 
by student’s t-test.  If experiment 1.5 is conducted, the results from experiment 1.4 and 
1.5 will be analyzed by two-way ANOVA to determine the main effect of IL-6, gp130 
knock-out and their interaction. If necessary, post-hoc analysis will be conducted using 
Student-Newman-Kelus (SNK) method. p < 0.05 will be considered as significant. 
 
Aim. 2: Determine if pathological, long term IL-6 and LIF exposure can suppress 
muscle protein synthesis through AMPK signaling.  
Aim 2.1: Determine if long term IL-6 or LIF exposure will suppress myotube protein 
synthesis.  
Aim 2.2: Determine if gp130 regulation of AMPK signaling is necessary for long term 
IL-6 or LIF regulation of myotube protein synthesis. 
Aim 2.3: Determine if in vivo long term IL-6 overexpression will suppress muscle 
protein synthesis through gp130 dependent mechanisms. 
 
Overview:  
We will use both in vitro and in vivo approaches in this this aim. Myotubes will be 
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treated with IL-6 or LIF for 24h, which mimics pathological elevation of inflammatory 
cytokines. The role of gp130 regulation of  AMPK signaling will investigated. The 
primary outcomes include protein synthesis regulation and gp130 downstream signaling 
pathways. We will also examine this regulation in vivo by long term IL-6 over-expression 
in control or muscle gp130 knock-out mice. 
In this aim, we will conduct four experiments. In experiment 2.1, we will determine if 
long term (24h) IL-6 or LIF exposure will induce AMPK signaling and suppress protein 
synthesis in cultured myotubes. In experiment 2.2, we will knock-down myotube gp130 by 
siRNA transfection before long term IL-6 or LIF exposure to determine if gp130 is 
necessary for pathological, long term IL-6 or LIF regulation of myotube protein synthesis. 
In experiment 1.3, we will inhibit myotube AMPK signaling by AMPK siRNA transfection 
before IL-6 or LIF treatment to determine if AMPK signaling is necessary for long term 
IL-6 or LIF regulation of myotube protein synthesis. In experiment 1.4, we will overexpress 
IL-6 into control or skm-gp130-/- mice to determine if long term in vivo IL-6 
overexpression will inhibit muscle mTOR signaling or protein synthesis through gp130 
dependent mechanisms. 
 
Experiment 2.1 will determine if long term 24h IL-6 or LIF exposure will activate 
AMPK signaling and suppress protein synthesis in cultured myotubes. 
Hypothesis 2.1: Long term IL-6 or LIF exposure will activate AMPK signaling and 
suppress in cultured myotubes. 
Design:  
This experiment will determine the effect of long term exposure of IL-6/LIF on 
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myotube AMPK, Akt-mTOR signaling and protein synthesis. C2C12 myotube will be 
treated with different level (20 or 100ng/ml) of IL-6 or LIF for 24h. To measure protein 
synthesis, puromycin (1μM) will be added to cell culture medium 30min before protein 
sample collection. The treatment groups are listed in table 6. All groups contains at least 6 
replicates from 2 independent experiments. 
Group Cytokine Dose (ng/ml) 
1 - - 
2 IL-6 20 
3 IL-6 100 
4 - - 
5 IL-6 20 
6 LIF 100 
 
Primary Outcomes: 
Protein synthesis: see experiment 1.1.  
AMPK signaling: The phosphorylation of AMPKα (T172) and total AMPKα protein will 
be measured by western blot. The phosphorylation of Acetyl-CoA Carboxylase (S79), a 
direct downstream target of AMPK will also be examined to determine the kinase activity 
of AMPK. 
Akt-mTOR signaling: see experiment 1.1 
Secondary Outcomes: 
gp130 downstream signaling pathways: see experiment 1.1 
REDD1 mRNA expression: see experiment 1.1. 
Myotube Diameter: The mean diameter of myotubes of each treatment group will be 
255 
 
determined by measuring diameters of myotubes from at least 10 randomly selected fields 
as previously described. 
Mitochondrial dynamics and oxidative metabolism: The protein level of FIS1 (Marker of 
mitochondrial fission), Overall 4HNE level (Marker of oxidative stress) will be measured 
by western blot. The PGC-1α mRNA will be examined by RT-PCR. 
Ubiquitin proteasome system: The mRNA level of Atrogin-1 and MURF-1 will be 
measured by RT-PCR. The Atrogin-1, MURF-1 protein and overall ubiquitination will be 
measured by western blot.  
 
Experiment 2.2 will determine if gp130 siRNA knock-down will block myotube 
protein synthesis regulation by long term IL-6 or LIF exposure. 
Hypothesis 2.2: gp130 siRNA knock-down will rescue myotube protein synthesis 
suppression by long term IL-6 or LIF exposure. 
Design: 
This experiment will determine if inhibition of gp130 dependent signaling pathways 
by gp130 siRNA knock-down will affect myotube protein synthesis regulation by long term 
IL-6 or LIF exposure. C2C12 myotubes will be transfected with control (scramble) siRNA 
or gp130 siRNA for 24h prior to long term IL-6 or LIF treatment as described in experiment 
2.1. The control or gp130 siRNA transfection mix will also be added into culture medium 
during IL-6 or LIF administration. To measure protein synthesis, puromycin (1μM) will be 
added to cell culture medium 30min before protein sample collection. The treatment groups 




Group Cytokine siRNA 
1 - Control 
2 IL-6 Control 
3 LIF Control 
4 - gp130 
5 IL-6 gp130 
6 LIF gp130 
 
Primary Outcomes: 
Protein synthesis: see experiment 1.1 
AMPK signaling: see experiment 2.1 
Akt-mTOR signaling: see experiment 1.1 
Secondary Outcomes: 
gp130 downstream signaling pathways: see experiment 1.1. 
REDD1 mRNA expression: see experiment 1.1. 
Myotube Diameter: see experiment 2.1 
Mitochondrial dynamics and oxidative metabolism: see experiment 2.1 
Ubiquitin proteasome system: see experiment 2.1 
 
Experiment 2.3 will determine if AMPK inhibition by AMPK siRNA knock-down 
will block myotube protein synthesis regulation by long term IL-6 or LIF exposure. 
Hypothesis 2.3: AMPK signaling inhibition by AMPK siRNA knock-down will rescue 




This experiment will determine if inhibition of AMPK signaling pathways by AMPK 
siRNA knock-down will affect myotube protein synthesis regulation by long term IL-6 or 
LIF exposure. C2C12 myotubes will be transfected with control (scramble) siRNA or 
AMPK siRNA for 24h prior to long term IL-6 or LIF treatment as described in experiment 
2.1. The control or gp130 siRNA transfection mix will also be added into culture medium 
during IL-6 or LIF administration. To measure protein synthesis, puromycin (1μM) will be 
added to cell culture medium 30min before protein sample collection. The treatment groups 
are listed in table 8. All groups contains at least 6 replicates from 2 independent 
experiments. 
Group Cytokine siRNA 
1 - Control 
2 IL-6 Control 
3 LIF Control 
4 - AMPK 
5 IL-6 AMPK 
6 LIF AMPK 
 
Primary Outcomes: 
Protein synthesis: see experiment 1.1 
AMPK signaling: see experiment 2.1 
Akt-mTOR signaling: see experiment 1.1 
Secondary Outcomes: 
gp130 downstream signaling pathways: see experiment 1.1. 
REDD1 mRNA expression: see experiment 1.1. 
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Myotube Diameter: see experiment 2.1 
Ubiquitin proteasome system: see experiment 2.1 
 
Experiment 2.4 will determine if in vivo long term IL-6 over-expression will 
suppress skeletal muscle mTOR signaling or protein synthesis. 
Hypothesis 1.4: In vivo long term IL-6 infusion will suppress induce AMPK signaling 
and suppress protein synthesis in skeletal muscles. 
Design: 
This experiment will examine the effect of long term IL-6 over-expression on muscle 
mTOR signaling and protein synthesis. Male C57BL/6 mice will be bred as described in 
experiment 1.4. The quadriceps muscle of ~8 week old WT or skm-gp130-/- mice will be 
will be electroporated with control or IL-6 expressing plasmid to induce IL-6 
overexpression as previously described. Mice will be fasted for 5h and sacrificed 2 weeks 
post plasmid transfection.  To measure the changes of plasma IL-6 level, blood samples 
will be collected from the retroorbital eye sinus under brief isoflurane anesthesia 7 days 
following each electroporation and at sacrifice. To measure protein synthesis, 0.04mmol/g 
body weight puromycin will be injected into mice (I.P. injection) 30min before sacrifice. 
To investigate the effect of long term IL-6 exposure on protein synthesis induction, all mice 
will be subjected to high-frequency electrical stimulation 3h before sacrifice (see Aim 3 
experiment design and experiment 3.6 for detail). The skeletal muscle of right TA muscle 





Plasmids control IL-6 
Number of Mice 8 8 
Total 16 (16 C57BL/6) 
 
Primary Outcomes:  
Protein synthesis: see experiment 1.4. 
AMPK signaling: The phosphorylation of AMPKα (T172) and Acetyl-CoA Carboxylase 
(S79) and total AMPKα in TA muscle will be measured by western blot. 
Akt-mTOR signaling: see experiment 1.4. 
Secondary Outcomes: 
gp130 signaling pathways: see experiment 1.4 
Serum IL-6 level:  To examine the changes in circulating IL-6 level post transfection, the 
IL-6 level in blood samples collected 1 week post electrophoration and at sacrifice will be 
measured by ELISA using specific mouse IL-6 kit. 
gp130 signaling pathways: The phosphorylation of STAT3 (Y705), ERK1/2 (T402/Y404) 
in TA muscle will be measured by western blot. The mRNA expression of SOCS3 in gastroc 
muscle will be measured by RT-PCR. 
Muscle weight: see experiment 1.4. 
Body composition: The proportion of bone, muscle and adipose tissue of each mouse at the 
time of electroporation and sacrifice will be measured by DEXA scan. 
 
Overall Aim 2 Interpretation: 
In experiment 2.1: 
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Increased myotube AMPK and Acetyl-CoA Carboxylase phosphorylation by long 
term IL-6 or LIF administration will indicate that long term IL-6 or LIF exposure 
can stimulate AMPK signaling in myotubes 
Decreased p70S6K, 4EBP1 phosphorylation and puromycin incorporation by long 
term IL-6 or LIF administration will indicate that long term IL-6 or LIF exposure 
can suppress mTOR signaling and protein synthesis in myotubes. 
In experiment 2.2: 
Attenuated AMPK increase and Acetyl-CoA Carboxylase phosphorylation by long 
term IL-6 or LIF administration in gp130 siRNA transfected myotubes will indicate 
gp130 is necessary for myotube AMPK signaling induction by long term IL-6 or 
LIF exposure. 
Attenuated p70S6K, 4EBP1 phosphorylation decrease by long term IL-6 or LIF 
administration in gp130 siRNA transfected myotubes will indicate gp130 is 
necessary for myotube protein synthesis suppression by long term IL-6 or LIF 
exposure. 
Attenuated puromycin incorporation decrease by long term IL-6 or LIF 
administration in gp130 siRNA transfected myotubes will indicate gp130 is 
necessary for myotube protein synthesis suppression by long term IL-6 or LIF 
exposure. 
In experiment 2.3: 
Attenuated p70S6K, 4EBP1 phosphorylation decrease by long term IL-6 or LIF 
administration in AMPK siRNA transfected myotubes will indicate gp130 is 




Attenuated puromycin incorporation decrease by long term IL-6 or LIF 
administration in AMPK siRNA transfected myotubes will indicate gp130 is 
necessary for myotube protein synthesis suppression by long term IL-6 or LIF 
exposure. 
In experiment 2.4: 
Decreased muscle p70S6K, 4EBP1 phosphorylation by IL-6 overexpression will 
indicate that in vivo long term IL-6 exposure can suppress mTOR signaling. 
Decreased muscle puromycin incorporation by IL-6 overexpression will indicate 




Methods of Aim 2: 
C2C12 cell culture: see Aim 1. 
RNA interference: see Aim 1. 
IL-6 Overexpression:  
An IL-6 plasmid was used to increase circulating IL-6 levels in C57BL/6 as previously 
described (125). Electroporation of plasmid DNA in the quadriceps muscle was used for 
endogenous IL-6 production and subsequent secretion in circulation. IL-6 plasmid (50 μg) 
driven by the CMV promoter or empty control vector was injected intramuscularly. Mice 
were anesthetized with a 2% mixture of isoflurane and oxygen (1L/min). The leg was 
shaved, and a small incision was made over the quadriceps muscle. Fat was dissected away 
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from the muscle, and the plasmids were injected in a 50-μl volume of PBS. A series of eight 
50-ms, 100-volt pulses was used to promote uptake of the plasmid into myofibers, and then 
the incision was closed with a wound clip. C57BL/6 and skm-gp130-/- mice were killed 
after 2 weeks of IL-6 overexpression.  
Protein Synthesis Measurement: see Aim 1. 
Protein Collection and Western Blot: See Aim 1. 
DNA Collection and genotyping: See Aim 1. 
RNA Collection and RT-PCR: See Aim 1. 
Myotube Diameter Measurement:  
Diameter of myotube will be measured as previously described (304). Briefly, myotube 
cultures were photographed under a phase-contrast microscope at ×40 after indicated 
treatment. The diameters were measured in a more than ≥150 myotubes from ≥10 random 
fields using ImageJ Software. Myotubes were measured at least 3 points evenly distributed 
along their length. The measurements were conducted in a blinded fashion, and results were 
expressed as micrometers. 
Statistical Analysis:  
All statistical analysis will be conducted by Prism Software. In experiment 2.1-2.3, the 
IL-6/LF, signaling inhibitions and their interactions will be determined by two-way 
ANOVA. In experiment 2.4, the effect of IL-6 overexpression will be determined by 
student’s t-test. If necessary, post-hoc analysis will be conducted using Student-Newman-
Kelus (SNK) method. p < 0.05 will be considered as significant. 
 
Aim 3: Determine if physiological or pathological administration of IL-6 or LIF 
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cytokines can regulate the induction of protein synthesis by mechanical stimuli.  
Aim 3.1 Determine if short term IL-6 or LIF exposure will potentiate stretch induction 
of myotube protein synthesis through gp130 regulation of Akt signaling. 
Aim 3.2 Determine if long term IL-6 or LIF exposure will disrupt stretch induction of 
myotube protein synthesis though gp130 or AMPK dependent mechanisms. 
Aim 3.3 Determine if in vivo short term IL-6 infusion or long term IL-6 overexpression 
will regulate muscle protein synthesis induction by eccentric contractions. 
 
Overview:  
We will use both in vitro and in vivo approaches in this this aim. Control or gp130 
deficient myotubes will be stretched in the presence of short term or long term 
inflammatory cytokine administration as in aim 1 and aim 2. The gp130 regulation of Akt 
or AMPK signaling will be examined. The primary outcomes include protein synthesis 
regulation and gp130 downstream signaling pathways. We will also examine if in vivo short 
term or long term IL-6 exposure which is similar to aim 1 and aim 2 will alter the acute 
protein synthesis induction by eccentric contractions. 
In this aim, we will conduct five experiments. In experiment 3.1, control or gp130 siRNA 
transfected myotubes will be stretched in the presence of short term IL-6/LIF exposure to 
determine if stretch induction of myotube protein synthesis will be potentiated by 
physiological elevation of inflammatory cytokines through gp130 dependent mechaisms. 
In experiment 3.2, control or gp130 siRNA transfected myotubes will be stretched after 
long term IL-6 or LIF exposure to determine if pathological elevation of inflammatory 
cytokines will suppress stretch induction of myotube protein synthesis. In experiment 3.3, 
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we will use PI3K inhibitor wortmannin to investigate the role of Akt signaling in the 
physiological IL-6 or LIF regulation of stretch induced myotube protein synthesis.  In 
experiment 3.4, we will use AMPK siRNA to investigate the role of AMPK signaling in 
the phathological IL-6 or LIF regulation of stretch induced myotube protein synthesis.  In 
experiment 3.5, we will examine the effect of in vivo short term IL-6 infusion or long term 
IL-6 overexpression on muscle protein synthesis induction by eccentric contractions. 
 
Experiment 3.1 will determine if short term IL-6 or LIF exposure will potentiate 
stretch induction of myotube protein synthesis through gp130 dependent mechanisms. 
Hypothesis 3.1: Firstly, short term IL-6 or LIF exposure will potentiate stretch 
induction of myotube protein synthesis. Secondly, knock-down myotube gp130 will block 
the regulation of short term IL-6 or LIF exposure on basal and stretch induced myotube 
protein synthesis. 
Design: 
C2C12 myoblasts will be grown and differentiate into myotubes on silastic membrane 
of stretching devices. Differentiated myotubes will be transfected with control or gp130 
siRNA for 24h as described in experiment 1.2. After 24h of siRNA transfection, myotubes 
will be stretched by 5% for 4h in the presence or absence of IL-6 (20ng/ml) or LIF 
(10ng/ml). To measure protein synthesis, puromycin (1μM) will be added to cell culture 
medium 30min before protein sample collection. The treatment groups are listed in table 

























Protein synthesis: see experiment 1.1. 
Akt-mTOR signaling pathway: see experiment 1.1. 
Secondary Outcomes: 
gp130 downstream signaling pathways: see experiment 1.1. 
AMPK signaling pathway: see experiment 1.2 
 
Experiment 3.2 will determine if long term IL-6 or LIF exposure will attenuate 
stretch induction of myotube protein synthesis through gp130 dependent mechanisms. 
Hypothesis 3.2: Long term IL-6 or LIF exposure will attenuate stretch induction of 




C2C12 myotubes grown on silastic membrane of stretching device will be transfected 
with control or gp130 siRNA as described in experiment 3.1. After 24h of siRNA 
transfection, myotubes will be administrated with IL-6 or LIF for 24h as described in 
experiment 2.1, and will be stretched by 5% in last 4h of IL-6/LIF administration. To 
measure protein synthesis, puromycin (1μM) will be added to cell culture medium 30min 
before protein sample collection. The treatment groups are listed in table 11. All groups 
contains at least 6 replicates from 2 independent experiments. 





















Protein synthesis: see experiment 1.1 
Akt-mTOR signaling pathway: see experiment 1.1 
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AMPK signaling pathway: see experiment 1.2 
Secondary Outcomes: 
gp130 downstream signaling pathways: see experiment 1.1. 
Myotube Diameter: see experiment 2.1 
 
Experiment 3.3 will determine if inhibition of Akt signaling by wortmannnin will 
block the regulation of short term IL-6 or LIF exposure on stretch induced myotube 
protein synthesis. 
Hypothesis 3.3: Inhibition of Akt signaling by wortmannnin will block the potentiation 
effect of short term IL-6 or LIF exposure on stretch induced myotube protein synthesis. 
Design: 
C2C12 myotubes will be cultured on silastic membrane of stretch devices and will be 
stretched for 4h in the presence or absence of IL-6 or LIF as described as described in 
experiment 3.1. To inhibit myotube PI3K-Akt signaling, myotubes will be pretreated with 
DMSO or wortmannin 1h before stretch as described in experiment 1.3. To measure protein 
synthesis, puromycin (1μM) will be added to cell culture medium 30min before protein 
sample collection. The treatment groups are listed in table 12. All groups contains at least 
































Myotube protein synthesis: see experiment 1.1. 
Akt-mTOR signaling pathway: see experiment 1.1. 
Secondary Outcomes: 
gp130 downstream signaling pathways: see experiment 1.1. 
Myotube Diameter: see experiment 2.1 
 
Experiment 3.4 will determine if inhibition of AMPK signaling by AMPK siRNA 
knock-down will block the regulation of long term IL-6 or LIF exposure on stretch 
induced myotube protein synthesis. 
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Hypothesis 3.4: AMPK siRNA knock-down will restore the stretch induction myotube 
protein synthesis in long term IL-6 or LIF treated myotubes. 
Design: 
C2C12 myotubes grown on silastic membrane of stretching device will be transfected 
with control or AMPK siRNA as described in experiment 3.1. After 24h of siRNA 
transfection, myotubes will be treated with IL-6 or LIF for 24h and will be stretched by 5% 
in last 4h of IL-6/LIF incubation as described in experiment 3.2. To measure protein 
synthesis, puromycin (1μM) will be added to cell culture medium 30min before protein 
sample collection. All groups contains at least 6 replicates from 2 independent experiments. 
siRNA Cytokine Stretch 
Control - 
0% (same cohort of experiment3.2) 
5% (same cohort of experiment3.2) 
Control IL-6 
0% (same cohort of experiment3.2) 
5% (same cohort of experiment3.2) 
Control LIF 
0% (same cohort of experiment3.2) 












Protein synthesis: see experiment 1.1. 
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Akt-mTOR signaling pathway: see experiment 1.1. 
AMPK signaling pathway: see experiment 1.2 
Secondary Outcomes: 
gp130 downstream signaling pathways: see experiment 1.1. 
Myotube Diameter: see experiment 2.1 
 
Experiment 3.5 will determine if in vivo short term IL-6 exposure will affect 
muscle protein synthesis induction by eccentric contractions. 
Hypothesis 3.5: Short in vivo term IL-6 exposure by infusion will potentiate muscle 
protein synthesis induction by eccentric contractions, while long term IL-6 exposure by IL-
6 overexpression will attenuate muscle protein synthesis induction by eccentric 
contractions. 
Design: 
This experiment will determine if short term IL-6 infusion or long term IL-6 
overexpression will potentiate or attenuate muscle protein synthesis induction by eccentric 
contractions, respectively. To induce short term IL-6 elevation in vivo, male C57BL/6 mice 
(~8 weeks old) will be injected with PBS or IL-6 as described in experiment 1.4 after 1.5h 
fasting. The eccentric contractions of TA and EDL muscles on left leg will be induced by 
High-frequency Electrical Stimulations 30min post IL-6 injection. The sedentary right leg 
will be used as intra-animal control. All mice will be sacrificed 3h post electrical 
stimulation and 0.04mmol/g body weight puromycin will be injected into mice (I.P. 









Number of Mice 8 8 
Total 16 (16 C57BL/6) 
Primary outcomes: 
Muscle protein synthesis: see experiment 1.1. 
Muscle Akt-mTOR signaling pathway: see experiment 1.1. 
Secondary Outcomes: 
Plasma IL-6 level:  Blood samples will be collected from retroorbital eye sinus before, 
after high frequency electrical stimulation and at sacrifice time. see experiment 1.4.  
gp130 downstream signaling pathways: 
 
Experiment 3.6 will determine if in vivo long term IL-6 overexpression will affect 
muscle protein synthesis induction by eccentric contractions. 
Hypothesis 3.6: Long term IL-6 overexpression will attenuate muscle protein synthesis 
induction by eccentric contractions. 
Design:  
This experiment use the same cohort of mice as experiment 2.4. The control or IL-6 
plasmid transfected C57BL/6 mice will be subjected to high frequency electrical 
stimulation as described in experiment 3.5. The mice will be sacrificed 3h post contraction. 
The protein sample of right TA muscle will be analyzed in experiment 2.4 and both right 




Muscle protein synthesis: see experiment 1.1. 
Muscle Akt-mTOR signaling pathway: see experiment 1.1. 
Secondary Outcomes: 
AMPK signaling: see experiment 1.4. 
Plasma IL-6 level:  see experiment 1.4. 
Muscle weight: see experiment 1.4. 
Body composition: see experiment 2.4. 
 
Overall Aim 3 Interpretation: 
In experiment 3.1 
Increased protein synthesis induction by stretch in the presence of short term IL-6 or 
LIF exposure (significant interaction term between cytokines and stretch) in control siRNA 
transfected myotubes will indicate that short term IL-6 or LIF can potentiate stretch 
induction of myotube protein synthesis. 
Attenuated protein synthesis induction by stretch in short term IL-6 or LIF treated gp130 
deficient myotubes will indicate that gp130 is necessary for short term IL-6 or LIF 
stimulation of stretch induced myotube protein synthesis. 
In experiment 3.2 
Attenuated protein synthesis induction by stretch in the presence of long term IL-6 or 
LIF exposure (significant interaction term between cytokines and stretch) in control siRNA 
transfected myotubes will indicate that long term IL-6 or LIF can suppress stretch induction 
of myotube protein synthesis. 
Restored stretch induction of protein synthesis long term IL-6 or LIF treated, gp130 
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deficient myotube will indicate that gp130 is necessary for long term IL-6 or LIF 
suppression of stretch induced myotube protein synthesis. 
In experiment 3.3 
Attenuated protein synthesis induction by stretch in IL-6 (or LIF) and wortamannin 
treated myotubes will indicate that PI3K-Akt signaling is necessary for short term IL-6 or 
LIF stimulation of stretch induced myotube protein synthesis. 
In experiment 3.4: 
Restored stretch induction of protein synthesis long term IL-6 or LIF treated, AMPK 
deficient myotube will indicate that AMPK signaling induction is necessary for long term 
IL-6 or LIF suppression of stretch induced myotube protein synthesis. 
In experiment 3.5: 
Increased muscle protein synthesis induction by eccentric contraction in IL-6 treated 
mice will indicate that in vivo short term IL-6 exposure can potentiate eccentric contraction 
induced muscle protein synthesis. 
In experiment 3.6: 
Attenuated muscle protein synthesis induction by eccentric contraction in IL-6 
overexpressing mice will indicate that in vivo long term IL-6 exposure can suppress 
eccentric contraction induced muscle protein synthesis. 
 
Methods of Aim 3: 
C2C12 cell culture: see Aim 1. 
Cell stretch:  
Cell stretch experiments will be conducted using methods previously described (86, 
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305). Static stretching device consists a small frame with two axles (part 1 in Fig. B5A, B) 
separated by lateral supports (part 2 in Fig. B5A, B). The axles were threaded to accept 
screw nuts (part 3 in Fig. B5A, B). Silastic membranes (GLOSS/GLOSS, 0.02’’, Speciality 
Manufacturing, Saginaw, MI, USA, part 5 in Fig. B5A, B) were mounted onto the devices 
by two friction-fit C-clamps (part 4 in Fig. B5A, B). The assembled stretching device was 
then immersed into distilled H2O, autoclaved and transferred into sterile 100mm petri-dish 
(Fig. B5A). The screw nuts were set to 30 cycles from baseline when stretching device was 
assembled (Fig. B5B, left). Approximately 300-400 µL type-I collagen solution (Advanced 
Biomatrix, San Diego, CA, USA, diluted to ~500μg/ml by PBS, adjust final pH to 7-8 by 
sterile 10N NaOH) was evenly scraped onto the silastic sheet attached onto stretching 
device and incubate in 4“C overnight. After incubation, stretching device was washed by 
sterile distilled H2O twice and air dried under UV overnight. C2C12 myoblasts were 
suspended (~1 × 106 cells/mL) and plated onto silastic membrane mounted in a stretching 
device (~1.5-2 × 105 cells/ stretching device). The cells were grown to ~95% confluence 
and differentiated into myotubes. To induced 5% stretch, screw nuts on both axles were 
rotated by 1.5 cycles using sterile forceps (Fig. C5B, right). Myotubes were constantly 













RNA interference: see Aim 1. 
High Frequency Electrical Stimulation (HFES):  
HFES of the left hindlimb was performed as previously described, with modifications 
(90). During each stimulation procedure, mice will be anesthetized by isoflurane (2% in 
O2 with 1.5% maintenance), the left leg/hip region will be shaved, and two needle 
Figure B5. Schematic figure of cell stretch method. A: Cell stretch device. 
Static stretching device is a small frame with two threaded axles (part 1) and 
two lateral supports (part 2). The distance between two lateral supports was 
adjusted by rotating screw nuts (part 3) on both axles. The silastic membrane 
where cells were grown (part 5) was fixed on lateral supported by two friction-
fit C-clamps (part 4). B. Representative image of cell stretch. The screw nuts 
were set to 30 cycles from the base line when stretch device was assembled 




electrodes will be placed on the left leg subcutaneously posterior to the femur to stimulate 
the sciatic nerve. Tetanic muscle contractions will be generated using a Grass Stimulator 
(Grass Instruments, Quincy, MA) for 10 sets of 6 repetitions (100 Hz, 6–12 V, 1ms duration, 
3s repetition duration). Ten seconds of rest will be given between repetitions, and 50 s of 
rest will be given between sets. This stimulation protocol recruits all motor units of the 
hindlimb. The maximal force production of the plantar flexors (gastrocnemius, soleus, and 
plantaris) are greater than the dorsiflexors (TA and EDL) (306, 307), which results in net 
plantar flexion of the ankle (90). Therefore, the dorsiflexors undergo lengthening eccentric 
muscle contractions against the shortening concentric plantar flexors. Each session lasts 
~20 min in duration. Following each stimulation procedure, mice will be given an 
intraperitoneal injection of warm saline and returned to cages upon complete recovery. 
Mice will be killed 3h after the last set of stimulation procedure. Mice will be fasted since 
2h before HFES until sacrifice, but had free access to water ad libitum. 
Protein Synthesis Measurement: see Aim 1. 
Protein collection and western blot: see Aim1. 
Statistical Analysis:  
All statistical analysis will be conducted by Prism Software. In experiment 3.1-3.4, 
two-way ANOVA will be used to determine the main effects of IL-6/LIF, main effects of 
mechanical stretch and their interactions. In experiment 3.5 and 3.6, two way repeated 
measures (RM-ANOVA) will be conducted to measure the main effects of IL-6, main 
effects of eccentric contractions and their interactions. If possible, post-hoc analysis will 





Limitations and Pitfalls 
IL-6 or LIF administration on myotubes:  
Administration of IL-6 and LIF on myotubes will be conducted in serum-free 
environment, which will exclude the combined effects of IL-6/LIF with other cytokines. It 
has been reposted that IL-6 can cooperate with other cytokines to induce muscle wasting. 
Serum starvation regulates insulin sensitivity in cultured myotubes (308), which may 
influence mTOR signaling and protein synthesis. Therefore, serum starvation effects is a 
pontential confounder of experiments in Aim 1 and 2. The in vitro myotube culture 
experiment also excludes the systematic effects of IL-6 and LIF, including the potential 
global metabolic and immune effects of IL-6 and LIF (204, 309, 310).  
RNA interference:  
RNA interference can not fully block the target protein. It is possible that the results of 
mechanistic studies using siRNA (gp130 and AMPK) is influenced by residual targeted 
signaling pathways in siRNA transfected cells. 
In vivo IL-6 infusion and IL-6 overexpression:  
It is difficult to control serum level of IL-6 in IL-6 injected or IL-6 overexpressing 
mice, and it is possible that plasma IL-6 level in animal models of this proposal is different 
from those under certain physiological or pathological conditions. It has been reported the 
mice injected with IL-6 showed higher plasma IL-6 level compared with IL-6 level post 
resistance exercise (301, 311).  It is possible that plasma IL-6 levels in IL-6 
overexpressing mice are different from those in animal models of muscle wasting diseases, 




In vitro cell stretch:  
Cell stretch is a different mechanical stimuli model from in vivo eccentric contractions. 
Myotubes are passively stretched and no myotubes contractions will be induced in cell 
stretch experiment, which is different from in vivo muscle eccentric contractions. The 
neuron-muscular interactions in in vivo muscle eccentric contractions is also absent in 
myotube stretch model. Furthermore, the IL-6 added in cell culture media during stretch 









Table C.1: Fig. 3.1B raw data (Puromycin, different doses of IL-6) 
 
 




64.011  59.83575 0.975 
69.350  65.17494 1.062 




113.659  109.4841 1.784 
125.626  121.4512 1.979 




125.933  121.7581 1.984 
148.885  144.7105 2.358 




180.859  176.6842 2.879 
178.589  174.4135 2.842 




198.227  194.0519 3.162 
178.589  174.4135 2.842 
160.914  156.739 2.554 
 
Table C.2: Fig. 3.1B raw data (Puromycin, different doses of LIF) 
 
 




63.533  59.83575 0.975 
68.872  65.17494 1.062 







106.799  103.1016 1.68 
95.875  92.17774 1.502 
109.315  105.6178 1.721 
131.162  127.4655 2.077 
120.484  116.7871 1.903 




265.624  261.9272 4.268 
283.237  279.5404 4.555 




154.851  151.1543 2.463 
164.425  160.728 2.619 




153.869  150.1724 2.447 
161.479  157.7823 2.571 





Table C.3: Fig. 3.1B raw data (Puromycin, different doses of TNF - α) 
 
 
  Signal -bg Normalized 
Control 81.576  78.7917 1.135 
  68.316  65.53248 0.944 
  66.164  63.38046 0.913 
5ng/ml 62.416  59.63178 0.859 
  57.973  55.1889 0.795 
  85.602  82.81806 1.193 
10ng/ml 83.797  81.01314 1.167 
  63.527  60.7425 0.875 
  66.164  63.38046 0.913 
20ng/ml 49.920  47.13618 0.679 
  32.773  29.98944 0.432 
  57.487  54.70296 0.788 
 
Table C.4: Fig. 3.1C raw data (p-NFκB, different doses of TNF-α) 
 







64.079  62.70887 0.735  
69.402  68.03192 0.797  
118.911  117.5407 1.377  
96.632  95.26176 1.116  
82.803  81.43344 0.954  




311.910  310.5397 3.638  
273.242  271.8716 3.185  




298.167  296.7967 3.477  
330.774  329.4042 3.859  




344.005  342.635 4.014  
279.388  278.0175 3.257  





Table C.5: Fig. 3.1D raw data (p-p70S6K, different doses of IL-6) 
 




82.863  81.97332 1.124 
64.995  64.10547 0.879 




203.927  203.0371 2.784  
232.662  231.7715 3.178  




165.128  164.2384 2.252  
291.078  290.1885 3.979  




283.785  282.8955 3.879  
186.278  185.3881 2.542  




85.635  84.74466 1.162  
76.883  75.99306 1.042  
114.223  113.3332 1.554  
 
Table C.6: Fig. 3.1D raw data (p-p70S6K, different doses of LIF) 
 




82.863  81.97332 1.124 
64.995  64.10547 0.879 




339.358  338.4681 4.641  
405.141  404.251 5.543  




243.747  242.8569 3.330  
257.312  256.4219 3.516  




133.987  133.0973 1.825  
74.185  73.29465 1.005  




47.565  46.6752 0.640  
9.496  8.60574 0.118  





Table C.7: Fig. 3.1D raw data (p-4EBP1 different doses of IL-6) 
 
  Signal -bg Normalized 
Control 89.712  88.82176 1.024 
  94.309  93.41898 1.077 
  79.043  78.15274 0.901 
5ng/ml 78.436  77.54556 0.894  
  129.786  128.8956 1.486  
  111.657  110.767 1.277  
10ng/ml 99.340  98.4499 1.135  
  76.007  75.11684 0.866  
  110.356  109.4659 1.262  
20ng/ml 70.109  69.21852 0.798  
  98.559  97.66924 1.126  
  102.202  101.3123 1.168  
100ng/ml 91.013  90.12286 1.039  
  80.517  79.62732 0.918  
  104.891  104.0013 1.199  
 
Table C.8: (Fig. 3.1D raw data, p-4EBP1, different doses of IL-6) 
 




81.576  78.7917 1.135 
68.316  65.53248 0.944 




89.351  86.56674 1.247 
92.266  89.48238 1.289 




82.409  79.62474 1.147 
85.394  82.6098 1.19 




89.351  86.56674 1.247 
92.266  89.48238 1.289 




65.811  63.02699 1.027 
63.356  60.57219 0.987 










52.975  51.94938 1.074 
46.591  45.56454 0.942 
48.622  47.59608 0.984 
Control siRNA + IL-6 
  
  
44.414  43.38789 0.897 
58.441  57.41519 1.187 




11.377  10.35118 0.214 
10.652  9.62563 0.199 
14.134  13.10827 0.271 
gp130 siRNA + IL-6 
  
  
14.521  13.49523 0.279 
10.652  9.62563 0.199 
15.247  14.22078 0.294 
 
Table C.10: Fig. 3.2A raw data (gp130 protein level, Control/gp130 siRNA + LIF) 
 




54.681  51.69615 0.935 
57.888  54.90297 0.993 
63.251  60.2661 1.09 
Control siRNA + LIF 
  
  
67.730  64.74459 1.171 
54.571  51.58557 0.933 




19.683  16.69758 0.302 
18.687  15.70236 0.284 
14.098  11.11329 0.201 
gp130 siRNA + LIF 
  
  
19.683  16.69758 0.302 
18.687  15.70236 0.284 





Table C.11: Fig. 3.2B raw data (Puromycin, Control/gp130 siRNA + IL-6/LIF) 
 








55.275  52.378  1.059  
53.588  50.424  0.912  50.923  48.026  0.971  
55.745  52.581  0.951  51.566  48.669  0.984  
Control siRNA + IL-6 
  
  
135.473  132.309  2.393  
Control siRNA + LIF 
  
  
152.415  149.518  3.023  
193.472  190.308  3.442  185.602  182.705  3.694  








45.878  42.981  0.869  
59.173  56.009  1.013  47.559  44.662  0.903  
43.747  40.583  0.734  46.669  43.772  0.885  
gp130 siRNA + IL-6 
  
  
65.365  62.201  1.125  
gp130 siRNA + LIF 
  
  
54.434  51.537  1.042  
63.541  60.377  1.092  50.824  47.927  0.969  
57.238  54.074  0.978  58.836  55.939  1.131  
 
Table C.12: Fig. 3.2C raw data (p-p70S6K, Control/gp130 siRNA + IL-6/LIF) 
 
  Signal -bg Normalized   Signal -bg Normalized 
Control siRNA 49.819  46.92179 1.109  Control siRNA 48.524  46.24483 1.093  
  30.229  27.33226 0.646    35.535  33.25566 0.786  
  55.573  52.67595 1.245    50.724  48.44495 1.145  
Control siRNA + IL-6 87.305  84.40845 1.995  Control siRNA + IL-6 92.611  90.33185 2.135  
  97.375  94.47823 2.233    139.110  136.8305 3.234  
  106.810  103.91336 2.456    127.347  125.0684 2.956  
gp130 siRNA 17.790  14.89312 0.352  gp130 siRNA 17.172  14.89312 0.352  
  37.168  34.2711 0.810    36.508  34.22879 0.809  
  36.068  33.17104 0.784    35.450  33.17104 0.784  
gp130 siRNA + IL-6 42.372  39.47523 0.933  gp130 siRNA + IL-6 39.216  36.93663 0.873  
  67.039  64.14196 1.516    57.959  55.67996 1.316  





Table C.13: Fig. 3 raw data (p-STAT3, different duration of IL-6/LIF treatment) 
 








28.36514 25.23514 0.922 
31.76463 28.78463 0.917 30.19893 27.06893 0.989 








182.07506 178.9451 6.538  
244.4319 241.45188 7.692  161.41071 158.2807 5.783  








176.57369 173.4437 6.337  
159.5533 156.57332 4.988  139.1589 136.0289 4.970  








39.8058 36.6758 1.340  
93.91683 90.93683 2.897  29.9526 26.8226 0.980  








40.29846 37.16846 1.358  
43.53588 40.55588 1.292  24.99863 21.86863 0.799  
27.58976 24.60976 0.784  25.87447 22.74447 0.831  
 
Table C.14: Fig. 3 raw data (p-ERK1/2, different duration of IL-6/LIF treatment) 
 




32.39569 30.26569 1.027 Control 20.58432 18.03432 0.922 
30.30332 28.17332 0.956   21.89484 19.34484 0.989 




35.81421 33.68421 1.143  30min 149.85636 147.3064 7.531  
39.82213 37.69213 1.279    127.22544 124.6754 6.374  




50.31345 48.18345 1.635  1h 25.2396 22.6896 1.160  
42.47443 40.34443 1.369    19.5672 17.0172 0.870  




41.0304 38.9004 1.320  2h 24.4572 21.9072 1.120  
22.1696 20.0396 0.680    17.8068 15.2568 0.780  




24.8219 22.6919 0.770  4h 15.6552 13.1052 0.670  
43.0933 40.9633 1.390    29.7384 27.1884 1.390  





Table C.15: Fig. 3 raw data (p-Akt, different duration of IL-6/LIF treatment) 
 








25.908  22.898  0.947  
34.288  31.638  1.049  30.551  27.541  1.139  








44.696  41.686  1.724  
38.782  36.132  1.198  31.736  28.726  1.188  








105.485  102.475  4.238  
93.552  90.902  3.014  111.699  108.689  4.495  








125.458  122.448  5.064  
85.892  83.242  2.760  120.912  117.902  4.876  








144.802  141.792  5.864  
123.592  120.942  4.010  129.689  126.679  5.239  
98.257  95.607  3.170  152.346  149.336  6.176  
 
 
Table C.16: Fig. 3.4A raw data (p-Akt, Wortmanin + IL-6/LIF) 
 








25.878  22.748  1.016  
23.803  21.153  0.868  29.080  25.950  1.159  








63.090  59.960  2.678  
50.878  48.228  1.979  73.345  70.215  3.136  








30.356  27.226  1.216  
28.044  25.394  1.042  19.743  16.613  0.742  








34.252  31.122  1.390  
33.941  31.291  1.284  23.975  20.845  0.931  





Table C.17: Fig. 3.4B raw data (p-p70S6K, Wortmanin + IL-6/LIF) 
 








27.849  24.829  0.938 
35.752  33.482  1.174  34.096  31.076  1.174  








91.165  88.145  3.330  
89.798  87.528  1.742  77.560  74.540  2.816  








N.D N.D 0.000  
N.D. N.D. 0.000  N.D. N.D. 0.000  








N.D. N.D. 0.000  
N.D N.D 0.000  N.D N.D 0.000  
N.D N.D 0.000  N.D N.D 0.000  
 
Table C.18: Fig. 3.4C raw data (Puromycin, Wortmanin + IL-6/LIF) 
 








27.813  24.633  0.785 
44.911  42.641  1.109  39.141  35.961  1.146  








101.525  98.345  3.134  
79.708  77.438  2.014  86.463  83.283  2.654  








8.640  5.460  0.174  
10.921  8.651  0.225  10.241  7.061  0.225  








10.523  7.343  0.234  
10.806  8.536  0.222  9.644  6.464  0.206  





Table C.19: Fig. 3.4D raw data, (p-p70S6K, Rapamycin + IL-6/LIF) 
 
IL-6 Signal -bg Normalized LIF Signal -bg Normalized 
Control 68.528  66.178  1.174 Control 59.778  55.518  1.174 
  55.225  52.875  0.938    48.618  44.358  0.938  
  52.801  50.451  0.895    46.585  42.325  0.895  
IL-6 159.002  156.652  2.779  LIF 209.026  204.766  4.330  
  202.013  199.663  3.542    170.532  166.272  3.516  
  130.141  127.791  2.267    144.049  139.789  2.956  
Rapamycin N.D. N.D. 0.000  Rapamycin N.D. N.D. 0.000  
  N.D. N.D. 0.000    N.D. N.D. 0.000  
  N.D. N.D. 0.000    N.D. N.D. 0.000  
Rapamycin +IL-6 N.D. N.D. 0.000  Rapamycin +LIF N.D. N.D. 0.000  
  N.D. N.D. 0.000    N.D. N.D. 0.000  
  N.D. N.D. 0.000    N.D. N.D. 0.000  
 
Table C.20 Fig. 3.4E raw data (Puromycin, Rapamycin + IL-6/LIF) 
 








65.883  62.933  0.785 
91.145  87.405  1.117  94.825  91.875  1.146  








199.687  196.737  2.454  
161.336  157.596  2.014  174.995  172.045  2.146  








16.900  13.950  0.174  
21.346  17.606  0.225  20.988  18.038  0.225  








77.989  75.039  0.936  
44.587  40.847  0.522  63.398  60.448  0.754  





Table C.21: Fig. 3.5A, B raw data (p-STAT3, LLL12 + IL-6/LIF) 
 








50.846  48.706  1.074 
60.062  56.682  1.128  49.213  47.073  1.038  








40.098  37.958  0.837  
175.537  172.157  3.426  60.415  58.275  1.285  








8.262  6.122  0.135  
14.485  11.105  0.221  12.162  10.022  0.221  








10.938  8.798  0.194  
11.169  7.789  0.155  2.140  0.000  0.000  
8.204  4.824  0.096  3.591  1.451  0.032  
 
Table C.22: Fig. 3.5C, Puromycin (LLL12 + IL-6/LIF) 
 




59.245  56.875  0.957 
64.058  61.688  1.038  




179.947  177.577  2.988  
108.512  106.142  1.786  




220.954  218.584  3.678  
248.172  245.802  4.136  




15.147  12.777  0.215  
19.426  17.056  0.287  




37.850  35.480  0.597  
48.963  46.593  0.784  




49.260  46.89027 0.789 
45.813  43.44333 0.731 





Table C.23: Fig. 3.5D raw data (p-p70S6K, LLL12 + IL-6/LIF) 
 




47.755  45.165  1.045 
47.409  44.819  1.037  




73.341  70.751  1.637  
93.957  91.367  2.114  




103.898  101.308  2.344  
138.560  135.970  3.146  




2.590  0.000  0.000  
2.590  0.000  0.000  




13.827  11.237  0.260  
12.012  9.422  0.218  




10.975  8.38468 0.194 
10.672  8.08214 0.187 
11.882  9.2923 0.215 
 
Table C.24: Fig. 3.6A raw data (p-ERK1/2, PD98059 + LIF, 30min exposure) 
 




36.241  33.451  1.035 
33.720  30.930  0.957  




210.672  207.882  6.432  
208.798  206.008  6.374  




11.646  8.856  0.274  
8.252  5.462  0.169  





Table C.25: Fig. 3.6B raw data (p-ERK1/2, PD98059 + LIF, 2h exposure) 
 
 Signal -bg Normalized 
Control 38.662  36.635  1.034 
  35.508  33.481  0.945  
  38.449  36.422  1.028  
LIF 41.106  39.079  1.103  
  35.544  33.517  0.946  
  38.839  36.812  1.039  
PD98059 15.278  13.251  0.374  
  16.022  13.995  0.395  
  16.305  14.278  0.403  
PD98059+LIF 15.809  13.782  0.389  
  15.384  13.357  0.377  
  14.144  12.117  0.342  
 
Table C.26: Fig. 3.6B raw data (Puromycin, PD98059 + LIF, 2h exposure) 
 
  Signal -bg Normalized 
Control 58.663  55.293  0.941 
  58.781  55.411  0.943  
  70.121  66.751  1.136  
LIF 222.839  219.469  3.735  
  220.136  216.766  3.689  
  190.462  187.092  3.184  
PD98059 239.233  235.863  4.014  
  217.080  213.710  3.637  
  212.673  209.303  3.562  
PD98059+LIF 231.065  227.695  3.875  
  207.208  203.838  3.469  





Table C.27: Fig. 3.7A raw data (SOCS3 mRNA expression, different duration of IL-6/LIF 
exposure) 
 




17.040  24.115  -7.075  0.023  1.016  
16.805  23.690  -6.885  0.213  1.159  




16.750  22.530  -5.780  1.318  2.494  
16.140  22.222  -6.082  1.016  2.023  




16.850  21.620  -4.770  2.328  5.022  
16.435  21.207  -4.772  2.326  5.015  




16.370  22.870  -6.500  0.598  1.514  
16.265  22.520  -6.255  0.843  1.794  




16.745  22.360  -5.615  1.483  2.796  
16.970  22.640  -5.670  1.428  2.691  




16.875  22.712  -5.837  1.261  2.397  
16.970  22.472  -5.502  1.596  3.023  




17.045  21.444  -4.399  2.699  6.495  
16.890  21.152  -4.262  2.836  7.142  




16.495  22.285  -5.790  1.308  2.476  
16.550  22.672  -6.122  0.976  1.967  




16.725  22.727  -6.002  1.096  2.138  
17.015  22.708  -5.693  1.405  2.649  





Table C.28: Fig. 3.7B, Puromycin (different duration of IL-6/LIF exposure) 
 








39.605  37.225  0.754 
61.997  58.877  1.129  58.119  55.739  1.129  








85.322  82.942  1.680  
58.868  55.748  1.069  76.534  74.154  1.502  








213.091  210.711  4.268  
219.855  216.735  4.156  227.260  224.880  4.555  








123.978  121.598  2.463  
96.260  93.140  1.786  131.680  129.300  2.619  
77.903  74.783  1.434  132.075  129.695  2.627  
 
Table C.29: Fig. 3.7C raw data (SOCS3 mRNA expression, SOCS3 siRNA + IL-6/LIF) 
 




18.440  24.115  -5.675  0.097  0.940  
18.155  23.690  -5.535  0.237  1.140  
17.710  23.815  -6.105  -0.333  0.921  
Control siRNA + IL-6 
  
  
17.866  21.088  -3.222  2.549  5.854  
17.680  20.616  -2.936  2.836  7.138  
17.631  21.119  -3.488  2.284  4.869  
Control siRNA + LIF 
  
  
18.204  21.094  -2.890  2.882  7.372  
17.665  20.872  -3.207  2.564  5.915  




17.605  24.649  -7.044  -1.272  0.414  
17.695  24.767  -7.072  -1.301  0.406  
18.030  25.205  -7.175  -1.404  0.378  
SOCS3 siRNA + IL-6 
  
  
17.680  22.506  -4.826  0.946  1.926  
17.965  22.363  -4.398  1.374  2.591  
18.320  22.921  -4.601  1.171  2.251  
SOCS3 siRNA + LIF 
  
  
17.915  22.425  -4.510  1.261  2.397  
18.250  23.005  -4.755  1.016  2.023  





Table C.30: Fig. 3.7D raw data (Puromycin, SOCS3 siRNA + IL-6/LIF) 
 
IL-6 Signal -bg Normalized 
Control siRNA 57.145  53.475  0.967 
  58.362  54.692  0.989  
  61.459  57.789  1.045  
Control siRNA + IL-6 107.136  103.466  1.871  
  97.348  93.678  1.694  
  99.837  96.167  1.739  
Control siRNA + LIF 122.233  118.563  2.144  
  106.694  103.024  1.863  
  110.344  106.674  1.929  
SOCS3 siRNA 82.473  78.803  1.425  
  79.929  76.259  1.379  
  91.652  87.982  1.591  
SOCS3 siRNA + IL-6 118.473  114.803  2.076  
  161.773  158.103  2.859  
  170.344  166.674  3.014  
SOCS3 siRNA + LIF 188.483  184.8126 3.342 
  121.957  118.2867 2.139 
  140.095  136.4251 2.467 
 
Table C.31: Fig. 4.1A raw data (Puromycin, 24h IL-6/LIF treatment) 
 




70.089  66.199  0.943 
67.772  63.882  0.910  




48.467  44.577  0.635  
44.115  40.225  0.573  




20.668  16.778  0.239  
26.003  22.113  0.315  




27.688  23.798  0.339  
21.931  18.041  0.257  




22.423  18.533  0.264  
30.145  26.255  0.374  




Table C.32: Fig. 4.1B raw data (p-p70S6K p-4EBP1, 24h IL-6/LIF treatment) 
 








69.178  66.798  0.923 
83.435  80.455  0.905  76.849  74.469  1.029  








36.177  33.797  0.467  
37.118  34.138  0.384  44.282  41.902  0.579  








18.229  15.849  0.219  
44.496  41.516  0.467  15.262  12.882  0.178  








49.203  46.823  0.647  
71.878  68.898  0.775  53.401  51.021  0.705  








27.492  25.112  0.347  
39.607  36.627  0.412  17.505  15.125  0.209  
28.317  25.337  0.285  17.795  15.415  0.213  
 
Table C.33: Fig. 4.2A raw data (p-STAT3 p-ERK1/2, 24h IL-6/LIF treatment) 








22.846  20.656  0.963 
34.337  31.357  1.085  24.262  22.072  1.029  








87.432  85.242  3.974  
137.481  134.501  4.654  90.929  88.739  4.137  








112.550  110.360  5.145  
233.689  230.709  7.983  108.925  106.735  4.976  








30.332  28.142  1.312  
31.707  28.727  0.994  33.786  31.596  1.473  








30.011  27.821  1.297  
31.678  28.698  0.993  32.971  30.781  1.435  





Table C.34: Fig. 4.2A raw data (p-Akt, 24h IL-6/LIF treatment) 
 
 




40.149  37.569  1.135 
34.819  32.239  0.974  




28.233  25.653  0.775  
24.856  22.276  0.673  




11.649  9.069  0.274  
13.669  11.089  0.335  




20.355  17.775  0.537  
18.104  15.524  0.469  




9.829  7.249  0.219  
6.982  4.402  0.133  
9.101  6.521  0.197  
 
Table C.35: Fig. 4.2B raw data (SOCS3 mRNA expression, 24h IL-6/LIF treatment) 
 
  GAPDH Ct SOCS3 Ct ΔCt ΔΔCt Fold Change 
Control 15.760  22.971  -7.211  -0.089  0.940  
  15.605  22.589  -6.984  0.138  1.100  
  14.840  22.019  -7.179  -0.057  0.961  
20ng/ml IL-6 15.816  22.225  -6.409  0.713  1.639  
  15.060  22.214  -7.154  -0.032  0.978  
  14.621  21.628  -7.007  0.115  1.083  
100ng/ml IL-6 15.734  22.663  -6.929  0.193  1.143  
  15.385  22.428  -7.043  0.079  1.056  
  15.585  22.411  -6.826  0.296  1.228  
20ng/ml LIF 14.895  21.189  -6.294  0.828  1.775  
  15.145  21.321  -6.176  0.946  1.927  
  15.870  21.947  -6.077  1.045  2.063  
100ng/ml LIF 15.380  21.934  -6.554  0.568  1.482  
  15.575  21.829  -6.254  0.868  1.825  





Table C.36: Fig. 4.2C raw data (p-AMPK, 24h IL-6/LIF treatment) 
 




45.487  42.707  1.065 
38.228  35.448  0.884  




182.147  179.367  4.473  
140.403  137.623  3.432  




158.168  155.388  3.875  
141.646  138.866  3.463  




122.438  119.658  2.984  
113.697  110.917  2.766  




160.934  158.154  3.944  
181.947  179.167  4.468  
170.077  167.297  4.172  
 
Table C.37: Fig. 4.3B raw data (p-STAT3, C-188-9 + 24h IL-6/LIF treatment) 
 








49.678  47.488  0.923 
53.758  51.498  0.968  50.502  48.312  0.939  








60.534  58.344  1.134  
229.637  227.377  4.274  47.620  45.430  0.883  








19.529  17.339  0.337  
22.529  20.269  0.381  24.416  22.226  0.432  
23.806  21.546  0.405  20.403  18.213  0.354  
C-188-9 + IL-6 
  
  
27.211  24.951  0.469  
C-188-9 + LIF 
  
  
24.159  21.969  0.427  
23.912  21.652  0.407  27.966  25.776  0.501  





Table C.38: Fig. 4.3C raw data (p-p70S6K, C-188-9 + 24h IL-6/LIF treatment) 
 




49.078  47.098  1.091 
44.071  42.091  0.975  




29.997  28.017  0.649  
32.717  30.737  0.712  




13.506  11.526  0.267  
14.456  12.476  0.289  




10.528  8.548  0.198  
11.607  9.627  0.223  
10.355  8.375  0.194  
C-188-9 + IL-6 
  
  
13.550  11.570  0.268  
12.211  10.231  0.237  
12.945  10.965  0.254  
C-188-9 + LIF 
  
  
12.729  10.74933 0.249 
14.197  12.21711 0.283 
13.506  11.52639 0.267 
 
Table C.39: Fig. 4.3D raw data (Puromycin, C-188-9 + 24h IL-6/LIF treatment) 




83.989  79.709  0.947 
99.560  95.280  1.132  




48.974  44.694  0.531  
55.540  51.260  0.609  




36.685  32.405  0.385  
41.567  37.287  0.443  




23.723  19.443  0.231  
26.922  22.642  0.269  
20.104  15.824  0.188  
C-188-9 + IL-6 
  
  
22.292  18.012  0.214  
18.336  14.056  0.167  
20.188  15.908  0.189  
C-188-9 + LIF 
  
  
23.387  19.10659 0.227 
20.525  16.24481 0.193 




Table C.40: Fig. 4.3E raw data (p-STAT3, STAT3 siRNA + 24h IL-6/LIF treatment) 








67.518  63.148  0.987 
77.767  73.117  1.032  62.080  57.710  0.902  
71.462  66.812  0.943  75.452  71.082  1.111  
Control siRNA + IL-6 
  
  
243.769  239.119  3.375  
Control siRNA + LIF 
  
  
77.371  73.001  1.141  
155.986  151.336  2.136  73.788  69.418  1.085  
202.109  197.459  2.787  64.127  59.757  0.934  
STAT3 siRNA  
  
  
60.409  55.759  0.787  
STAT3 siRNA  
  
  
56.130  51.760  0.809  
56.654  52.004  0.734  53.123  48.753  0.762  
60.976  56.326  0.795  50.692  46.322  0.724  
STAT3 siRNA + IL-6 
  
  
57.221  52.571  0.742  
STAT3 siRNA + LIF 
  
  
54.210  49.840  0.779  
57.008  52.358  0.739  51.907  47.537  0.743  
61.401  56.751  0.801  48.964  44.594  0.697  
 
Table C.41: Fig. 4.3E raw data (total STAT3, STAT3 siRNA + 24h IL-6/LIF treatment) 








60.832  55.942  0.941 
66.872  63.222  0.967  63.210  58.320  0.981  
67.919  64.269  0.983  69.096  64.206  1.080  
Control siRNA + IL-6 
  
  
71.907  68.257  1.044  
Control siRNA + LIF 
  
  
65.767  60.877  1.024  
67.199  63.549  0.972  62.140  57.250  0.963  
67.984  64.334  0.984  61.070  56.180  0.945  
STAT3 siRNA  
  
  
34.575  30.925  0.473  
STAT3 siRNA  
  
  
36.815  31.925  0.537  
38.432  34.782  0.532  28.432  23.542  0.396  
39.674  36.024  0.551  29.443  24.553  0.413  
STAT3 siRNA + IL-6 
  
  
40.851  37.201  0.569  
STAT3 siRNA + LIF 
  
  
29.086  24.196  0.407  
37.844  34.194  0.523  29.562  24.672  0.415  





Table C.42: Fig. 4.3F raw data (Puromycin, STAT3 siRNA + 24h IL-6/LIF treatment) 
 








93.508  88.618  1.088 
70.444  66.374  0.907  79.091  74.201  0.911  
75.128  71.058  0.971  86.421  81.531  1.001  
Control siRNA + IL-6 
  
  
49.808  45.738  0.625  
Control siRNA + LIF 
  
  
46.674  41.784  0.513  
47.466  43.396  0.593  53.108  48.218  0.592  
54.345  50.275  0.687  48.792  43.902  0.539  
STAT3 siRNA  
  
  
30.708  26.638  0.364  
STAT3 siRNA  
  
  
34.538  29.648  0.364  
26.609  22.539  0.308  29.977  25.087  0.308  
31.513  27.443  0.375  35.434  30.544  0.375  
STAT3 siRNA + IL-6 
  
  
32.171  28.101  0.384  
STAT3 siRNA + LIF 
  
  
36.574  31.684  0.389  
24.341  20.271  0.277  37.551  32.661  0.401  
31.805  27.735  0.379  21.587  16.697  0.205  
 
Table C.43: Fig. 4.4B raw data (p-AMPK, 24h IL-6/LIF treatment + Compound C) 




96.511  94.441  1.03 
90.001  87.931  0.959  




237.897  235.827  2.572  
193.060  190.990  2.083  




217.266  215.196  2.347  
200.946  198.876  2.169  




41.955  39.885  0.435  
37.462  35.392  0.386  
38.012  35.942  0.392  
Compound C + IL-6 
  
  
63.777  61.707  0.673  
55.709  53.639  0.585  
41.222  39.152  0.427  
Compound C + LIF 
  
  
25.543  23.47264 0.256 
33.061  30.99122 0.338 





Table C.44: Fig. 4.4C raw data (p-p70S6K, 24h IL-6/LIF treatment + Compound C) 
 




57.468  54.078  1.118 
48.422  45.032  0.931  




26.656  23.266  0.481  
22.351  18.961  0.392  




21.335  17.945  0.371  
24.141  20.751  0.429  




85.087  81.697  1.689  
109.949  106.559  2.203  
87.264  83.874  1.734  
Compound C + IL-6 
  
  
116.914  113.524  2.347  
98.002  94.612  1.956  
118.269  114.879  2.375  
Compound C + LIF 
  
  
96.454  93.06388 1.924 
106.128  102.73788 2.124 
95.148  91.75789 1.897 
 
Table C.45: Fig. 4.4D raw data (Puromycin, 24h IL-6/LIF treatment + Compound C) 




28.541  24.761  0.976 
32.017  28.237  1.113  




17.531  13.751  0.542  
20.753  16.973  0.669  




16.034  12.254  0.483  
17.404  13.624  0.537  




225.412  221.632  8.736  
193.116  189.336  7.463  
209.074  205.294  8.092  
Compound C + IL-6 
  
  
215.239  211.459  8.335  
205.269  201.489  7.942  
210.140  206.360  8.134  
Compound C + LIF 
  
  
222.546  218.76551 8.623 
203.569  199.78875 7.875 




Table C.46: Fig. 4.4E raw data (p-AMPK, AMPK siRNA + 24h IL-6/LIF treatment) 




34.037  30.257  0.963 
39.159  35.379  1.126  




81.482  77.702  2.473  
93.767  89.987  2.864  




103.224  99.444  3.165  
102.250  98.470  3.134  




25.114  21.334  0.679  
22.412  18.632  0.593  




26.937  23.157  0.737  
30.079  26.299  0.837  




27.753  23.97346 0.763 
30.676  26.89552 0.856 
32.466  28.68646 0.913 
 
Table C.47: Fig. 4.4E raw data (total AMPK, AMPK siRNA + 24h IL-6/LIF treatment) 




59.791  57.101  1.003 
65.655  62.965  1.106  




63.890  61.200  1.075  
66.736  64.046  1.125  




62.637  59.947  1.053  
62.410  59.720  1.049  




27.568  24.878  0.437  
28.593  25.903  0.455  




31.667  28.977  0.509  
26.714  24.024  0.422  




28.081  25.39078 0.446 
27.682  24.99227 0.439 




Table C.48: Fig. 4.4F raw data (Puromycin, AMPK siRNA + 24h IL-6/LIF treatment) 
 




77.287  74.597  0.942 
90.274  87.584  1.106  




60.578  57.888  0.731  
55.985  53.295  0.673  




62.320  59.630  0.753  
63.825  61.135  0.772  




36.900  34.210  0.432  
43.631  40.941  0.517  




37.771  35.081  0.443  
39.988  37.298  0.471  




36.108  33.41818 0.422 
33.178  30.48815 0.385 
42.047  39.35743 0.497 
 
Table C.49: Table 4.1 raw data (Plasma IL-6 in IL-6 overexpression mice) 
 
Standard Curve   Group D-0 (pg/ul) D-4 (pg/ul) D-5 (Sac) (pg/ul) 








N.D. N.D. N.D. 
0 0.16 N.D. N.D. N.D. 
16 0.392 N.D. N.D. N.D. 
31 0.465 N.D. N.D. N.D. 
63 0.581 N.D. N.D. N.D. 
125 0.831 N.D. N.D. N.D. 










N.D. 213.5  257.7  
1000 3.488 N.D. 134.4  467.0  
  
N.D. 105.1  524.0  
N.D. 106.5  414.0  
N.D. 136.9  542.0  
N.D. 95.2  537.0  
N.D. 98.1  225.0  
















23.7 9 18 121 6 42 17.10 
25.6 6 15 130 9 39 17.25 
26.3 7 17 118 10 48 16.90 
22.9 6 19 135 8 42 17.20 
25.8 8 16 121 9 41 17.15 
26.4 9 17 116 7 45 16.95 









26.2 8 18 118 10 42 16.95 
24.8 7 15 115 9 50 16.90 
25.3 6 16 109 7 39 17.15 
23.9 6 19 127 6 43 17.20 
24.1 9 14 130 8 44 16.85 
26.2 6 17 125 9 47 17.00 
25.8 7 19 122 7 45 17.05 
23.2 6 18 119 9 48 16.95 
 
Table C.51: Fig. 4.5A raw data (p-STAT3, IL-6 overexpression cage control) 
 








29.730  26.541  1.047  
26.739  23.550  0.929  
31.226  28.037  1.106  
37.285  34.096  1.345  
21.999  18.810  0.742  
24.204  21.015  0.829  









111.864  108.675  4.287  
149.940  146.751  5.789  
122.131  118.942  4.692  
155.644  152.455  6.014  
98.049  94.860  3.742  
151.563  148.374  5.853  
105.578  102.389  4.039  





Table C.52: Fig. 4.5B raw data (p-p70S6K, IL-6 overexpression cage control) 
 








48.152  44.717  0.793  
57.851  54.416  0.965  
73.471  70.036  1.242  
72.738  69.303  1.229  
54.299  50.864  0.902  
49.280  45.845  0.813  









52.100  48.665  0.863  
39.637  36.202  0.642  
28.190  24.755  0.439  
16.236  12.801  0.227  
23.510  20.075  0.356  
52.438  49.003  0.869  
43.697  40.262  0.714  
48.885  45.450  0.806  
 
Table C.53: Fig. 4.5C raw data (Puromycin, IL-6 overexpression cage control) 
 








131.844  128.409  1.245  
126.068  122.633  1.189  
129.060  125.625  1.218  
90.382  86.947  0.843  
92.857  89.422  0.867  
80.274  76.839  0.745  









89.969  86.534  0.839  
92.342  88.907  0.862  
95.952  92.517  0.897  
78.108  74.673  0.724  
76.149  72.714  0.705  
103.275  99.840  0.968  
90.279  86.844  0.842  





Table C.54: Fig. 5.1B raw data (Puromycin, Short term IL-6/LIF with Stretch) 
 








84.561  80.891  1.038 
81.022  78.332  1.116  80.197  76.527  0.982  








184.857  181.187  2.325  
180.481  177.791  2.533  165.998  162.328  2.083  








196.079  192.409  2.469  
152.546  149.856  2.135  230.836  227.166  2.915  








99.914  96.244  1.235  
97.868  95.178  1.356  85.263  81.593  1.047  
106.010  103.320  1.472  93.445  89.775  1.152  
 
Table C.55: Fig. 5.1C raw data (p-p70S6K, Short term IL-6/LIF with Stretch) 
 








56.654  52.984  1.129 
52.169  49.479  1.016  51.163  47.493  1.012  








176.044  172.374  3.673  
215.704  213.014  4.374  137.327  133.657  2.848  








72.047  68.377  1.457  
126.242  123.552  2.537  91.382  87.712  1.869  








60.737  57.067  1.216  
49.588  46.898  0.963  68.199  64.529  1.375  





Table C.56: Fig. 5.2A raw data (Puromycin, Long term IL-6/LIF with Stretch) 
 








71.541  68.871  1.029 
74.858  72.168  0.917  62.714  60.044  0.897  








134.924  132.254  1.976  
149.308  146.618  1.863  118.994  116.324  1.738  








33.324  30.654  0.458  
47.706  45.016  0.572  22.615  19.945  0.298  








34.194  31.524  0.471  
49.438  46.748  0.594  29.844  27.174  0.406  
46.605  43.915  0.558  26.832  24.162  0.361  
 
Table C.57: Fig. 5.2B raw data (p-p70S6K, Long term IL-6/LIF with Stretch) 




72.776  70.086  0.932 
71.874  69.184  0.920  




154.068  151.378  2.013  
142.788  140.098  1.863  




47.660  44.970  0.598  
45.704  43.014  0.572  




48.712  46.022  0.612  
47.359  44.669  0.594  




32.093  29.403  0.391  
19.685  16.995  0.226  




19.309  16.6192 0.221 
25.400  22.7104 0.302 





Table C.58: Fig. 5.3A raw data (Plasma IL-6, IL-6 overexpression + HFES) 
 
Standard Curve   Group D-0 (pg/ul) D-4 (pg/ul) D-5 (Sac) (pg/ul) 





N.D. N.D. 151.4  
0 0.157 N.D. N.D. 43.0  
16 0.384 N.D. N.D. 266.0  






N.D. 218.5  337.7  
125 0.84 N.D. 194.3  592.0  
250 1.329 N.D. 105.1  1344.0  
500 2.137 N.D. 76.5  914.0  
1000 3.359         
 
Table C.59: Fig. 5.3B raw data (p-STAT3, IL-6 overexpression + HFES) 
 




29.780  27.090  1.075 
31.342  28.652  1.137  




56.946  54.256  2.153  
71.864  69.174  2.745  




90.361  87.671  3.479  
129.295  126.605  5.024  




107.925  105.235  4.176  
118.333  115.643  4.589  





Table C.60: Fig. 5.3C raw data (p-p70S6K, IL-6 overexpression + HFES) 
 




40.192  37.502  1.202 
29.054  26.364  0.845  




215.256  212.566  6.813  
109.488  106.798  3.423  




25.435  22.745  0.729  
30.115  27.425  0.879  




279.590  276.900  8.875  
234.693  232.003  7.436  
154.915  152.225  4.879  
 
Table C.61: Fig. 5.3D raw data (Puromycin, IL-6 overexpression + HFES) 
 




40.365  36.235  
59.537  55.407  




89.208  85.078  
72.721  68.591  




63.285  59.155  
31.517  27.387  




102.705  98.575  
61.274  57.144  
69.008  64.878  
 
 
 
 
